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Abstract 
 
Background: Patients suffering from chronic kidney disease (CKD) are at high risk 
of cardiovascular related premature death. In addition, traditional strategies for 
preventing cardiovascular disease (CVD) in patients with normal kidney function are 
less successful in patients with CKD. Vascular calcification (VC) and cardiac 
hypertrophy are common consequences. Recent evidence suggests that activation of 
the vitamin D receptor (VDR) is protective and is associated with significantly better 
survival in end stage renal disease (ESRD).  
Vascular smooth muscle cells (VSMCs) play a key role in the process of CKD-
related arteriopathy and are capable of phenotype transformation into 
chondro/osteoblast-like cells, which promotes the deleterious vascular effects, 
including calcification.  
Although the kidney is the main site of 1,25(OH)2D synthesis, some other non-renal 
tissues also express, VDR, 25-hydroxyvitamin D 1α-hydroxyalse (1α-OHase) an 
enzyme responsible for the synthesis of 1,25(OH)2D, and 1,25(OH)2D 24-
hydroxylase (24-OHase), an enzyme responsible for the catabolism of 1,25(OH)2D. 
Extra-renal 1,25(OH)2D can affect a multitude of pathways in an autocrine/paracrine 
way, without the involvement of the endocrine system.  
 
Aims: This project aimed to investigate the role of autocrine vitamin D signalling in 
human VSMCs using both arterial tissue from ESRD and non-ESRD patients and 
primary cultures of human aortic smooth muscle cells (HAoSMCs). Specific aims 
were to characterise the expression and functionality of vitamin D system in 
vasculature as well as to examine the effect of classical regulators of the endocrine 
vitamin D system – 1,25(OH)2D3, calcium, phosphate, TNF-α and other interleukins, 
as well as novel factors such as FGF-23 and Klotho, on the local vitamin D 
metabolism in arteries.  
 
Results: We have demonstrated the presence of VDR, 1-OHase and 24-OHase in 
human kidney, artery and HAoSMCs. To our knowledge, we are the first to 
demonstrate the presence of 24-OHase in arteries. Our data suggested diminished 
expression of VDR mRNA and protein, with significantly decreased levels of 1α-
OHase protein expression in CKD patients. Further crucial finding was the apparent 
increase of 24-OHase protein in CKD arteries suggested higher local vitamin D 
catabolism in CKD. In order to establish which factors regulate expression of 1α-
OHase, 24-OHase and VDR in HAoSMCs, further studies were undertaken. Results 
confirmed that treatment with high calcium, phosphate, TNF-α, INF-γ, IL-6, IL-17A, 
FGF-23 or Klotho modulated VDR protein expression, which had further effect on 
expression of 1α-OHase and 24-OHase mRNA and protein.  
 
Conclusions: The results suggest that altered mineral and inflammatory 
environment, characteristic to CKD may favour local 1,25(OH)2D3 catabolism, 
potentially driving transdifferentiation of VSMCs, leading to VC. Vascular VDR 
activation, in particular through local metabolic activation, is crucial for vascular 
health, especially, under stress conditions. Local inducers and inhibitors of vascular 
vitamin D system have been determined, however further examination is required for 
potential application in future treatment of CKD related VC. 
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Chronic Kidney Disease (CKD) is like every chronic condition,  
untreatable and unpreventable – in the UK alone, one CKD patient dies  
prematurely every 15 minutes - every other one due to the development of 
cardiovascular complications

. 
 
Over 45,000 lives in the UK were lost between 2009 and 2010 due to CKD (Kerr 
2012), which is equivalent to a disappearance of a whole population of Banbury or 
Lancaster. In USA the number of people diagnosed with CKD is growing and in 
2010 it exceeded 20 million (CDC 2010) – the number of people inhabiting the 
largest city of the southern hemisphere, San Paulo. What is more, individuals with 
CKD are 16 to 40 times more likely to die than to reach ESRD. Over £1.45 billion 
were spent on CKD patient care between 2009 and 2010, where majority of the cost 
were dialysis and kidney transplantation. Over £8 million was spent in that time on 
vitamin D therapy (Kerr 2012).  
 
This thesis investigates the role of vitamin D signalling in human artery in health and 
disease – all with a perspective of identifying factors for future application in 
treatment of CKD related cardiovascular complications. 
 
 
 
                                                        
 Calculated based on data from (Kerr 2012). 
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Chapter 1  
 
General Introduction 
 
 
 
 
 
 
1.1 Vitamin D and Artery in CKD 
 
Vitamin D is essential for human health. The synthesis of the active vitamin D 
hormone 1,25(OH)2D, from the major circulating prohormone 25(OH)D is catalysed 
by the enzyme 25-hydroxyvitamin D 1-hydroxylase (1α-OHase) and its catabolism 
is facilitated by vitamin D 24-hydroxylase (24-OHase). Generation of 1,25(OH)2D 
circulating in the blood occurs in the kidneys and chronic damage and degeneration 
of kidney tissue, such as seen in chronic kidney disease (CKD) results in diminished 
blood levels of 1,25(OH)2D. This causes the abnormal calcium and phosphate 
homoeostasis, which is associated with CKD. 1,25(OH)2D acts through binding to 
vitamin D receptors (VDR), which are present in almost every tissue of the human 
body, including arteries.  In CKD activation of the VDR by 1,25(OH)2D3 is 
attenuated, which can have deleterious effect on the physiology of arteries. The 
current understanding of the molecular mechanisms underlying uraemic 
arteriopathies is still quite basic. Vascular calcification (VC), one of the most 
important CKD pathology is currently untreatable and non-preventable, with the lack 
of ideal biomarkers.  
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This thesis aims to investigate the human vascular vitamin D system, its interaction 
with the endocrine system, changes in disease with focus on CKD with failure of the 
endocrine vitamin D system and lastly, regulation of the vascular vitamin D system.  
 
1.2 Vitamin D   
 
1.2.1 The History 
 
 
The concept of vitamins, which were initially known as “vital amines” – organic 
micronutrients present in foods from natural sources and essential for health, 
emerged in early 19
th
 century, following episodes of scurvy in sailors and endemic 
beriberi in Asian communities. Rickets, which is a condition induced by the vitamin 
D deficiency, was first described in the 15
th
 century and later, more clearly by 
Whistler as “a condition in which the skeleton was poorly mineralised and 
deformed”, however, the cause was still a mystery (Whistler 1645). The end of 19th 
century witnessed a significant emergence of rickets in the low-sun light countries, 
especially in England, where the condition was known as an “English disease”. This 
epidemic of rickets struck during industrial revolution, when the rate of urbanisation 
increased, ultimately leading to atmosphere pollution further reducing peoples’ 
exposure to sun light (Hess 1929). Cod liver oil has been suggested to have a 
beneficial effect in the treatment of English disease, although, initially not much 
attention was paid (DeLuca H. 2005). McCollum was an American scientist, who by 
studying fat soluble properties of vitamin A in cod liver oil, has shown that an 
aeration and heat inactivation of this nutrient has not compromised the ability of cold 
liver oil to cure rickets, suggesting that there was another essential nutrient. This was 
how McCollum discovered vitamin D (McCollum 1922). Further experiments on 
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dogs, cows, chickens and goats have led scientists to rightly associating the sun 
exposure with calcium balance in animal body. The irradiation of plant sterols and 
eventually human skin with ultraviolet light has led first to isolation of  
ergocalciferol - vitamin D2 and six years later, 7-dehydrogestrel – the human 
precursor of vitamin D3 by Askew et al. (Askew 1931, Windaus 1937).  
Only four decades ago, 25(OH)D was thought to be the active form of vitamin D 
(Blunt 1968). The scientific curiosity, however, has turned out to have phenomenal 
consequences, when few years after Blunt’s discovery, Fraser and Kodicek disproved 
his hypothesis, to confirm that 1,25(OH)2D, was the peak metabolite in the analysed 
chick kidney homogenate, pointing out the kidney as the site of vitamin D final 
activation step (Fraser DR; Kodicek, E. 1970). 
It is now known that 1,25(OH)2D is not a true vitamin (because healthy individuals 
with adequate exposure to sunlight do not require dietary supplementation), it is a 
steroid hormone, which when acting via the endocrine way is responsible mainly for 
mineral homeostasis and bone growth.  
 
In recent years it was suggested that 1,25(OH)2D can be synthesised in various other 
tissues of the human body, such as macrophages, keratinocytes, pancreatic β-cells, 
neurons, parathyroid, bone and many more, suggesting other roles for this 
astonishing compound, such as acting on proliferation, differentiation and immunity 
(Adams and Gacad 1985, Bland et al. 2001, Bland et al. 2004, Equils et al. 2006, 
Hewison et al. 1994, Jones et al. 1998, Liu Philip 2006, Stoffels et al. 2006, Zehnder 
et al. 2001, Zehnder et al. 2002a). The topic remains controversial, as some strongly 
argue against the existence of extra-renal 1,25(OH)2D  synthesis (Vanhooke et al. 
2006). 
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1.3  The Vitamin D Hormonal System 
 
1.3.1  Metabolic Origin, Activation and Catabolism 
 
 
There are two different isoforms of vitamin D - D2 and D3 and both are thought to be 
biologically inert. Provitamin D is either produced in the skin (cholecalciferol - D3), 
under the exposure to ultraviolet B (UVB) light at 290-315 nm wavelengths, or 
ingested by consuming oily fish, some plants (especially from Solanaceae family: 
potatoes, tomatoes, aubergines, chilli peppers and tobacco), (ergocalciferol – 
D2). UVB mediates a photolytic, non-enzymatic reaction that converts endogenous 7-
dehydrocholesterol into a previtamin D3. Following that, the precursor of the active 
hormone undergoes a non-enzymatic thermal isomerisation conversion to vitamin D3, 
which via circulation is transported to the liver (since vitamin D2 is ingested, it is 
absorbed through the gut and transported with blood to the liver, together with 
vitamin D3. In the liver, vitamin D2 and D3 further undergo hydroxylation to produce 
25(OH)D (calcidiol), as depicted below (Figure 1.1), which is the main circulating 
pro-hormone. It is the most abundant form of vitamin D and exists in circulation 
bound to vitamin D binding protein (DBP), which stabilises it. In fact 25(OH)D is a 
mixture of 25(OH) D2 and 25(OH)D3, however for the simplicity, throughout this 
thesis calcidiol it will be referred to as 25(OH)D. Levels of 25(OH)D < 5 ng/ml or  
12 nM are indicative of severe vitamin D deficiency, 5-15 ng/ml or 12-37 nM 
indicate mild deficiency and those of 16-30 ng/ml or 40-75 nM – 25(OH)D 
insufficiency. The second hydroxylation and bio-activation stage occurs primarily in 
the proximal tubule cells in the kidneys, where the renal 1-OHase, produces the 
circulating fraction of the active form of vitamin D, the sterol hormone - 1,25(OH)2D 
(calcitriol). 24-OHase, which is present in virtually all vitamin D target tissues 
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catabolises both 25(OH)D (to 24,25(OH)2D) and 1,25(OH)2D (to 1,24,25(OH)3D, as 
represented by Figure 1.2.  
 
 
Figure 1.1: Initial stages of vitamin D2 and D3 synthesis from natural precursors, 
in humans and in plants.   
 
1.3.2 Receptors and Other Proteins Involved in Vitamin D Signalling 
 
The majority of 1,25(OH)2D actions are mediated by its binding to the high-affinity 
nuclear receptor, the vitamin D receptor (VDR). This complex then forms a 
heterodimer with retinoid X receptor (RXR), which binds to vitamin D response 
elements (VDREs) in the promoter of 1,25(OH)2D-responsive genes. The rate of 
transcription by the VDR is regulated by the recruitment of nuclear co-regulator  
 6 
 
 
Figure 1.2: Vitamin D metabolism. The image is a schematic representation of the multiple step process required for the production of fully active 
1,25(OH)2D3 in the kidneys. Vitamin D 25-Hydroxylase (25-OHase), 25-Hydroxyvitamin D 1-Hydroxylase (1-OHase), vitamin D 24-Hydroxylase 
(24-OHase).
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proteins into the transcription pre-initiation complex, as pictured below (Figure 1.3). 
VDR localisation is not restricted to nucleus, as presence of functional VDR was 
shown in cavolae-enriched plasma membrane, mitochondria, cytosol and perinuclear 
space (Gonzalez Pardo et al. 2008, Huhtakangas et al. 2004, Nemere et al. 1994). 
Furthermore, t-tubules of rat cardiac myocytes have also been shown to colocalise 
with VDR. Portion of these t-tubule bound VDR receptors upon exposure to 
1,25(OH)2D3 is translocated to nucleus. The remaining VDR is thought to be 
positioned ideally to exert an immediate effect on signal transduction mediators and 
ion channels, ultimately playing role in heart structure and function (Tishkoff et al. 
2008). 
 
 
Figure 1.3: Schematic representation of the VDR mRNA transcript. 
 
1.3.2.1  Vitamin D Binding Protein 
 
Since Vitamin D and its hydroxylated metabolites are lipophilic compounds, in order 
to be efficiently transported in plasma they must be bound to plasma proteins. 
Plasma proteins, such as DBP, albumin and some lipoproteins are present in excess 
compared to vitamin D metabolites and play an important role in extending their 
circulation half-life. The second most abundant serum glycoprotein is DBP - it binds 
to 25(OH)D and 24,25(OH)2D with highest affinity, and not as strongly to 
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1,25(OH)2D (Cooke and Haddad 1989). The ability of DBP to bind to 1,25(OH)2D is 
a mechanism that could have been developed to help to prevent intoxication 
(Bouillon et al. 1981).  
1.3.2.2  Proteins Involved in Crossing the Membrane 
 
 
25(OH)D-DBP complex is sequestered by cubilin on the cell surface to further bind 
to the endocytic megalin receptor and the receptor-associated protein (RAP), which 
facilitates its uptake (Birn et al. 2000, Nykjaer et al. 2001). Megalin has also the 
ability to bind the VDR co-activator SKI-interacting protein (Skip), which highlights 
another way of controlling the vitamin D signalling (Petersen et al. 2003).  
Megalin-mediated uptake may not be the only mechanism facilitating entry of 
vitamin D metabolites inside the cell. Interestingly, stimulation of various cell types 
with 1,25(OH)2D induced fast (too fast to be mediated by the nuclear VDR action) 
cellular responses, so called ‘non-genomic’ responses, such as increase in inositol 
triphosphate, diacylglycerol, intracellular calcium and intestinal phosphate fluxes (de 
Boland et al. 1994, Karsenty et al. 1985, Norman A. 1997, Slater et al. 1995, Wali et 
al. 1990). PKC, membrane bound VDR and more recently, membrane caveolae and 
membrane-associated rapid response steroid-binding (MARRS) have been suggested 
as possible membrane receptors (Nemere and Farach-Carson 1998, Nemere et al. 
1998, Slater et al. 1995).   Binding of 1,25(OH)2D may trigger activation of single or 
multiple second messenger systems, including phospholipase C (PLC), G-protein 
coupled receptors and protein kinase C (PKC) or phosphatidylinositol-3-kinase 
(PI3K), which may result in opening of the voltage-gated calcium channels or 
chloride channels, further facilitating the cross-talk with the nucleus modulating the 
gene expression.   
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1.3.2.3 Intracellular Vitamin D Binding Protein (IDBP) 
 
 
The intracellular part of the megalin receptor has been shown to interact with 
intracellular vitamin D binding proteins 1 and 2 (IDBP1 and IDBP2), which are 
homologous to the heat-shock proteins. Upon 25(OH)D-DBP complex entry into the 
cell, DBP is degraded by legumain, a naturally occurring cysteine endopeptidase. 
This allows the release of 25(OH)D, which remains bound to IDBP, responsible for 
targeting the metabolite to the inner mitochondrial membrane. 
1.3.2.4 The Vitamin D Receptor 
 
 
VDR belongs to the steroid-thyroid superfamily of nuclear receptors and it has been 
cloned first in chicken (McDonnell et al. 1987). Few years later the presence of VDR 
was shown in almost every human tissue, except red blood cells, highly 
differentiated brain cortex and mature striated muscle (Krill et al. 2001, Menezes et 
al. 2008, Perez-Fernandez et al. 1997, Segaert et al. 1998, Wu-Wong et al. 2007b, 
Zanello et al. 1997). VDR is homologous to other nuclear receptors, such as retinoid 
receptors (RXR) and constitutive androstane receptors (CAR), which bind bile acid 
metabolites and are able to activate CYP enzymes involved in drug detoxification. 
Interestingly, the presence of VDR has also been detected in jawless primitive fish 
(Petromyzon marinus) suggesting that vitamin D system emerged even before the 
development of calcified structures, perhaps serving as a detoxifying mechanism 
(Whitfield et al. 2003). VDR acts via dimerising with any of the three RXR isomers. 
Both VDR and RXR are inactive when not bound to their ligands, 1,25(OH)2D and 
9-cis-retinoic acid, respectively. There are at least three different VDR splice 
variants- two of them produce 427 amino acid long protein (difference is in 5’ 
untranslated region) and one a 477 amino acid long protein, due to 50 amino acid N-
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terminal extension). The longer protein structural variant is called VDR-B1 and 
makes up about 30% of total VDR found in kidney. In vitro studies using different 
cell lines derived from kidney (COS1 and HEK293) breast (HS578T and MCF7) and 
intestine tissue (Caco-2, LS174T and HCT15) have shown that there are differences 
in the transactivation capacity of the 24-hydroxylase promoter in each cell-line 
(Esteban et al. 2005). These differences seemed to be attributed to the to the fact that 
A/B domains possess promoter- and cell context-dependent activity proposing that 
the VDR N-termini may interact with cell-specific co-factors (McInerney et al. 1998, 
Tzukerman et al. 1994). VDR consists of two main domains – DNA binding domain 
(DBD) and ligand binding domain (LBD), linked by the hinge region, as depicted on 
the Figure 1.3. The DBD comprises two zinc fingers, which are essential for 
interaction of VDR with DNA regulatory elements and nuclear translocation of VDR 
from cytosol. Mutations in this area can be one of the causes of VDR resistance in 
humans and mice, they also inevitably lead to alopecia (Haussler 1986, Hsieh et al. 
1998, Malloy and Feldman 2003). The hinge region is longer than in other nuclear 
receptors ensuring sufficient flexibility for DNA-DBD interaction as well as the 
LBD-co-activators interaction. The LBD is formed by twelve α-helixes and three β-
sheets, folded to form a large pocket allowing accommodation of a long 1,25(OH)2D 
and anaologues’ side chain. Mutations in the LBD impair or abolish binding of the 
ligand (Bouillon et al. 2008). Activation factor-2 (AF-2) domain provides a platform 
for binding of co-activator proteins. Multiple polymorphisms have been identified in 
humans along the VDR gene, which have later been associated with cancer, diabetes, 
arthritis and other disorders (Arai et al. 1997, Nejentsev et al. 2004a, Nejentsev et al. 
2004b, Uitterlinden et al. 2004). 
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1.3.2.5 Vitamin D Response Element (VDRE) and Co-Activator and Co-
Repressor Proteins 
 
 
In response to 1,25(OH)2D, VDR is phosphorylated, which causes structural 
reconfiguration and leads to the release of co-repressors. Studies using mice revealed 
for the first time that VDR dimerises with RXR, which allows the complex to bind to 
two hexameric VDRE binding sites (Schrader et al. 1997). Genes regulated by VDR 
can have multiple VDREs present in their promoter (Meyer et al. 2006). 
Nuclear co-regulator molecules play an important role in positive and negative 
modulation of VDR. Two regions are of particular importance – residue 246 of the 
RXR heterodimerisation domain (E1) and the AF-2 domain. Nuclear co-activators, 
such as SRC-1 p160 and CBP/p300, which poses the histone acetyl transferase 
(HAT) DNA unfolding activity, act together with VDR to increase the effect 
1,25(OH)2D has on gene transactivation. Further, a complex of approximately 15 
transcriptional co-activators (DRIP-TRAP) is recruited and binds directly to VDR 
via DRIP205 forming a bridge with the basal transcription machinery creating a 
transcription pre-initiation complex to stimulate VDR-induced gene expression 
(Figure 1.4) (Dusso et al. 2005, Jurutka et al. 2001, Rachez and Freedman 2000).  
VDR can also act to repress expression of certain genes, for instance the one coding 
for PTH. In such situation, binding of the VDR-RXR complex to a negative VDRE 
recruits co-repressors, which de-acetylates histones preventing chromatin exposure, 
ultimately blocking binding of the transcriptional machinery. Interestingly, other set 
of VDR modulators, different to co-activators and co-repressors has been described. 
NCoA62/Skip has a double role – it can promote activation or repression, depending 
on the expression of other co-regulator molecules (Jurutka et al. 2001, Leong et al. 
2004, Rachez and Freedman 2000).   
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Figure 1.4: Schematic representation of steps necessary for gene transcription 
from the Vitamin D Response Element (VDRE). Histone Acetyl Transferase (HAT), 
Vitamin D Receptor Interacting Protein (DRIP), Vitamin D Receptor (VDR), Retinoid 
X receptor (RXR), polymerase (Poly), CREB binding protein/EA1 binding protein 
(CBP/p300), Steroid Receptor Co-activator 1/nuclear co-activator (SRC-1/ p160).  
 
 
1.3.3 Enzymes Involved in Vitamin D Metabolism -The Cytochrome 
P450 Enzyme System 
 
 
Mixed function oxidases are the enzymes responsible for the stereo-specific 
hydroxylation of steroids. They catalyse reduction of one atom of molecular oxygen 
to water and one atom of the hydroxyl group to be attached to the steroid or sterol 
hormone. The Cytochrome P450 enzymes are involved in the synthesis of essential 
cholesterol derived hormones, such as estrogens, androgens, mineralocorticoids, 
glucocorticoids and vitamin D. There are two types of cytochrome P450 enzymes, 
type 1 includes microsomal enzymes, such as 17α-OHase, 21-OHase, hepatic 
enzymes and aromatases. Within the microsomal endoplasmatic reticulum 
flavoprotein serves as an electron donor, passing the electrons to the enzymes. Type 
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2 P450 enzymes are localised in inner mitochondrial membrane and comprise major 
vitamin D regulating enzymes such as 25-OHase, 1α-OHase and 24-OHase.   
The electrons required for the oxygen reduction are derived from nicotinamide 
adenine dinucleotide phosphate (NADPH, reduced form), which is generated 
intramitochondrially during the tricarboxylic acid metabolism. They are then 
transferred to NADPH-ferredoxin reductase and ferredoxin (non-haeme iron-sulphur 
protein), which shuttles between mitochondrial matrix and the cytochrome P450 
(specific for each hydroxylase) (Solish et al. 1988). 
 
1.3.3.1 25-Hydroxylation: The Vitamin D 25-Hydroxylase (25-OHase) 
 
 
25-OHase, an enzyme found in the hepatic mitochondria, requires two mitochondrial 
protein cofactors: ferredoxin and ferredoxin reductase in order to function 
(Hanukoglu and Gutfinger 1989). Interestingly, intestine, keratinocytes, kidney, 
macrophages have been confirmed as an extra-hepatic site of 25-hydroxylation, after 
original studies by Olson, in which hepatectomy was shown to only reduce, but not 
eliminate the plasma 25(OH)D (Bjorkhem et al. 1994, Lehmann et al. 1999, Olson et 
al. 1976). 25-OHase is a multifunctional enzyme, with the same enzyme expressed in 
various tissues. Its activity is not restricted to vitamin D metabolism, as it can also 
hydroxylate other intermediates of cholesterol synthesis, (Okuda et al. 1995). 25-
OHase is involved in the cholesterol clearance from the extra-hepatic tissues (Cali et 
al. 1991, Leitersdorf et al. 1994). Out of vitamin D hydroxylases, it is the most stable 
one, with the half-life of about 24 hours, ensuring a slow response to modulation 
(Stravitz et al. 1996). 25-OHase is suppressed by PTH, levels of which are increased 
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in CKD, ultimately resulting in diminished hepatic synthesis of 25(OH)D in uraemia 
(Michaud et al. 2010).  
 
1.3.3.2 1α-Hydroxylation: The 25-Hydroxyvitamin D 1-Hydroxylase  
(1α-OHase) 
 
 
Studies on VDR-knockout mice overexpressing 1α-OHase allowed cloning of 
CYP27B1 cDNA (Takeyama et al. 1997). Evidence from further genetics studies on 
humans shows that renal and extra-renal 1α-OHase arise from the same gene product 
giving rise to proteins with 501 to 508 amino acids. The gene CYP27B1 has been 
mapped to chromosome 12 and is split into nine exons (I-IX), where seven are of a 
similar size 170–200 bp encoding 57–67 amino acids each and two smaller ones, 
encoding 26 and 37 amino acids. The 1,25(OH)2D binding region is encoded by exon 
VI and the haeme-binding region, positioned around the cysteine residue that is 
present in all mitochondrial P450s is encoded by exon VIII. The intron size ranges 
from approximately 80 to 660 bp, overall making the CYP27B1 gene small in size 
compared with other mitochondrial cytochrome P450s. The intron/exon organisation 
is highly conserved across the genes coding for these enzymes (Diaz L. et al. 2000b, 
Fu et al. 1997, Monkawa et al. 1997, St-Arnaud et al. 1997).  1α-OHase protein is 
highly conserved between species and knockout in mice results in development of 
hypertension, cardiac hypertrophy, impaired cardiac function, together with an up-
regulation of the renin-angiotensin system in both renal and cardiac tissues (Zhou et 
al. 2008). 
1α-OHase is a mixed function oxidase, which reduces one atom of molecular oxygen 
to water and allows 1α-hydroxyl group to be stereospecifically attached to the A ring 
of the sterol – 25(OH)D, which produces 1,25(OH)2D (Midgett et al. 1973). The use 
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of a highly specific assay based on isotope-dilution mass spectrometry showed that 
human mitochondrial 1α-OHase has a maximal hydroxylation velocity (Vmax) of 1.7 
± 0.2 μM/min/mg protein and the apparent Michaelis constant (Km) of 14 μM  (where 
Km is a concentration of substrate required to reach half of the maximal velocity) 
(Hagenfeldt and Berlin 1992). These findings differ significantly from previous 
reports of Fu and co-workers, where the Km for 1α-OHase was found to be 0.27 μM 
(Fu et al. 1997). Other reports from studies using a cloned human 1α-OHase cDNA 
into E.coli JM109 showed values similar to those of Fu – 24,25(OH)2D had a lower 
Km value (1.1 μM) and higher Vmax, compared to 24(OH)D, Km (2.7 μM) and lower 
Vmax, which indicated that 24,25(OH)2D would be a better substrate for 1α-OHase 
than 25(OH)D (Sawada et al. 1999).  
 
Studies on rabbits, chicks and humans have shown strong 1α-OHase activity in the 
inner mitochondrial membrane of proximal tubule cells of the kidney (Akiba et al. 
1980, Brunette et al. 1978, Kawashima et al. 1981, Zehnder et al. 1999).  
 
The important regulators of renal 1α-OHase activity are 1,25(OH)2D, PTH, FGF-23, 
calcitonin, dietary calcium and phosphate, and also other steroidal hormones such as 
estrogen. Studies on kidneys of intact animals and human proximal tubule cells 
(HKC-8) cells have shown that 1,25(OH)2D3, calcium and phosphate inhibit 
CYP27B1 mRNA and stimulate increase in CYP24A1 gene transcription (Bland et al. 
1999, Murayama et al. 1999, Rosenthal et al. 1980, Zierold et al. 2000).  The exact 
mechanism may involve regulation of the promoter activity leading to a decrease in 
mRNA or an indirect transcriptional process or post-transcriptional/post-translational 
modifications. Further, experiments on parathyroidectomised animals have 
demonstrated diminished 1α-OHase activity and consequently PTH treatment has 
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been shown to induce CYP27B1 levels above basal (Armbrecht et al. 2003, Booth et 
al. 1985, Walker et al. 1990). Increase in PTH induces cAMP and the probol esther 
protein kinase C (PKC) in renal cells, which results in induction of CYP27B1 
expression (Armbrecht et al. 2003, Dunlay and Hruska 1990). cAMP and forskolin, 
(which is a labdane diterpene, a chemical produced by a plant Coleus forskohlii 
previously shown to strongly induce adenylate cyclase) both independently exert the 
same action on 1α-OHase (Fukase et al. 1982, Henry H. L. 1985). PKC activator – 
TPA, also mimics the action of PKC in rat model, but not in the chick, where 1α-
OHase and 24-OHase inhibition has been observed (Ro et al. 1992, Tang C. et al. 
1993). The inhibition of 1α-OHase expression by 1,25(OH)2D and TPA has additive 
effect, indicating that both regulators act via distinct pathways. Previous studies in 
vitro and using normocalcaemic rat models have shown contrary data as to the effect 
of calcitonin on renal 1α-OHase. In human, calcitonin appeared to upregulate 1α-
OHase promoter, similarly in rats, 1α-OHase expression was increased, but VDR 
levels dropped (Shinki et al. 1999, Yoshida N. et al. 1999). Opposite results or no 
change were reported in a number of in vitro studies, suggesting that the regulation 
of calcium homeostasis by calcitonin may require actions of other elements present 
in the circulation (Henry HL. et al. 1982 , Larkins et al. 1974, Rasmussen et al. 
1972).   
1.3.3.3  24-Hydroxylation: The 1,25-Dihydroxyvitamin D 24-Hydroxylase 
 (24-OHase) 
 
 
The human 24-OHase gene CYP24A1 has been mapped to chromosome 20 at q13.2-
q13.3 (Labuda et al. 1993). It is about 15 kb in length and so far, no known diseases 
have been linked to this gene. Just like 25-OHase and 1α-OHase - 24-OHase is also a 
mixed-function monooxigenase. It metabolises 25(OH)D to 24,25(OH)2D 
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(significant serum levels of 2-5 ng/ml; 1/5
th
 to 1/10
th
 of the 25(OH)D concentration) 
and 1,25(OH)2D to 1,24,25(OH)3D (concentration thought to be insignificant). The 
catalysis involved binding oxygen and directing the regiospecific and stereospecific 
hydroxylation and oxidation of secosteroid substrate molecule utilising electrons 
obtained from NADPH (Ohyama and Okuda 1991). Previous enzyme kinetics studies 
have shown that Km values for 1,25(OH)2D are 1/4 to 1/30 that of 25(OH)D, 
indicating that 24-OHase has higher preference for 1,25(OH)2D. Other studies have 
shown directly opposite results, which may be explained by the sequestrial-
multicatalytic properties of 24-OHase together with the effect of the electron transfer 
and dissociation of intermediate reactants from the enzyme (Taniguchi et al. 2001).  
 
The 24-OHase is expressed in a variety of VDR-expressing tissues, including kidney, 
intestine, bone, macrophages, and keratinocytes as well as in colon, prostate and 
mammary cancers (Akeno et al. 1997, Fischer et al. 2009, Lechner et al. 2007, 
Ornoy et al. 1978, Overbergh et al. 2000, Xie et al. 2002, Yang et al. 1999). It 
localises to inner mitochondrial membrane, just like 1α-OHase (Ohyama and Okuda 
1991).  
 
Due to its broad tissue distribution, the expression of CYP24A1 is influenced by a 
vast range of regulatory agents. In kidney and osteoblasts 1,25(OH)2D is the 
strongest inducer of CYP24A1 (Figure 1.5). Studies of CYP24A1 rat promoter 
revealed 2 tandem-arranged VDREs constitute the CYP24A1 promoter. VDRE-1 and  
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Figure 1.5: The endocrine effect of 1,25(OH)2D on Vitamin D Receptor (VDR), 1α-
Hydroxylase gene product (CYP27B1) and 24-Hydroxylase gene product 
(CYP24A1). (+) induction, (-) inhibition. 
 
 
 
VDRE-2 were found on the non-coding strand, about 100 bp apart. Low expression in 
the absence of 1,25(OH)2D is maintained by a repressor complex bound to 
unliganded VDR/RXR. When 1,25(OH)2D is abundant, it binds to VDR, it is thought 
that the repressor complex dissociates and is replaced by the co-activator complex 
with the histone acetyltransferase (HAT) activity, which role is to unwind the 
chromatin, to ultimately be replaced by the mediator complex (Sutton and 
MacDonald 2003).  This last step would stimulate interaction with RNA polymerase 
II and ultimately induce CYP24A1 gene transcription (Omdahl J;  May, BK; 2005, 
Vidal et al. 2002). Recent studies demonstrated a micro RNA (miRNA) miR-125b 
recognition element (MRE125b) in the 3'-untranslated region of human CYP24A1. 
Using normal and cancerous breast tissue it has been confirmed that CYP24A1 
mRNA can also be affected by dysregulated miRNA (Komagata et al. 2009). 
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1.3.3.4 Other Metabolic Pathways 
 
 
There are numerous other complex vitamin D metabolic pathways, but the 
physiological significance of some is yet to be clarified.  Over 30 vitamin D 
metabolites have been identified, but only some of them have been shown to be 
biologically active. 24-OHase can use both 25(OH)D and 1,25(OH)2D as substrates 
and for both can catalyse reactions at carbon 23 (C-23) as well as C-24. 24-OHase 
can produce at least 18 forms of metabolites in human (Corvol et al. 1978, Henry H. 
L. and Norman 1978, Ornoy et al. 1978, Sakaki et al. 2000, Shima et al. 1990). The 
enzyme was initially shown to be able to induce three successive oxidations – two at 
carbon C-24 and one at carbon C-23, producing an intermediate that is further 
cleaved to calcitroic acid (from 1,25(OH)2D substrate), a metabolite that is thought to 
have very low biological activity (Beckman et al. 1996). More recent studies 
confirmed that C-23 hydroxylation pathway of 25(OH)D in fact consists of four-step 
monooxygenation. Below are pictured the two parallel pathways of 25(OH)D and 
1,25(OH)2D catabolism by 24-OHase (Figure 1.6) All four reactions occurring on 
the side chain are the same and are catalyzed by a single active site on 24-OHase 
(Henry H. L. 2011, Sakaki et al. 2000).  
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Figure 1.6: The reactions facilitated by the 25(OH)D-/1,25(OH)2D-24 Hydroxylase 
(24-OHase). 24-OHase catalyses catabolism of both 25(OH)D and 1,25(OH)2D, two 
parallel pathways are pictured. Reproduced with permission from (Henry H. L. 2011)  
 
Recent evidence indicates that a single specific mutation in CYP24A1 converts 
human 25(OH)D 24-OHase into 23-OHase, generating 1,25(OH)2D-26,23-lactone 
(Prosser et al. 2007). It has been suggested that some 24-OHase metabolites can be 
potent VDR antagonist (Ishizuka et al. 2005, Toell et al. 2001, St Arnaud R. 2010). 
 
1.3.4 Knockout in Animals  
 
1.3.4.1 VDR Knockout 
 
Critical analysis of mice with engineered deletion of VDR gene, allowed re-
evaluation of the specific mode of action and the spectrum of activities of 
1,25(OH)2D and its metabolites. The VDR expression is ubiquitous in both mice and 
human cells, with almost all cells responding to 1,25(OH)2D. Most astonishing is the 
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fact that approximately 3% of the mouse and human genome is regulated by the 
vitamin D hormonal system.  
VDR-knockout mice exhibited a normal phenotype at birth. With age their growth 
retards and mice develop hypocalcaemia, hypophosphataemia, secondary 
hyperparathyroidism, severe rickets and osteomalacia (Li et al. 1997, Van 
Cromphaut et al. 2001, Yoshizawa et al. 1997). Despite the lack of functional VDR, 
serum levels of 1,25(OH)2D levels were increased (increased 1α-OHase activity and 
decreased 24-OHase activity) due to secondary hyperparathyroidism (Amling et al. 
1999, Yoshizawa et al. 1997).  
Further, VDR (or CYP27B1) knockout in mice that were subsequently maintained on 
a rescue diet resulted in hyperproliferation of distal colon cells, as measured by 
increased levels of cyclin D1. Furthermore, it also lead to the direct DNA damage, as 
evaluates by increased levels of 8-hydroxy-2-deoxyguanosine (Kallay et al. 2002, 
Kallay et al. 2001). Other studies using VDR or CYP27B1-knockout mice 
demonstrated that skin of these animals was significantly more prone to 
tumorigenesis, following oral administration of carcinogen. The skin of VDR-
knockout mice not exposed to carcinogen, aged faster, become wrinkled and cystitic 
(Zinser et al. 2002). VDR ablation has been positively correlated tumour growth in 
epithelia of the mammary gland (Welsh 2004). Tumor development in ovary, uterus, 
lung, or liver was not different between VDR wild type and VDR-knockout mice. 
Interestingly, lung metastatic cancer growth was hugely reduced in VDR-knockout 
mice, which may suggest that optimal VDR signalling may contribute to suppression 
of carcinogenesis (Nakagawa et al. 2004).  
Importantly, there is a clear relationship between the presence of a functioning VDR 
and healthy vasculature, as VDR knockout in mice resulted in the development of 
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hypertension, elevated trombogenicity and cardiac hypertrophy (Bouillon et al. 
2008). 
1.3.4.2 CYP27B1 Knockout 
 
 
Mice with engineered deletion of CYP27B1 gene phenotypically resembled those 
with VDR gene knockout. Both displayed severe hypocalcaemia and 
hypophosphotaemia. Conversely to VDR-knockout mice, in mice with deficient 
CYP27B1 the serum 1,25(OH)2D levels were undetectable and 25(OH)D levels were 
elevated. Also, 24,25(OH)2D levels were decreased compared to VDR null mice 
(Dardenne et al. 2003, Panda et al. 2001, Rowling et al. 2007, Van Cromphaut et al. 
2001). Similar observations have been made in patients with pseudovitamin D-
deficiency rickets (Balsan et al. 1986, Kitanaka et al. 1998).  
 
The protective effect of 1,25(OH)2D on vasculature was demonstrated, during studies 
of the Wistar rat aorta organ culture. Data revealed that the treatment with 
1,25(OH)2D had an effect on myosin production, overall enhancing contractility 
(Ishibashi and Bukoski 1997). More recent evidence from studies on CYP27B1- 
knockout mice suggests that administration of 1,25(OH)2D3 not only normalised 
serum calcium and phosphorus levels, but also normalised blood pressure, cardiac 
structure and function and the renin-angiotensin system (Zhou et al. 2008).  
 
1.3.4.3 CYP24A1 Knockout 
 
 
CYP24A1 knockout animal models include mice, rats, pigs and chicks (Akeno et al. 
1997, Chen K. S. et al. 1993, Jehan et al. 1998, Ohyama et al. 1991, Zierold 2001). 
There are no known human diseases that can be attributed to CYP24A1 gene 
deficiency. CYP24A1-knockout mice suffer from severe hypercalcaemia and 
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nephrocalcinosis, due to excess of 1,25(OH)2D that simply cannot be catabolised. 
They also exhibit excessive undermineralised bone matrix and hardly ever survive 
past neonatal period (Hock et al. 1986). This was readdressed in a recent study in 
mice, which demonstrated that maintaining normocalcaemia is more important than 
skeletal integrity, and that to minimize skeletal calcium storage, 1,25(OH)2D not 
only increases calcium release from bone, but also stops calcium from being 
incorporated in bone (Lieben et al. 2012). Mice that survive weaning display 
inefficient clearing of the exogenous 1,25(OH)2D compared to wild type mice, where 
hormone is eliminated between 6 and 12 hours. Interestingly, 25(OH)D serum levels 
are very low in CYP24A1 deficient mice. Treatment with 25(OH)D does not result in 
24,25(OH)D formation, as opposed to wild type mice. Also, both VDR-knockout 
mice and CYP24A1-knockout mice fail to catabolise 1,25(OH)2D, indicating the 
importance of the 1,25(OH)2D-inducible, VDR-mediated, C-24 oxidation pathway 
(Masuda et al. 2005). 
 
 
1.4 Regulatory Processes - Endocrine Vitamin D and Mineral 
Homeostasis 
 
1.4.1 Calcium and Phosphate Homeostasis 
 
 
Minerals from the diet are essential for our survival. The process of their uptake and 
mineral “re-shuffling” is controlled by intestine, bone, kidney, parathyroid and their 
hormones 1,25(OH)2D, parathyroid hormone (PTH), fibroblast growth factor 23 
(FGF-23) and calcitonin, which regulate the homeostasis. Most of them act via 
specific receptors, such as: 1,25(OH)2D binds to VDR, calcium – calcium sensing 
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receptor (CaSR), PTH – PTH receptor (PTHr), FGF-23 – FGF receptor (FGFR) and 
co-factor Klotho, calcitonin – calcitonin receptor; specific receptor for phosphorous 
is unknown. Calcium and phosphorus are of particular importance – they both build 
our skeleton and create a buffer in extracellular fluids. Human body contains about 
1000 grams (g) of calcium and about 600 g of phosphate. 99% of total calcium and 
85% of total phosphorus is present in the skeleton in the form of hydroxyapatite 
(HAP) and crystalline, respectively. The rest - 1% of total calcium and 15% of total 
phosphate are present in extracellular fluid at saturation point (kept in solution by 
various molecules) and soft tissues acting as an essential buffer. Multiple cellular 
processes such as muscle contraction, relaxation, functioning of nervous system, 
cellular transport, blood clotting and many more are dependent on very tight 
regulation of free ionised calcium (Ca
2+
: 1.13- 1.34 mM). Importantly, intracellular 
calcium can also act as a second messenger in many intracellular responses to 
chemical and electrical stimuli and required by various enzymes for full activity. The 
concentration of intracellular calcium is strictly controlled through action of calcium 
channels, calcium pumps and calcium exchangers. Ionised calcium is not distributed 
throughout the whole cell, but mostly localized to sarcoplasmatic reticulum in 
muscle, Golgi apparatus and mitochondria, which act as intracellular calcium stores. 
Intracellular heterogeneity of calcium, in form of calcium sparks or calcium waves is 
observed in a range of cells (myocardium, hepatocytes, oocytes and more) (Camacho 
and Lechleiter 1993, Cobbold et al. 1983, Pinton et al. 1998, Rooney et al. 1990, 
Takamatsu et al. 1991). Extraskeletal phosphate is present either in the form of 
inorganic phosphate ions or esters, serving as body’s energy storage (inositol 
trisphosphate, cyclic adenosine monophosphate (cAMP), and cyclic guanosine 
monophosphate). Phosphate is also present in DNA, cell membranes’ phospholipids 
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and is essential in signalling cascades where it acts as a regulator of protein function. 
Crucially, calcium and phosphorus product (Ca x PO4) is maintained constant, and so 
for instance any decrease in calcium concentration results in an increase in phosphate 
ions.  
1.4.1.1 Calcium and the Hormones Involved 
 
 
The daily intake of calcium is about 1000 mg, which is comparable with consuming 
a litre of milk. Of that, approximately 300 mg is absorbed through the small 
intestine; 150 mg is secreted through the gut, giving a net absorption of 150 mg for a 
healthy adult (Barger-Lux et al. 1989, Mallette 1989, Yanagawa 1992). Ionised 
calcium in blood is under tight regulation of PTH, which is an 84-amino acid peptide 
with a half life of less than 4 minutes, that is synthesised by the chief cells of the 
parathyroid gland (Segre et al. 1974). When calcium concentration is high, PTH 
increases to counterbalance the changes. This negative feedback is mediated by the 
extracellular Calcium Sensing Receptor (CaSR), which belongs to the family of G-
protein coupled receptors. The biological actions of PTH in regulating calcium 
homeostasis are exerted via binding to the PTH receptors and involve: stimulation of 
osteoclastic bone resorption and release of calcium and phosphate from bone, 
stimulation of reabsorption and inhibition of phosphate resorption from the renal 
tubules and stimulation of renal production of 1,25(OH)2D, which in turn, increases 
intestinal absorption of calcium and phosphate.  
Another hormone involved in calcium regulation is calcitonin – a 32-amino acid 
peptide, that is secreted by the parafollicular cells of the thyroid gland (Deftos 1993). 
Any increase in ionised calcium concentration induces secretion of calcitonin, which 
binds to calcitonin receptor and inhibits osteoclastic bone resorption via cyclic cAMP 
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pathway. Interestingly, aparathyroid patients do not experience alterations in calcium 
homeostasis, suggesting that this hormone may play a role in fine-tuning, i.e. 
additional but non-essential, rather than tight regulatory exerted by PTH.  
Lastly, the steroid hormone 1,25(OH)2D, as mentioned earlier is critical for calcium 
homeostasis. After hydroxylation in the liver, abundant 25(OH)D serves as a 
substrate for 1α-hydroxylation in the kidney to render the biologically potent form of 
the hormone -1,25(OH)2D, with a half-life of about 5 hours. This renal 1α-
hydroxyalation is the major control point in vitamin D metabolism and depends on 
local phosphate, calcium and PTH concentrations. When PTH and phosphate 
decrease, 1,25(OH)2D synthesis is  induced. It increases plasma calcium and 
phosphate concentrations by increasing the absorption of calcium from the intestinal 
tract. 1,25(OH)2D acts on bone to increase calcium resorption and on the nephron by 
enhancing the effect of PTH, also to increase calcium reabsorption (Norman A. W. et 
al. 1982).   
 
In healthy individual, the response to hypocalcaemia, i.e. a drop in ionised calcium 
concentration is instantly detected by the parathyroid glands, which respond by 
increasing the secretion of PTH. PTH increases osteoclastic bone resorption and, 
releasing calcium and phosphate from bone into extracellular fluid. At the same time, 
PTH also enhances renal absorption of calcium and inhibition of phosphate 
reabsorption. 1,25(OH)2D is stimulated by the rise in PTH, effect of which is further 
increase in the absorption of the dietary calcium and phosphate in the gut (Figure 
1.7). The exact opposite is observed in hypercalcaemia, where increase in ionised 
calcium leads to decrease in PTH secretion and 1,25(OH)2D synthesis, leading to 
increase in renal calcium secretion and decrease in intestinal calcium absorption. 
Increase in calcium concentration can also be detected directly by CaSR in the 
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kidney proximal tubule, which can then downregulate synthesis of 1,25(OH)2D by 
inhibition of 1α-OHase (Bland et al. 1999, Kantham et al. 2009). 
 
 
 
 
Figure 1.7: Hormonal response to hypocalcaemia leading to normocalcaemia. 
Ca
2+
 - ionised calcium, Pi – phosphate. When concentration of calcium in the serum 
drops, PTH levels increase, which leads increased bone resorption and release of 
calcium and phosphate from bone into extracellular fluid. Raise in PTH also 
stimulates 1,25(OH)2D, which acts on the gut to increase calcium absorption. 
 
1.4.1.2 Phosphate and the Hormones Involved 
 
 
Similarly to calcium, the daily intake of phosphate is about 1000 mg; 80% is 
absorbed in duodenum and jejunum and filtered through the kidney (Murer et al. 
2000). Renal proximal tubules are the major site of reabsorption of phosphate 
through three types of sodium dependent phosphate-co-transporters (Na-Pi-co-
transporters): NaPi-IIa, NaPi-IIb, NaPi-IIc, also called NaPi2a, NaPi2b, NaPi2c, 
respectively (Coloso et al. 2003, Takeda et al. 1999). NaPi-IIa is expressed 
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exclusively in the proximal tubules, whereas NaPi-IIb is expressed predominantly in 
the small intestine’s enterocytes. Regulation of transporters is exerted via actions of 
1,25(OH)2D, PTH, calcitonin and indirectly via FGF-23 (Katai et al. 1999, Kempson 
1996).  
 
Two main hormones, which control phosphate homeostasis, are PTH secreted by the 
parathyroid and FGF-23 produced by osteocytes and osteoblasts in bone. In normal 
physiology, low serum phosphate leads to inhibition of FGF-23 and induction of 
1,25(OH)2D, which increases phosphate uptake in the intestine and phosphate 
reabsorption from bone, and decrease in PTH, which facilitates phosphate uptake in 
the kidney (Figure 1.8). Conversely, high serum phosphate leads to increase in FGF-
23 and decrease in PTH, which reduce expression of NaPi-IIa and Na-Pi-IIc in the 
proximal renal tubules, ultimately reducing phosphate reabsorption and increasing 
urinary phosphate excretion (Bergwitz and Juppner 2010, Gattineni and Baum 2010).  
Furthermore, FGF-23 suppress expression of 1-OHase, leading to decrease in 
1,25(OH)2D levels in circulation, thus reducing intestinal calcium and phosphate 
absorption. There is also evidence that FGF-23 enhances the expression of CYP24A1 
mRNA (Quarles 2008, Shimada et al. 2004b).  
FGF-23 is a 30 kDa protein with 251 amino acids, which signals via FGF receptor 
(FRFR1 to 5) and Klotho co-receptor, that converts canonical receptor for FGFs, 
FGFR1 into a specific FGF-23 receptor (Urakawa et al. 2006). Presence of FGF 
receptors has been demonstrated in parathyroid, bone, kidney and vasculature, as 
well as in other tissues (Ben-Dov et al. 2007, Lim et al. 2012). In parathyroid FGF-
23 acts on the receptor complex to decrease PTH gene expression and PTH secretion 
by activation of MAPK pathway (Lavi-Moshayoff et al. 2010). In CKD both FGF-23 
and PTH are increased, suggesting resistance of parathyroid glands to FGF-23. PTH 
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increases 1α-OHase in the kidney and consequently 1,25(OH)2D synthesis. Recent 
evidence suggests that PTH induces expression and synthesis of FGF-23, which 
negatively controls 1,25(OH)2D level (Hasegawa et al. 2010, Imanishi and Kawata 
2005, Imanishi et al. 2012, Juppner 2011).  
 
 
Figure 1.8: Hormonal response to hypophosphataemia leading to 
normophosphataemia. Ca
2+
 - ionised calcium, Pi – phosphate.  When concentration 
of phosphate in serum drops, FGF-23 levels drop and 1,25(OH)2D is induced. 
1,25(OH)2D increases phosphate uptake in the intestine and reabsorption from bone, 
whereas decrease in PTH facilitates phosphate uptake in the kidney.  
 
 
1.4.2 FGF-23 and Klotho – Novel Regulators of the Vitamin D System 
 
FGF-23 and Klotho were studied separately until 2004, when Shimada and co-
workers discovered that Klotho-deficient mice and FGF-23 deficient mice share the 
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same phenotype (Shimada et al. 2004a). Klotho was first identified over a decade 
ago, as a gene mutated in a mouse that developed premature aging syndrome and its 
name has been attributed to Klotho – a Greek goddess, who spins the thread of life 
(Kuro-o et al. 1997). The homozygous double Klotho mutant mice had elevated 
serum levels of 1,25(OH)2D as well as increased calcium and phosphate  (increased 
phosphate resembling change observed in CKD) (Yoshida T. et al. 2002). The 
Klotho gene is mapped to chromosome 13q12 and contains 5 exons and 4 introns. It 
encodes a single pass transmembrane protein with the large extracellular domain 
containing two repeats (KL1 and KL2 domains). It is a member of the 1 glycosidases 
protein family. Due to alternative splicing, several isoforms of Klotho have been 
identified. Membrane bound (mb) Klotho, which has a molecular weight of 130 kDa 
is thought to be critical for FGF-23 signaling by forming a ternary ligand-binding 
complex with FGF receptors, as described earlier. 
To date, Klotho expression has been shown in distal renal tubules, proximal tubules, 
VSMCs and parathydoid glands (Komaba et al. 2010, Kuro-o 2009, Lim et al. 2012, 
Liu S. et al. 2008, Mian 1998).  Recent evidence suggests that in addition to the 
membrane bound form, Klotho also exists in a soluble (s) form (where membrane 
bound protein is post-translationally cleaved by disintegrin and metalloproteinase 
(ADAM) family- ADAM10 and ADAM17, and released in a 130 kDa and 68 kDa 
Klotho fragments or it is generated through alternative splicing of exon 3 resulting in 
translation of 80 kDa protein), which has been detected in serum, urine and cerebro-
spinal fluid (Imura et al. 2004, Matsumura et al. 1998, Saito et al. 1998, Wang Y. 
and Sun 2009). The role of sKlotho is different to the membrane-bound and involves 
regulation of the nitric oxide production in the endothelium, regulation of calcium 
homeostasis in the kidney as well as inhibition of intracellular insulin and insulin-
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like growth factor-1 (IGF-1) signalling and Wnt signalling (Chang et al. 2005, Imura 
et al. 2007, Kurosu et al. 2005, Liu H. et al. 2007, Saito et al. 2000, Saito et al. 
1998).   
In vascular endothelial cells the sKlotho has been shown to inhibit TNF-α induced 
expression of adhesion molecules, such as intracellular adhesion molecule-1 (ICAM-
1) and vascular cell. In the kidney epithelial cells of distal convoluted tubule, the 
KL1 and KL2 domains of Klotho have been shown to have β-glucuronidase 
properties, which allow hydrolisation of the extracellular N-glycans on the calcium 
channel, transient receptor potential cation channel, subfamily V, member 5 
(TRPV5). Cleavage of TRPV5 by Klotho entraps and activates the receptor at the 
plasma membrane modulating the intracellular calcium fluxes (Chang et al. 2005). 
Suppression of insulin/IGF-1 signalling results in induction of mammalian forkhead 
box O (FOXO) transcription factors, which are negatively regulated by insulin/IGF-1 
signalling. Conversely, activation of insulin/IGF-1 signalling induces 
phosphorylation and activation of serine-threonine kinase Akt, which inactivates 
FOXOs. Inactivation of insulin/IGF-1 signalling by Klotho allows FOXOs to bind to 
the promoters of anti-oxidant enzymes, including the mitochondrial manganese-
superoxide dismutase (SOD2) and induce their mRNA expression (Wang Y. and Sun 
2009). Therefore, it is not unreasonable to assume that Klotho may be directly or 
non-directly involved in the mitochondrial 1α-OHase or 24-OHase metabolism.  
The Wnt signalling is essential for stem cell proliferation, however when chronically 
stimulated, it can lead to rapid stem cell apoptosis. Klotho’s anti-aging properties are 
thought to be attributed to its ability to inhibit the Wnt signalling (Kuro-o 2008).   
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1.5 Paracrine -Autocrine Role of Vitamin D – The Non-Classical 
Effects   
 
1.5.1 Expression and Regulation 
 
 
Presence of extra-renal 1α-OHase was first documented in calvarial cells, then 
chondrocytes, keratinocytes and macrophages (Adams et al. 1983, Bikle D. D. et al. 
1986, Pedrozo et al. 1999, Schwartz Z. et al. 1992, Turner et al. 1980). More 
recently in cells of the hematopoietic system, pancreas, placenta, parathyroid, 
prostate, and brain (Bland et al. 2004, Diaz L. et al. 2000b, Ritter et al. 2012, Somjen 
et al. 2007, Zehnder et al. 2001). Levels of locally produced 1,25(OH)2D are difficult 
to measure, but it is known that disease-activated macrophages (e.g. tuberculosis) 
and placenta can produce high concentrations of 1,25(OH)2D, which can be detected 
in the circulation (Adams and Hewison 2012).  
 
Regulation of the extra-renal vitamin D hormonal system, in particular 1α-OHase is a 
growing area of research. Evidence demonstrates, that the renal and extra-renal 1α-
OHase is regulated differentially by the same stimuli. Below is the table compiling 
the results from a number of studies on regulation of 1α-OHase (it does not 
differentiate between mRNA, protein and activity) in kidney, macrophages, 
parathyroid and bone (Table 1.1).  
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Table 1.1: Regulation of the extra-renal vitamin D 1α-Hydroxylase. Parathyroid 
hormone (PTH), Fibroblast Growth Factor 23 (FGF-23), dihydroxyvitamin D3 
(1,25(OH)2D3), Interferon gamma (INF-γ), Tumour Necrosis Factor alpha (TNF-α). 
Increase (), decrease (), *conflicting evidence. Results represent expression of 
either mRNA, protein or enzyme activity. (Anderson et al. 2003, 2005, Anderson et 
al. 2010, Bacchetta J. et al. 2012, Dunlay and Hruska 1990, Gao et al. 2002, Ito et 
al. 2012, Samadfam et al. 2008, Tang W. J. et al. 2010, Wohrle et al. 2011). 
 
 
 
 
First significant difference concerns action of PTH  - in kidney it was shown to 
stimulate CYP27B1 expression (Dunlay and Hruska 1990, Gao et al. 2002) 
(conflicting evidence showed no effect of PTH on CYP27B1, suggesting that the 
enzyme is influenced by calcium, not directly by PTH (Anderson et al. 2003)). In 
macrophages PTH exerts no effect on CYP27B1 mRNA, neither does 1,25(OH)2D, 
nor calcium - classical regulators of the endocrine vitamin D system. Interestingly, 
1α-OHase activity was shown to be increased by inflammatory stimuli, such as INF-
γ and TNF-α (Adams and Gacad 1985, Pryke et al. 1990, Stoffels et al. 2006). 
Increased concentration of calcium inhibits the kidney CYP27B1, but stimulates the 
expression of CYP27B1 in parathyroid and bone. FGF-23 appears to not only 
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suppress renal 1α-OHase, as it was shown to exert the same effect in macrophages 
and bone. In parathyroid, on the other hand, FGF-23 stimulates the expression of 
CYP27B1 (Anderson et al. 2003, 2005, Anderson et al. 2010, Bacchetta J. et al. 
2012, Dunlay and Hruska 1990, Gao et al. 2002, Ito et al. 2012, Samadfam et al. 
2008, Tang W. J. et al. 2010, Wohrle et al. 2011).  
Similarly to 1α-OHase, the 24-OHase protein and mRNA is expressed in a variety of 
tissues, such as intestine, bone, parathyroid, skin and many more. It has also been 
found in colon, prostate and mammary cancers (Overbergh et al. 2000, Wood et al. 
2004, Xie et al. 2002, Yang et al. 1999).  
 
Nonetheless, the expression and regulation of extra-renal vitamin D hormonal 
systems will be addressed in more detail in individual results chapters.    
 
1.5.2 Local Actions 
 
 
1,25(OH)2D has been recognised to be involved in suppression of cell growth, 
regulation of apoptosis, control of differentiation in the skin and maintenance of 
healthy nervous system. It has also been shown to be an important regulator of the 
rennin-angiotensin system, insulin secretion in pancreas, angiogenesis, normal 
functioning of skeletal and heart muscle, cellular calcium homeostasis as well as an 
important modulator of both innate and adaptive immune responses.  
 
 
1.5.2.1 Proliferation and Differentiation 
 
 
VDR knockout studies on mice demonstrated increased colonic proliferation, as 
assessed by the proliferating cell nuclear antigen activity. Interestingly, heterozygous 
      1. General Introduction 
 
 35 
VDR
+/-
 mice exhibited a rate of proliferation that was intermediate between the 
knockout and wild type mice (Kallay et al. 2002). 1,25(OH)2D has been shown to 
induce cell cycle dependent kinase inhibitor p21, which stops action of cyclin-
dependent kinase 1 (CKD-1, responsible for cell cycle progression)  in many cell 
types and to ultimately cause an arrest at transition from the post mitotic gap 
checkpoint (G0/1) to synthetic phase (S) (Moffatt et al. 2001). 
Evidence shows that 1,25(OH)2D is also important in differentiation of the cells from 
the haematopoietic system into macrophages – cells from VDR knockout mice did 
not differentiate into macrophages upon treatment with 1,25(OH)2D, as opposed to 
the cells from the wild type animals treated in the same way (Gombart et al. 2006). 
Treatment of mouse keratinocytes with picomolar concentrations of 1,25(OH)2D 
increased cellular proliferation, whereas higher -nano to micromolar concentrations 
of 1,25(OH)2D stunned the growth entirely (Bollag et al. 1995). Interestingly, 
presence of 1α-OHase can also influence proliferation. It has been shown that when 
levels of 25(OH)D are too low to sufficiently activate VDR, cells expressing 1α-
OHase reacted to environmental stress by suppressing their growth (Barreto et al. 
2000). Conversely, cells lacking 1α-OHase did not exhibit such anti-proliferative 
action (Holick 2003).  There is no evidence of how high the local tissue 
concentrations of extra-renal 1,25(OH)2D can be, as they are almost impossible to 
measure. The locally produced 1,25(O)2D can overspill to circulation or other 
tissues. In tuberculosis, bacterial infection triggers formation of aggregates of white 
blood cells in various organs. These white blood cells contain macrophages, which 
overproduce 1,25(OH)2D, that in turn can overspill to circulation and surrounding 
tissue (Adams et al. 1983). 
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In bone basal CYP24A1 mRNA levels are very low and stimulation with 1,25(OH)2D 
leads to 400,000-fold induction. Also, in proliferating osteoblasts higher rate of 
1,25(OH)2D synthesis and, accordingly lower levels of 24-OHase have been reported 
(Anderson et al. 2003). It is possible that 24-OHase maintains low 1,25(OH)2D 
levels during proliferating phase, to diminish hormone’s antiproliferative activity, to 
then increase the levels of 1,25(OH)2D during the mineralisation phase (Ylikomi et 
al. 2002). In other extra-renal tissues 1,25(OH)2D has been shown not to have an 
inhibitory effect on the expression of keratinocyte 24-OHase, nor macrophage 24-
OHase (Overbergh et al. 2000, Schuster et al. 2001, Xie et al. 2002).  
The current knowledge in the area of local regulation of non-renal vitamin D system 
is not yet extensive. A consequence of which the research described in this thesis has 
been undertaken. What is known, is that 1,25(OH)2D and VDR interact with various 
transcription factors and cell signalling systems, which often are cell-specific and 
which influence cellular growth. Evidence shows that 1,25(OH)2D enhances 
expression of the androgen receptor and inhibits expression of the estrogen receptor 
(Zhao et al. 1999). It also binds to IGF-1 receptor and various IGF binding proteins 
in breast cancer cells (Demirpence et al. 1994). All of these actions can potentially 
induce p21 expression and growth inhibition (Boyle et al. 2001).   Other studies, 
primarily on colon, prostate or breast cancers have shown that treatment with 
1,25(OH)2D3 decreases abundance of EGFR (colon) (Tong et al. 1998), or increases 
mRNA and protein of transforming growth factor β (TGFβ) (colon, breast, 
keratinocytes) which have antiproliferative effect (Chen A. et al. 2002, Colston and 
Hansen 2002).  
1,25(OH)2D3 has also been shown to regulate angiogenesis i.e. the formation of new 
blood vessels from existing vasculature. Angiogenesis plays an important role in 
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tumour growth and metastasis, atherosclerosis, psoriasis and many other pathological 
conditions. Evidence from mouse model MCF-7 breast carcinoma studies indicates 
that 1,25(OH)2D3 inhibits VEGF-induced endothelial cell proliferation, suggesting 
the potential use of 1,25(OH)2D3 in both prevention and regression of pathological 
angiogenesis  (Mantell D. et al. 2000). 
 
1.5.2.2 Apoptosis 
 
 
Depending on the cell type, it has been reported that 1,25(OH)2D can either inhibit or 
lead to cell death.  In some colon cancer cell lines and retinoblastoma cells 
1.25(OH)2D was shown to upregulate the expression of pro-apoptotic B-cell 
lymphoma 2 associated X protein (Bax) and B-cell lymphoma 2 homologous 
antagonist (Bak), simultaneously downregulating the anti-apoptotic protein  Bcl-2 
and Bcl-XL (Beer et al. 2004, Diaz G. D. et al. 2000a, Wagner et al. 2003). Studies 
in breast cancer also demonstrated pro-apoptotic actions of 1,25(OH)2D, however via 
different mechanism – suppression of IGF receptors, upregulation of MAP kinase 
and inhibition of Akt kinase (Colston and Hansen 2002). On the other hand, in 
ovarian cancer 1,25(OH)2D was shown to prevent the death receptor-mediated 
apoptosis (Zhang X. et al. 2005). This demonstrates the scope of 1,25(OH)2D actions 
with respect to apoptosis may be vast and potentially depends on the cell specific 
receptors.  
1.5.2.3  Inflammation 
 
 
1,25(OH)2D has been shown to enhance the phagocytic and chemotactic capacity of 
macrophages and to increase the pro-differentiating actions of monocytes, 
contributing to antibacterial and antiviral defences (Oh et al. 2009). Studies have 
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demonstrated that bacterial activation of Toll-like receptor 4 (TLR4) and Toll-like 
receptor heterodimers TLR2/1 in macrophages and monocytes results in upregulation 
of 1-OHase, VDR and other VDR-target genes, and leads to induction of 
cathelicidin antimicrobial peptide (CAMP) and β-defensin 2 and killing of 
Mycobacterium tuberculosis (Liu P. T. et al. 2006). The CAMP promoter –CAMP 
and β-defensin 2 promoter (HBD2) have recently been shown to have NF-κB binding 
sites, which highlights the involvement of vitamin D signalling in the innate 
immunity (Liu P. T. et al. 2009). Another native mechanism of pathogen detection 
and elimination involves detection of the microbial structures by expression pattern 
recognition receptors. Recent studies confirmed that VDR can directly induce the 
expression of the gene encoding receptor NOD2/CARD15 (nucleotide 
oligomerisation domain protein 2/caspase recruitment domain containing protein 15). 
Disruption of NOD2 signalling has been associated with Crohn’s disease, in which 
intestine becomes prone to microbial infection (Wang T. T. et al. 2010). 
What is more, 1,25(OH)2D was shown to inhibit the expression of co-stimulatory  
molecules (CD40, CD80, CD86) and major histocompatibility complex class II 
(MHC-II) on the cell surface of antigen presenting cells, ultimately leading to the 
inhibition of the production of inflammatory cytokines such as interleukin-12 (IL-
12). Through this action, the cell’s T-cell polarisation becomes shifted from a 
proinflammatory T helper 1 (Th1) to a protective T helper 2 (Th2) and regulatory T-
cell phenotype. This is enhanced by 1,25(OH)2D’s ability to directly modulate T-cell 
responses, by inhibition of Th1 and Th17 cytokines and up-regulation of Th2 
cytokines (Verstuyf et al. 2010).  
1α-OHase and 24-OHase promoter activities are tightly regulated also in 
inflammatory environment to maintain high levels of 1,25(OH)D. In macrophages, a 
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mechanism, which allows the maintenance of high local concentrations of 
1,25(OH)2D involves action of Stat-1α (signal transducers and activators of 
transcription -1α) which is normally induced by INF-γ and acts to inhibit the 
transcription of 24-OHase (Vidal et al. 2002). 
Cells of the immune system are a good model of auto/paracrine actions, as they are 
able to both respond and locally synthesise 1,25(OH)2D (Stoffels et al. 2007, Stoffels 
et al. 2006). This process is regulated differently from the one in kidney cells, with 
immune stimuli rather than calcaemic stimuli regulating levels of 1,25(OH)2D in 
inflammatory foci. Current evidence confirms that there are vast differences between 
regulation of renal and extra-renal 1α-OHase. For instance, 1α-OHase in sarcoid or 
cytokine activated macrophages, is not inhibited by 1,25(OH)2D3, calcium or PTH 
(Adams and Gacad 1985, Dusso et al. 1997, Gates et al. 1986). Induction of 1α-
OHase in these cells occurs by exposure to inflammatory stimuli, such as 
lipopolysacharide (LPS) or inflammatory mediators such as tumour necrosis factor 
alpha (TNF-α) or interferon gamma (INF-γ), often via NFκB signalling pathway. 
This suggests that the regulatory pathways involved in control of extra-renal 1α-
OHase may be different to those characterised in kidney. Regulation of renal and 
extra-renal 1α-OHase will be addressed in more detail, with regard to calcium, 
phosphate, TNF-α, INF-γ, interleukin -6 (IL-6), interleukin 17A (IL-17A), FGF-23 
and Klotho in the following results chapters.   
1.5.2.4 Regulation of Cellular Calcium 
 
 
Evidence shows that 1,25(OH)2D is involved in modulation of cytoplasmic signalling 
in some cell types, such as osteoblasts, cells of parathyroid gland and cardiac 
myocytes. In osteoblastic ROS 17/2.8 cells, it has been demonstrated that 
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1,25(OH)2D can act rapidly to exert exocytosis which couples with intracellular 
calcium increase. This occurs partially via activation of L-type calcium channels. 
Intracellular calcium increase in these cells has been further reported to activate Akt 
signalling, which suppresses apoptosis (Xiaoyu et al. 2007). On the other hand, in 
parathyroid 1,25(OH)2D-induced elevation in intracellular calcium,  activates the 
pro-apoptotic proteases, such as microcalpain and caspase 12 (Silver and Levi 2005).  
In cardiac myocytes, the rate and force of contraction is primarily mediated by the 
rate of calcium influx through calcium channels. VDR present in myocyte cell 
membrane has been shown to be involved in regulation of these calcium currents 
(Brette and Orchard 2003). 1,25(OH)2D induce the phosphorylation of protein 
kinase C (PKC) targets: phospholamban B and cardiac troponin I, which modulate 
intracellular calcium, accelerating muscle relaxation (Green et al. 2006).  
 
1.5.3 Vitamin D and Vasculature 
 
 
Data from microarray analyses revealed that the treatment of human bronchial and 
aortic SMCs with 1,25(OH2)D induced upregulation in genes involved in 
morphogenesis, cell growth, survival and  tissue remodelling (Bosse et al. 2007, Wu-
Wong et al. 2006b, 2007b). VDR is present in VSMCs in a number of 200-25,000 
copies per cell (Bouillon et al. 2008) and astonishingly it activates transcription of at 
least 103 genes in human, including plasminogen activator inhibitor-1 (PAI-1) and 
thrombospondin-1 (THBS1). It is also involved in down-regulation of the 
transcription of at least 78 genes, including those encoding PTH, PTHrP (autocrinely 
produced PTH related protein), and 1-OHase (Wu-Wong et al. 2007b).  
VSMCs respond to circulating levels of 1,25(OH)2D and PTH, which stimulate 
increase in adenylate cyclase activity, macrophage chemoattractant protein-1 (MCP-
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1), collagen, β-1 integrin, and cell proliferation. 1-OHase involvement in a local 
synthesis of 1,25(OH)2D and PTH levels in VSMCs, may be a protective mechanism 
from variations in circulating levels of these two hormones (Somjen et al. 2005), also 
the local synthesis can cater for the local requirements of 1,25(OH)2D and disconnect 
the systemic calcaemic and phosphataemic effects from the local ones.  Experimental 
evidence suggests that in VSMCs 1α-OHase is up-regulated in a dose dependent 
manner by estrogenic compounds, such as phytoestrogens and estradiol (Somjen et 
al. 2005). 
1.6 Chronic Kidney Disease (CKD) 
 
1.6.1 Definitions and Consequences 
 
 
The kidneys are the body’s main blood filtering organs, which regulate water and 
electrolyte content, but also act as endocrine glands. Through their ability to secrete 
hormones including 1,25(OH)2D they can regulate calcium metabolism and bone 
homeostasis. The functional unit of a kidney is a nephron, with each kidney being 
made up of 400,000 – 800,000, this number is inversely correlated with age and 
kidney health (O'Callaghan 2009). One functioning kidney provides enough adequate 
renal tissue to have no negative implications on patient’s health. However, in the 
case of a renal insult, tissue can become damaged and fibrose, which can 
subsequently lead to the development of chronic kidney disease (CKD) with the 
potential consequence of kidney failure (Longenecker et al. 2002).  
 
The definition of CKD relates to the reduced renal function or kidney disease of any 
form that has been present for a period of time, from months to years. It can be a 
consequence of primary or secondary forms of glomerular, tubulo-interstitial or 
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vascular disease in the kidney (Mangione and Dal Canton 2010). It is a progressive 
and irreversible condition, which is commonly associated with old age, type 2 
diabetes mellitus, hypertension and vascular disease. CKD is present throughout the 
world, with the prevalence reaching 15% in some countries, and still rising 
(O'Callaghan 2009). Progression of CKD in some patients may cause serious 
complications, resulting in the need for dialysis and kidney transplantation. The 
classification of CKD comprises of 5 stages (Table 1.2), each of which refers to an 
estimated glomerular filtration rate (eGFR), the estimated rate at which the fluid and 
small molecules, primarily creatinine are filtered by the glomerulus from the plasma 
before being reabsorbed (Sarnak et al. 2003).   
 
Table 1.2: Progression stages in CKD. Adapted from (Levey et al. 2003). 
 
 
 
In the UK eGFR is calculated using Modification of Diet in Renal Disease (MDRD) 
formula, which is based on serum creatinine, age, race, gender (eGFR= 175 x Serum 
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Creatinine
-1.154
 x Age
-0.203
 x [1.212 if African American] x [0.742 if Female], 
measured in ml/min/1.73 m
2 
(Levey et al. 1999). Stage 1 (eGFR>90) describes the 
mildest form, indicating onset of kidney disease, whereas stage 5 (eGFR<15) refers 
to most severe conditions, also described as ESRD, which often requires renal 
replacement therapy. 
It is however important to note, that eGFR is somewhat a one-dimensional 
parameter, as it only reflects a single aspect of a deteriorating kidney function. In 
order to have a fuller picture, it is also important to account for the endocrine failure, 
which is reflected by decrease in VDR activation, erythropoietin synthesis failure, 
changes in PTH etc.  
1.6.2 Clinical Impact – Mortality 
 
 
Life expectancy of patients with CKD, compared with healthy individuals is 
significantly decreased (Figure 1.9).   
 
Figure 1.9: Life expectancy across three age groups of patients with chronic kidney 
disease (CKD) Stage 3. Haemodialised (HD) and healthy controls (Schell et al. 
2013).  
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Despite increased mortality at older age and at haemodialysis stage, CKD remains a 
killer in all age groups, leading to premature death even in children. CVD starts early 
in the course of CKD and is the most common cause of death in pre-dialysis, dialysis 
and post renal transplantation patients, including children with CKD (Go et al. 2004, 
Herzog et al. 2007, Shroff R. 2011). It has been reported that 50% of individuals 
suffering from ESRD die from CVD (Wang A. Y. et al. 2003). 
CKD is more common among women than men and the likelihood of developing 
CKD increases with age (incidence of ESRD is higher in the adults over 65 years of 
age). Interestingly though, men are 50% more likely to progress to ESRD than 
women. Most important risk factors predisposing to CKD is diabetes, hypertension, 
CVD, obesity, high cholesterol and a family history of CKD. Acute kidney injury, 
infections, drugs or toxins can contribute to progression of CKD. In terms of 
ethnicity, Hispanics have 1.5 times the rate of kidney failure compared to non-
Hispanic whites (CDC 2010). In UK, Asian population is more likely to develop 
diabetes and consequently CKD, compared to British whites (Kerr 2012).  
 
1.6.3 Failure of the Vitamin D Hormonal System in CKD and its 
Consequences 
 
1.6.3.1 Endocrine Vitamin D Hormonal System 
 
 
The levels of 1,25(OH)2D fall with loss of renal function, which usually starts early 
(eGFR of around 60 ml/min/1.73 m
2
) resulting in high incidence of 1,25(OH)2D 
deficiency in CKD.  Defective 1,25(OH)2D production contributes to the onset of 
secondary hyperparathyroidism (sHPTH), which is a marker of increased mortality 
rates in kidney disease. Kidney failure causes phosphate accumulation in the serum. 
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Further, in response to that plasma FGF-23 levels increase steadily, as the CKD 
progresses, also contributing to the failure of the normal functioning of the vitamin D 
hormonal system by suppression of 1α-OHase. Increased levels of FGF-23 are 
synthesized in bone. FGF-23 binding to FGF receptor-Klotho complexes enhances 
the excretion of phosphate in kidney. However, it also inhibits 1α-OHase and 
stimulates 24-OHase in kidney, leading to decreased serum blood 1,25(OH)2D levels. 
Increase in FGF-23 leads to raise in PTH secretion by parathyroid, which results in 
the drop of 1,25(OH)2D and consequently, hypocalcaemia (Figure 1.10).  
 
 
Figure 1.10: Consequences of Chronic Kidney Disease (CKD) induced high levels 
of Fibroblast Growth Factor 23 (FGF-23) on vitamin D metabolism. (+) induction, 
(-) inhibition, (PTHR) parathyroid hormone receptor, (CYP27B1) gene encoding 
vitamin D 1α-Hydroxylase, (CYP24A1) gene encoding vitamin D 24-Hydroxylase. 
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As this process progresses, the bone-kidney-parathyroid axis becomes more 
disrupted, and resistant due to reduced tissue Klotho and also failure of the vitamin D 
hormonal system, which enhances hyperphosphataemia (Gutierrez et al. 2005, 
Hasegawa et al. 2010, Juppner 2011).  
To confirm the direct effect of FGF-23, studies in rats with induced, early-stage CKD 
were performed, which have showed that exogenous administration of FGF-23 
antibodies resulted in an increase in 1,25(OH)2D levels, a normalization of serum 
calcium concentration and a decrease in PTH (Hasegawa et al. 2010) 
Recent data suggest, that plasma concentrations of FGF-23 in ESRD can be elevated 
by several orders of magnitude (0-500 normal; 100 – 10,000 early stages of CKD; 
10,000 – 100,000 ESRD) (Gutierrez et al. 2005, Isakova et al. 2009, van Husen et al. 
2010). DMP1 (dentin matrix acidic phosphoprotein 1) is a negative regulator of FGF-
23. In CKD, levels of DMP1 are high, suggesting that the protein function is either 
attenuated or that the FGF-23 becomes resistant to its action. High FGF-23 levels 
have been associated with CKD, LVH and mortality (Jean et al. 2009). 
Administration of oral phosphate binders to prevent intestinal absorption or long-
acting PTH analogues have been proposed as potential ways of preventing CKD-
related FGF-23 increase (Juppner 2011). 
 
1.6.3.2 Paracrine/Autocrine Vitamin D Hormonal System 
 
In CKD, local activity of 1-OHase is attenuated and this results in failure of local 
production of 1,25(OH)2D. This may be attributed to high phosphate load, decreased 
numbers of nephrons induced by necrosis or apoptosis, as well as increased 
concentrations of FGF-23 in the serum of CKD patients (Coburn J W 1994, Portale 
et al. 1984, Zhang M. Y. et al. 2002).  
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1.7 Artery 
 
1.7.1 Normal Function 
 
Arteries are muscular and elastic tubes that transport blood under a high pressure 
exerted by the pumping action of the heart. By contraction (systole) and relaxation 
(diastole) of the heart vascular cells change the luminal diameter, which allows blood 
vessels to maintain a pulse pressure to transform a pulsating blood flow into a 
continuous flow for the peripheral tissue. During diastole, the pulse reflection allows 
a flow-back into the coronary arteries.  Systemic arteries carry blood from the heart 
through the smaller arterioles and capillaries to the rest of the body, whereas 
pulmonary arteries carry blood from the heart to the lungs.  
Arteries are composed of three main layers: external layer of connective tissue and 
elastic membrane called tunica adventitia, followed by the layer of SMCs – tunica 
media and internally located monolayer of endothelial cells resting on connective 
tissue and internal elastic membrane – tunica intima (Figure 1.11A). 
 
  
Figure 1.11: Cross-section of normal artery and schematic representation of 
vascular smooth muscle cell (VSMC) phenotypes present in the media. (A) 
Schematic representation of the layers of artery. (B) Different phenotypes of VSMC 
present in the media. 
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Systemic arteries are divided into two main types – muscular, which tend to be larger 
(>10 mm in diameter), and elastic, which tend to be smaller (0.1 – 10 mm in 
diameter) with corresponding differences in the proportion of these layers. Aorta, for 
instance is the main systemic artery, which is connected directly to the heart 
(approximately 30 mm in diameter) (Hager et al. 2002) It acts as an elastic buffering 
chamber behind the heart, modulating wall elasticity to regulate compliance (the 
Windkessel function) (Belz 1995). It branches out to form coronary arteries, which 
branch further out into the brachiocephalic artery, left common carotid and the left 
subcalvian arteries. Renal arteries (arteria renalis) are muscular and branch out of 
the abdominal aorta and have diameter of about 25 mm (Turba et al. 2009). The role 
of muscular arteries and arterioles is to regulate the blood reflection, distribution and 
conductance. 
1.7.1.1 Structural Components of the Artery and Their Role in Adaptation, 
Protection and Repair 
 
1.7.1.1.1 Endothelium 
 
Since endothelium is the most inner layer of the artery, it is submitted to continuous 
shearing forces of the circulating blood. It also is in constant contact with circulating 
cells and plasma components. Endothelial cells are smooth and elongated, contain 
myofibrils and renew every 2-6 years (Tedgui 1999). Their luminal surface is coated 
with glycoprotein coat forming glycocalix responsible for the anti-thrombogenic 
properties of this surface. ABO antigens, factor VIII antigen, and many others give 
endothelial cells distinctive immunologic characteristics (Tedgui 1999). Endothelial 
cells are packed tightly, connected by tight junctions forming zona occludens, which 
provides a tight seal, allowing 1-10% of luminal protein to penetrate into the wall 
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(Simionescu et al. 1976, Tedgui 1999). The movement of a material from the lumen 
into the vessel wall occurs via abundant pynocitic vesicles.  
 
1.7.1.1.2 Tunica Media and Smooth Muscle Cells 
 
The function of the medial layer of the artery is generation of force for 
vasoconstriction. This is due to the presence of thick layer of SMCs, embedded in the 
mesh of basal lamina and collagen fibrils, tied to a system of elastic fibrils. Factors 
that influence contraction and relaxation of SMCs are G protein-coupled receptors’ 
modulators, pressure, tension, agents acting on ion channels or signalling systems, 
growth factors and extracellular matrix components, cell adhesion molecules and 
integrins (Hunt 2002).  
There are many different phenotypes of VSMC, with contractile and synthetic 
representing two most distinct morphologies. Interestingly, the vastness of 
phenotypes translates into the diversity of functions (Figure 1.11B). What is more, 
VSMCs have a remarkable capacity to switch between phenotypes, also referred to 
as ‘phenotypic modulation’ (Hao et al. 2003). The main purpose of such biological 
plasticity is adaptation and repair. The contraction of VSMCs is involuntary and is 
regulated by the cytosolic calcium concentration, as well as the sensitivity of calcium 
of the contractile elements reacting to changes in the cell-surrounding environment. 
The contractile state is maintained by binding of hormones, neurotransmitters such as 
adrenaline and other auto/paracrine chemical signals to their receptors on the cell. 
The contraction then involves calcium influx to the cell, which is exerted via 
multiple mechanisms. The next step involves calmodulin binding and activation of 
myosin light chain kinase (MLCK), with calmodulin-MLCK complex catalysing 
phosphorylation of myosin light chains enabling actin-myosin interaction and force 
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generation. -actin is one of the most abundant proteins of the VSMC cytoskeleton, 
hence why it is often used as an endogenous indicator of phenotype (Hunt 2002). 
Healthy contractile phenotype of VSMCs is characterised by abundant proteins 
involved in the process of contraction, such as -actin, desmin and vimentin. Also 
cell morphology has a characteristic elongated, spindle like shape. During transition 
to secretory phenotype cells become more rounded and irregular in shape. 
Progressive changes in the cytoskeleton result in reduction of -actin and expression 
of specific transcription factors.  Secretory phenotype is a response to adaptation 
and/or repair – cells are capable of releasing matrix vesicles containing minerals or 
other unwanted compounds into the ECM in order to maintain intracellular 
homeostasis (Thyberg et al. 1997). 
1.7.1.1.3 Adventitia  
 
The cells of the adventitia are sparse and the majority are fibroblasts. The supply of 
oxygen and nutrients to adventitia and media is facilitated by a network of 
microvasculature - vasa vasorum (present only in larger arteries) (Heistad et al. 
1981). Adventitia also contains nerves, which regulate SMCs function; lymphatic 
network and perivascular connective tissue. Pericytes have enormous differentiation 
capabilities and depending on the need they can become fibroblasts, SMCs or 
macrophages. They are important in angiogenesis and have been implicated in the 
regulation of the blood flow (Peppiatt et al. 2006). 
 
1.7.2 Normal Regulation 
 
 
Arteries have a natural capacity to regulate lumen diameter in response to changes in 
the blood flow. Vascular endothelium plays an important role in regulation of 
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vascular homeostasis. One of essential functions of the endothelium is the synthesis 
and release of the vasodilator nitric oxide (NO) (Ignarro et al. 1987). NO is 
synthesized from the amino acid substrate L-arginine by the enzyme endothelial 
nitric oxide synthase (eNOS) (Palmer et al. 1988). In response to mechanical shear 
stress or binding of acetylcholine or bradykinin to their receptors, NO diffuses 
through the basal membrane to SMCs, where it initiates conversion of GTP to cyclic 
GMP through soluble guanylyl cyclase orchestrating VSMC relaxation, vasodilation, 
proliferation and permeability (Moncada 1993, Scott-Burden et al. 1993).  
 
1.7.3 Pathological Processes 
 
 
Chronic stress on vasculature can be caused by diabetes, smoking, infection, CKD. 
In principle, it can be divided into localised (effect of which may be atherosclerosis –
formation of atheroma, localised fat and cholesterol containing plaque in the intimal 
layer of the artery) and systemic (arteriosclerosis – loss of elasticity and 
consequently hardening of the arteries due to prolonged blood overload occurs 
typically in old age).  
Both atherosclerotic and arteriosclerotic changes may lead to calcification. 
Progression of intimal calcification can result in plaque dislodgement causing 
myocardial infarction, i.e. downstream occlusion of the artery. Small areas of 
calcifications with sparse calcium phosphate crystals seem to be more bioactive than 
larger calcification plaques, resulting in triggering an inflammatory response and 
eventually cell death (Ewence et al. 2008) 
Eutrophic inward remodelling is the physiological response to raised blood pressure. 
However, if the high blood pressure overpowers arteries’ ability to autoregulate, then 
a blood vessel, which is exposed to high stress, switches to replace eutrophic inward 
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remodelling with hypertrophy. Important modulators of tissue remodelling are matrix 
metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases 
(TIMPs). MMPs are collagenases with the ability to degrade polymerised, 
supramolecular collagen, that has been organised into fibrils (type I, II, III).  
 
1.8 Artery and CKD 
 
1.8.1 CKD and Consequences to Arteries and Heart 
 
Abnormal changes in the structure and function of the vasculature begin very early in 
the course of renal decline, regardless of age (Shroff R. 2009).  As kidney function 
reduces, the balance between salts and fluid alters affecting blood pressure. Increased 
blood pressure consequently contributes to higher tension of the artery wall. Further, 
the disrupted mineral homeostasis, i.e. lower capacity of maintaining minerals in 
solution contributes to ectopic soft tissue calcifications. Hormonal failure in CKD 
may be further exacerbated by local stressors, such as anaemia, hypoxia, low levels 
of circulating 1,25(OH)2D and increased inflammation.   
In hypertension and chronic uraemia, arterial stiffness increases blood velocity, 
causing vessel constriction and triggering myogenic response, which involves tissue 
remodelling, especially in smaller arteries (Khavandi et al. 2009). The signalling 
pathways involve modulation of transient receptor potential (TRP)-like channels 
(located mostly on plasma membrane, non-selectively permeable to cations such as 
sodium magnesium and calcium), changes in levels of diacylglycerol and protein 
tyrosine kinases, but also changes to intracellular calcium (Hill et al. 2006, Khavandi 
et al. 2009). 
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A study by Luksha (Luksha et al. 2011) analysed changes in peripheral arteries of 
ESRD patients undergoing haemodialysis. The group reported no NO contribution to 
flow, increase in asymmetrical dimethyl-L arginine (ADMA; inhibitor of NO, also 
referred to as ‘a ureamic toxin’) high expression of heat shock protein 70 and 27, no 
arterial remodelling and reduced arterial distensibility reflecting passive properties of 
the vascular wall. Loss of elasticity is also caused by the elastic fibre 
defragmentation and may be triggered by the arterial insults mentioned above, as 
well as a reduction in local and systemic calcification inhibitors, such as fetuin A, 
albumin and osteopontin (OPN), leading to pathological arterial stiffness (Schoppet 
et al. 2008) (Chung et al. 2009, Van Herck et al. 2009). Furthermore, it is thought 
that changes in vasa vasorum branching pattern, observed in arteriosclerosis may 
further contribute to vascular dysfunction (Mulligan-Kehoe 2010).  
 
Uraemia is an accumulation of waste products, normally excreted in the urine (urea, 
creatinin, phosphate) in the circulating blood, as a result of a diminished kidneys’ 
filtration ability in CKD patients. This is often observed together with low 
haemoglobin levels, low to normal calcium levels and abnormally high cytokine 
levels in the blood. Overall, uraemia associated alterations are observed mainly in 
high circulating volume and increased salt content in the blood. These biochemical 
and physical changes initiate development of arteriopathies, which are further 
aggravated by the ingress of cholesterol into the vessel wall as well as oxidation and 
modification of LDL cholesterol, mineral imbalance.  
What is more, ESRD is characterised by presence of low-grade systemic 
inflammation, which also causes damage to vasculature. Inflammation induced 
pathological changes within arteries are characterised by the expression of adhesion 
molecules, recruitment of inflammatory cells, activation and migration of VSMCs 
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and secretion of calcium pyrophosphate crystals. Importantly, in uraemia, changes 
also occur as a result of a disrupted endocrine hormonal system at two levels – first, 
being a result of the vasculature insult itself and second, being a consequence of an 
endocrine imbalance caused by kidney pathology in CKD. Taken together, all the 
insults to the arteries accompanied by decreased oxygen levels, which are common in 
uremic patients contribute towards structural changes in vasculature. Left ventricular 
hypertrophy (LVH), decreased capillary density, progressive cardiac fibrosis and 
osteoblastic transformation of VSMCs, all ultimately link with alterations in cell 
function, such as mitochondrial dysfunction, apoptosis, changes in extracellular 
matrix, build up of bone-forming proteins, eventually resulting in myocardial 
infarction (Talmor et al. 2008) (Schiffrin et al. 2007, Yerkey et al. 2004) 
(McCullough et al. 2008).  
   
1.8.2 Vascular Calcification and its Contribution to the Loss of Arterial 
Elasticity 
 
Calciphylaxis is a calcification of skin arterioles, an extreme form of medial 
calcification, which can occur as a consequence of dialysis. It is very rare (only when 
the skin barrier function is damaged and can be breached) complication of dialysis 
can ultimately cause local tissue death and lead to severe infections. Medial 
calcification of the peripheral arteries can be detected by increased pulse wave 
velocity, high cardiac load and lowered perfusion (London et al. 2003). Evidence 
suggests that in patients undergoing dialysis, changes are even more pronounced, as 
calcification can be present in the heart valves and even the myocardium. 
Widespread calcification leads to hardening of the arteries, which increases afterload 
and end-systolic left ventricular pressure during every heartbeat through decreasing 
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aortic compliance and premature repercussion of the systolic pulse wave. Taken 
together, these changes lead to ventricular dysfunction and predispose to sudden 
cardiac arrest (Shanahan 2006) (Merx et al. 2005). As mentioned before a known VC 
inhibitor Fetuin-A is an important player and patients on dialysis exhibit low serum 
levels of this crucial protein (Wang A. Y. et al. 2003). In vitro studies in Fetuin-A 
knockout mice, which spontaneously develop soft tissue calcifications, demonstrated 
that compared to wild type the myocardial calcium content increased by 60% and 
was associated with strong induction of profibrotic TGF-β as well as downstream 
collagen and fibronecting mRNA synthesis (Merx et al. 2005).  
 
1.8.3 What happens -Vascular Fibrosis and Calcification 
 
 
VSMCs play a crucial role in the pathogenesis of VC. The mechanism of VC in 
uremic milieu is complex and not fully understood. It is unclear whether intimal and 
medial forms of calcification are identical or if they have different inciting factors 
leading to the same common pathogenic process, which parallels bone formation 
(Moe and Chen 2008). Until recently it has been considered to be an entirely passive 
unregulated process occurring due to plasma supersaturated with Ca and Pi, resulting 
in accumulation of Ca x Pi product (crystals of hydroxyapatite [Ca10(PO4)6(OH)2], 
carbonated hydroxyapatite and amorphous calcium phosphate), mainly released by 
VSMCs and pericytes, enclosed in pinching-off vesicles (Reynolds et al. 2004) 
(Tanimura et al. 1986). So far, evidence demonstrates that the processes leading to 
increased calcification triggers transformation of VSMCs to an osteoblastic or 
chondrocytic phenotype. However, it has been argued that the transformation itself 
may be the cause of VC (Shanahan et al. 1999, Tyson et al. 2003). Which of these is 
the primary event remains inconclusive. Interestingly, the bone proteins, such as 
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runt-related transcription factor 2 (RUNX-2), osteonectin (OSN), osteopontin (OPN), 
bone sialoprotein, type I collagen, alkaline phosphatase (ALP) and sclerostin have 
also been identified in extra skeletal calcifications, indicating that tissues other than 
bone, in pathological conditions may resemble bone phenotype (Reynolds et al. 
2004, Schoppet et al. 2008, Thambiah et al. 2012, Zhu et al. 2011).  
 
1.8.3.1 The Mechanism of Vascular Calcification  in VSMCs 
 
 
Despite superaturation of all extracellular fluids with calcium and phosphate, in 
normal physiology, tissue mineralisation only occurs in bone. Bone mineralisation is 
a highly regulated process, which is initiated by hypertrophic chondrocytes releasing 
small matrix vesicles. The microenvironment of such vesicles allows nucleation of 
hydroxyapatite (HAP) crystals. The bone matrix is then mineralised by action of 
multiple mineralisation-regulating proteins. This phenomenon of selective 
mineralisation is attributed to the powerful mechanism of calcification inhibitors. 
 
Normal VSMCs, do not calcify when exposed to supraphysiological concentrations 
of calcium and /or phosphate in vitro for prolonged periods of time. Interestingly 
though, VSMCs from CKD patients (both pre-dialysis and dialysis) are hugely prone 
to calcification. It is thought that VSMCs which were previously exposed to CKD 
milieu, whereas in vivo or in vitro, incur phenotypic changes and become primed for 
calcification, when further exposed to high calcium and phosphate concentrations 
(Shroff R. C. et al. 2010). One of the phenotypic adaptations of CKD VSMCs is a 
production of matrix vesicles containing calcium, phosphate and their product HAP 
crystals. Vesicles are released from both normal and apoptotic cells as a stress 
response directed to eliminate excess of intracellular calcium or in response to other 
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damage (aneurysms, hypertension, atherosclerosis, 1,25(OH)2D toxicity). Body’s 
natural response to presence of calcium-loaded vesicles excreted from VSMCs is 
phagocytosis. If however phagocytosis is impaired in CKD, calcification may be 
exacerbated. Interestingly, in absence of supraphysiological calcium and phosphate, 
in vitro studies have demonstrated that vesicles are loaded with mineralisation 
inhibitors, such as Matix Gla protein (MPG) and fetuin –A which deprive vesicles of 
mineralising properties. When the balance between inhibitors and inducers of VC is 
altered, vesicles can acquire mineralising properties.  
Evidence shows that VSMCs are capable of producing the same transcription factors 
and proteins as bone, and can be induced to do so with high concentrations of 
phosphorus, uremic serum, high glucose, oxidized lipids, cytokines, and several other 
factors (Moe and Chen 2008). 
Transformation of VSMCs into osteoblast-like cells is an active process, progression 
of which is dictated by the balance between inhibitors and inducers on a local and 
systemic level, in presence of systemic changes such as high PTH and low 
1,25(OH)2D (Jono et al. 2000, Reynolds et al. 2004). The simple model of the 
mechanism of VC is illustrated in Figure 1.12.  
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Figure 1.12: The mechanism of Vascular Calcification in Chronic Kidney Disease 
(CKD). Graphic representation of the phenotypic changes within an artery, as CKD 
progresses. Histology: human artery stained with Alizarin Red; abundant calcium 
deposits (brown) localize to medial (M) layer of the artery, only in patient 
undergoing dialysis. Intima (I), Adventitia (A). 
 
 
 
According to some reports, phosphate, which extracellular concentrations are 
increased in CKD appears to be one of the most important inducers (Wu-Wong et al. 
2006c). These high levels of phosphate cause phosphate influx into the cell via the 
activation of type III sodium dependent phosphate co-transporters (Pit-1). This might 
be the trigger initiating the osteogenic process in VSMCs confirmed by the up 
regulation of RUNX-2 and the regulation of bone associated proteins such as 
osteopontin and osteocalcin. Others reported that calcium is a more powerful 
calcification inducer than phosphate, as for the fixed calcium and phosphate 
concentrations, increased calcium was more potent stimulus to induce calcification 
(Reynolds et al. 2004, Shroff G. R. et al. 2004). Osteopontin, osteoprotegrin, MGP, 
Smad-1 and nucleotide pyrophosphatase phosphodiesterase-1 (NPP-1) are known 
endogenous inhibitors of VC in VSMCs.  
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Fetuin-A and 1,25(OH)2D  (the latter via a direct effect) are thought to be important 
inhibitors of vascular calcification both locally and systemically and progression of 
CKD correlates with their low serum level. It is important to note that an indirect 
effect of 1,25(OH)2D, through increased absorption of calcium may lead to an 
increase in VC (Ketteler 2005).  The VSMC endogenous regulators of VC and those 
present in the circulation have been summarised on the following page (Figure 1.13) 
(Bucay et al. 1998, Hruska et al. 2005, Johnson et al. 2005, Jono et al. 2000, 
Kendrick and Chonchol 2011, Ketteler et al. 2003, Luo et al. 1997, Schoppet and 
Shanahan 2008, Schoppet et al. 2008). 
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Figure 1.13: Endogenous (VSMC) and circulating regulators of vascular 
calcification (VC). PPi – pyrophosphate (Bucay et al. 1998, Hruska et al. 2005, 
Johnson et al. 2005, Jono et al. 2000, Kendrick and Chonchol 2011, Ketteler et al. 
2003, Luo et al. 1997, Schoppet and Shanahan 2008, Schoppet et al. 2008).  
 
1.8.4 1,25(OH)2D and Vasculature 
 
 
Newly emerged data from microarray analyses revealed that the treatment of human 
bronchial and aortic SMCs with 1,25(OH2)D induced upregulation in genes involved 
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in morphogenesis, cell growth, survival and  tissue remodelling (Bosse et al. 2007, 
Wu-Wong et al. 2006b, 2007b). Failure of cardiovascular VDR activation results in 
hypertension, cardiac hypertrophy, accelerated atherosclerosis with vascular 
calcification and renal failure. 1,25(OH)2D is VDR’s natural ligand. However, a 
spectrum of selective and non-selective analogues has been discovered in recent 
years. VDRA (VDR activator or agonist: paricalcitol, doxercalciferol and many 
more) therapy mainly involves suppressive effect of the parathyroid gland and 
regulation of calcium and phosphorus absorption in the intestine and mobilization in 
bone (Andress 2007). This, however, in clinical reality is not free of side effects. 
Non-classical VDR activation (i.e. with the use of analogues or in the local tissues) is 
a fascinating concept and we are just starting to deepen our understanding in this 
area. Various different proteins are involved in the VDR activation and different 
VDR activators can evoke different effects depending on the cell type and tissue. 
Despite the fact that the same gene is present in all body cells, when 1,25(OH)2D 
binds to VDR in a proximal tubule cell, the proteins recruited in the transcription 
process vary from the ones present in, for instance, VSMC.  
 
Recent studies on ApoE mice, an established model of atherosclerosis, show that the 
treatment with 1,25(OH)2D3 and its less calceamic analogue paricalcitol resulted in 
elevation of VDR expression in aorta. However, the dose dependent study further 
showed that paricalcitol reduced TGF-β expression in plaques, as opposed to 
1,25(OH)2D3, which additionally contributed to significant VC and increase in 
expression of bone related proteins (Becker et al. 2011). 
 
 
      1. General Introduction 
 
 62 
1.8.5 Therapeutic Concepts: Vitamin D - Active Metabolite 
 
 
The first treatment for CKD, in 1970s, was with aluminium. A decade later routinely 
used therapeutic agent was calcium carbonate, followed by calcium acetate few years 
later. The action exerted by these compounds was binding to phosphate, aiding its 
excretion and reducing abnormally high levels. In the late 1990s, calcitriol became 
the treatment of choice for CKD stage 3 to 5, which significantly improved survival 
in CKD patients (Brown and Slatopolsky 2007, Kovesdy et al. 2008a).  
Since plasma concentrations of circulating 1,25(OH)2D are 1000 fold lower than 
those of 25(OH)D, with the half life of the active metabolite being substantially 
lower, the preferred metabolite measured in assays is the latter.  The optimal 
concentration of 25(OH)D ranges between 40 and 120 nM. This wide range causes 
confusion and is an effect of differences in endpoints (fractures versus serum PTH) 
and differences in the analytical methods measuring serum 25(OH)D (Dawson-
Hughes et al. 2005). 
The therapeutic concept of administration of an active metabolite came from 
understanding the molecular mechanism of vitamin D bio-activation by 1-OHase, 
mainly in the kidney. In CKD, levels of this essential enzyme are significantly 
reduced impairing the bio-activation process. This is likely due to the uraemic 
mineral and metabolic imbalance and consequently tissue apoptosis/necrosis. 
 
1.8.6 Vitamin D Therapy versus Cardiovascular Complications and 
Patient Mortality 
 
 
In humans, there are well-documented benefits of active vitamin D therapy, such as 
control of secondary HPT, cure of osteomalacia and osteitis fibrosa cystica, 
demonstrated in studies using bone biopsies (Dusso et al. 2005, Olgaard and Lewin 
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2006). What is more, the recent study by Kovesdy compared the association between 
mortality and calcitriol treatment in patients undergoing and not undergoing dialysis 
(CKD stages 3-5) and concluded that therapy with 1,25(OH)2D significantly 
improved survival of non-dialysis patients (Kovesdy et al. 2008b). 
 
The safe correction of 25(OH)D and 1,25(OH)2D deficiency are essential in 
improvement of the outcomes in CKD (Dusso 2010). According to the current 
KDOQI guidelines for bone metabolism and CKD initial evaluation comprises 
assessment of calcium and phosphorus metabolism. If needed, the use of phosphate 
binders is recommended. Further, it is recommended to establish levels of 25(OH)D 
to prevent or treat insufficiency or deficiency.  Levels of 25(OH)D <5 ng/ml or 
12nM are indicative of severe vitamin D deficiency, 5-15 ng/ml or 12-37 nM 
indicate mild deficiency and those of 16-30 ng/ml or 40-75 nM – 25(OH)D 
insufficiency. Supplementation with vitamin D2 is normally initiated in all three 
cases (usually stages 3 and 4 CKD), as even in case of 25(OH)D insufficiency it has 
been shown to reduce the frequency and severity of secondary HPT. In patients with 
more advanced CKD (stage 5) and in those undergoing dialysis, ergocalciferol or 
cholecalciferol (i.e. the nutritional replacement) is not recommended as kidneys’ 
ability to generate 1,25(OH)2D is hugely reduced. 
 
In stage 5 of CKD or in dialysis, guidelines recommend therapy with active vitamin 
D sterol, such as 1,25(OH)2D, alfacalcidol, paricalcitol or doxercalciferol. (Noordzij 
et al. 2005) (KDIGO 2009). Treatment with active vitamin D sterols rapidly lowers 
PTH levels in the serum, improves hyperparathyroidism, bone disease and 
muskosceletal symptoms. Major side effect of active vitamin D sterols, including 
1,25(OH)2D and alfacalcidol is increased intestinal absorption of calcium and 
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phosphorus, which leads to increased serum levels of those minerals, which 
eventually may contribute to hypercalcaemia, exacerbates hyperphosphotaemia and 
reduce bone formation (due to low PTH). In order to reduce or abolish these negative 
effects, novel analogues of 1,25(OH)2D have been developed (paricalcitol and 
doxercalciferol – available in USA; maxicalcitol and falecalcitol – available in Asia). 
Animal studies confirmed that maxicalcitol and paricalcitol are less calceamic and 
phosphataemic than 1,25(OH)2D, whilst effectively suppressing PTH (Nishii et al. 
1991, Sjoden et al. 1984, Slatopolsky et al. 1995). Despite some advantages, none of 
the currently used vitamin D analogues has the ability to selectively target specific 
tissues, such as kidney or vasculature, instead they induce systemic changes triggered 
by the endocrine vitamin D system, which in consequence exacerbates the disease 
progression.  
 
Observational studies demonstrate that both 1,25(OH)2D deficiency and toxicity are 
common in CKD, narrowing the therapeutic window. In terms of cardiovascular 
complications, vascular homeostasis is observed within a tight therapeutic range of 
1,25(OH)2D treatment, however both vitamin D deficiency and overdose cause 
vascular damage (Figure 1.14) (Querfeld and Mak 2010).  
 
1.8.6.1 Potential Toxic Effects 
 
 
Vitamin D toxicity is a result of excessive number of ‘free’ 1,25(OH)2D, unbound to 
DBP, when there is already an excess of other vitamin D metabolites (Vieth 1990). 
In rats, 1,25(OH)2D hypercalcaemia is detected, only once the total of all vitamin 
metabolites exceed approximately 20% of the binding capacity of DBP (Shephard 
and Deluca 1980).  
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Previous studies using animal models confirm that the degree of toxicity is correlated 
to hypercalcaemia, type and concentration of vitamin D metabolite used.  
 
 
Figure 1.14: Biphasic U curve representing vitamin D dosage (1,25(OH)2D3) in 
relation to cardiovascular complications in children with Chronic Kidney Disease 
(CKD). sHPT-secondary hyperparathyroidism. Adapted from: (Querfeld and Mak 
2010).  
 
 
For instance, studies on mice revealed that alfacalcidol is more toxic than 
1,25(OH)2D, as high doses lead to nephrocalcinosis (Crocker et al. 1985). 
Calcification following 1,25(OH)2D intoxication has been identified in the large 
number of tissues, particularly kidney, aorta, lung, heart and subcutaneous tissue 
(Bills 1954, Jones 2008, Vieth 1990). 
All, 1,25(OH)2D, 25(OH)D and 24,25(OH)2D increase levels of Ca-ATPase, enhance 
uptake of free calcium and increase cytosolic calcium levels in VSMCs, with 
1,25(OH)2D being three times more potent than the other two metabolites (Inoue and 
Kawashima 1988, Kawashima 1988). This may explain toxicity of 1,25(OH)2D, 
supplementation – coupled with hampered calcium buffering in CKD it may 
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contribute to accumulation of calcium and phosphate product initiating the process of 
vascular calcification and influencing arterial tone. Oversuppresion of PTH with 
active vitamin D can lead to the development of adynamic bone disease 
(Brandenburg 2008). Also, decreased activity of 1-OHase mentioned earlier, is not 
the main obstacle in the treatment of patients with CKD. Another problem is the 
occurrence of 1,25(OH)2D resistance due to lower VDR numbers, accompanied by 
toxic composition of uraemic serum interfering with 1,25(OH)2D-VDR binding to 
DNA (Patel et al. 1995). Supplementation with higher doses 1,25(OH)2D in this 
situation may result in hypercalcaemia, hyperphosphataemia, accumulation of high 
calcium-phosphate product, eventually leading to the development of VC and higher 
mortality risk.  
Some however disagree - it has been postulated that if high levels of 25(OH)D can 
bind directly to VDR, this may also be triggering a response (Lou et al. 2004). In one 
of his papers DeLuca supports this notion by arguing that 1,25(OH)2D is not 
responsible for toxicity, and that in fact toxicity is caused by vitamin D or 25(OH)D. 
The argument was supported by evidence that 1α-OHase null mice experienced 
identical toxicity to wild type and measurements confirmed that 1,25(OH)2D3 was 
not synthesized in the -/- mice, excluding 1,25(OH)2D3 as a toxicant (Deluca H. F. et 
al. 2010).   
 
1.9 Research Purpose  
 
Our understanding of molecular mechanisms underlying uraemic arteriopathies is 
still quite basic. VC is a consequence of uremic stress factors and failure of systemic 
and local protective mechanisms in the artery wall. Calcium and phosphate take a 
special place in this process, as they can cause VC and are also the main ingredient 
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for calcium apatite crystals found in VC. Clinical and animal data have suggested an 
important contributing factor for accelerated VC may be the failure of the vitamin D 
hormonal system. Also treatment modalities with VDR activators have been 
associated with improved cardiovascular survival, the mechanisms of action are not 
well understood. In particular, it is not known, how the endocrine and the vascular 
vitamin D hormonal system complement each other (Figure 1.15). This is 
particularly important in the context of known harmful effects after treatment with 
active vitamin D, resulting in increased serum calcium and phosphate. Targeted 
utilisation of the vascular vitamin D system could help us to make VDR activation 
more targeted. For this we first need to characterize the human vascular vitamin D 
hormonal system in health and disease.  
 
 
Figure 1.15: Schematic representation of the highly complex interactions between 
endocrine, para/autocrine and inflammatory control of the vitamin D system in 
Vascular Smooth Muscle Cells (VSMC). (+) induction, (-) inhibition, (?) effect yet 
to be determined. 
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1.9.1 Hypothesis  
 
 
We postulate that the targeted vascular VDR activation in human, in particular 
through local metabolic activation, is crucial for vascular health, in particular under 
stress conditions. We hypothesise that vascular vitamin D system in human is 
regulated differently to the endocrine vitamin D system and that its regulation is 
altered in CKD.  
 
Aims: 
1. Demonstration of the expression of the vitamin D system in healthy and CKD 
human artery and in VSMCs. 
 
2. Investigation of regulation of the vitamin D hormonal system by 1,25(OH)2D3 
in healthy and CKD  human artery and in VSMCs. 
 
3. Evaluation of regulation of the arterial vitamin D hormonal system by the 
classical endocrine vitamin D system regulators: calcium, phosphate and 
inflammatory cytokines (IL-6, IL-17A, TNF-α, INF-γ). 
 
4. Evaluation of regulation of the arterial vitamin D hormonal system by the 
novel endocrine vitamin D system regulators: FGF-23 and Klotho. 
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Chapter 2  
 
Materials and Methods 
 
 
 
 
 
 
2.1  Introduction 
 
The procedures described below have all been used within this thesis. Tissue (healthy 
human arteries, arteries from patients with chronic kidney disease and healthy human 
kidneys) was obtained with Ethics Committee (for vascular tissue: 05/Q2802/26; for 
kidney tissue: 10 /H12111/36) and Research & Innovation Department (for vascular 
tissue and for kidney tissue: DZ077810) approval (Appendix). Informed written 
consent was obtained from the patient before undergoing a nephrectomy or a kidney 
transplant at the University Hospital Coventry and Warwickshire NHS Trust, 
Coventry, UK.  
 
A significant part of my laboratory work included the optimisation of methods to 
detect and quantify the proteins described in this thesis in human tissue and cells. 
This extensive development work is explained in this chapter. 
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2.2 Cell and Tissue Culture 
 
2.2.1 Principle 
 
 
Primary cell cultures have been shown to be a valuable tool in cell biology and 
although they do not reflect the exact physiology of the originating tissue, evidence 
shows that in certain types of cells, including smooth muscle cells (SMC) the 
homology to originating tissue is maintained in the early passages. Smooth muscle 
tissue is found in the tunica media of large and small blood vessels and in the walls 
of hollow organs like the bladder and the uterus. All SMC have the same types of 
filaments, however, depending on the tissue of origin, they differ significantly in 
mechanical and physiological properties. Methods for culturing SMCs were 
published first in 1971 by Campbell, where original Medium 199 was used (Morgan 
et al. 1950). More recently vascular smooth muscle cell (VSMC) culture conditions 
have been optimised (Dartsch et al. 1990) and more advanced basal media are now 
commercially available (where final supplement concentration after addition to the 
medium is as follows: 0.5 ml/ml foetal calf serum (FCS), 0.5 ng/ml epidermal 
growth factor, 2 ng/ml basic fibroblast growth factor, 5 µg/ml insulin).  
 
2.2.2 General Methods 
 
 
All cell and tissue culture procedures were performed under sterile conditions in a 
Walker Class II Microbiological Safety Cabinet and all media sterilised. Cells in 
culture were visualised using a Nikon Eclipse TS100 inverted light microscope 
(Nikon, Surrey, UK). Cultures were maintained in a Heraeus HERAcell 150 
incubator (Thermo Fisher Scientific, Leicestershire, UK) at 37°C and humidified 
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atmosphere containing 5% CO2. All media and culture reagents were pre-warmed to 
37°C for at least 45 minutes before use. 
 
2.2.2.1 Primary Human Aortic Smooth Muscle Cell Culture 
 
 
Primary SMCs from healthy human aortas (Human Aortic Smooth Muscle Cells, 
HAoSMCs) were purchased from (TCS Cellworks, Buckingham, UK). They had 
been isolated from different donors and frozen by the supplier at the end of passage 3 
in a medium containing cryoprotectant. On arrival they were store in liquid nitrogen 
and each vial contained a minimum of 500,000 cells. The approximate doubling time 
in log phase, as assessed by the supplier, was 27-30 hours and a minimum of 15 
doubling times was guaranteed.  
 
The donors included in this study were:  
1) 16 year old female – (26274T) – four batches of cells used;  
2) 18 year old male (27766T) – two batches of cells used;  
3) 43 year old female – (28375) – three batches of cells used.  
 
For culture HAoSMCs, were thawed rapidly at 37C and transferred to a 75 cm2 
flask (BD Falcon) containing 20 ml of pre-warmed Basal HAoSMC medium (TCS 
Cellworks, Buckingham, UK). All cells were grown routinely in 25cm
2
 or 75cm
2
 
flasks. Cells were subcultured when they reached 75% confluency using Trypsin-
EDTA (0.05%) (Sigma-Aldrich, Dorset, UK). Cells were split 1:2 when 75% 
confluent. For experimental treatments, cells were trypsinised, pelleted and 
resuspended accordingly to seed approximately 2,500 cells per cm
2
 (cells from one 
75cm
 2
 flask were split equally between 12 wells of 6-well plates). Cells in individual 
wells (6-well plate) were counted using the haemocytometer in order to assure 
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optimally equal distribution across wells.  24h prior to treatments culture medium 
was replaced with serum-free DMEM/F12 medium containing 0.1% bovine serum 
albumin (BSA) (Invitrogen, Paisley, UK). Negative controls were included for each 
individual experiment, where vehicle was added (0.1% ethanol for 1,25(OH)2D3 or 
25(OH)D3 treatments or 0.1 % BSA for all other treatments). 
 
Long-term primary cell culture (high number of passages) may lead to phenotypic 
changes in cells. Untreated samples of cells from each passage from different donors 
were tested for content of α-actin, β-actin, (Figure 2.1) and VDR, 1α-OHase and 24-
OHase (Figure 2.2). As no significant changes were observed between passages 1- 
and 5, all experiments were performed between those passages.  
 
 
Figure 2.1 The α-Actin protein expression in HAoSMCs across the consecutive five 
passages and a microscopic view of a cluster of cells  in culture at passage 5.   
A) Expression of α-actin protein is unchanged between the passages, as 
demonstrated by Western blot analysis. Protein expression was normalized to levels 
of β-actin, n=3, p=non-significant (NS), as assessed by one-way ANOVA. B) 
Individual HAoSMCs in passage 5 of culture, cells appear elongated and spindle 
like, exhibiting features of a contractile phenotype. 
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Figure 2.2: The Vitamin D Receptor (VDR), 1α-Hydroxylase (1α-OHase) and 24-
Hydroxylase (24-OHase) protein expression across the consecutive five passages, 
in HAoSMCs. Protein expression of A) VDR B) 1α-OHase C) 24-OHase is 
unchanged between five passages, as demonstrated by Western blot analysis. Protein 
expression was normalized to levels of β-actin, n=3, p=non-significant (NS), as 
assessed by one-way ANOVA. 
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2.2.2.2 Human Proximal Kidney Tubule Cell (HKC-8) Culture 
 
 
Human Proximal Kidney Tubule Cells (HKC-8) were kindly provided by Dr 
Rosemary Bland (University of Warwick, UK) and were used as positive controls in 
Western blot analyses and VDR antibody validation experiments (isolation of 
nuclear protein and flow cytometry). Cells were maintained as previously described 
(Bland et al. 1999, Prie et al. 1995) in DMEM/F-12 medium supplemented with 5% 
foetal calf serum (FCS) and 2 mM glutamine. For assessment of mRNA, and protein 
expression, cells were transferred to defined medium, which consisted of 
DMEM/F12 containing the following additives: glutamine (2 mM), insulin (5 g/ml), 
transferrin (5 g/ml), Na2SeO3 (5 ng/ml), T3 (0.37 nM), epidermal growth factor (2.5 
ng/ml), and hydrocortisone (1 nM); Sigma Chemical Co., Poole, UK) for 24 h before 
adding specific treatment.  
2.2.3 Cell Counting 
 
 
Cells grown in 75cm
2
 flasks were split 1:2 when 75% confluent. For experimental 
treatments, cells were trypsinised, pelleted and resuspended accordingly to seed 
approximately 2,500 cells per cm
2
 (cells from one 75cm
 2
 flask were split equally 
between 12 wells of 6-well plates). Cells in individual wells (6-well plate) were 
counted using the haemocytometer in order to assure optimally equal distribution 
across wells.  
2.2.4 Arterial Explant Culture 
 
 
Fresh, surgically removed human renal and epigastric arterial rings (approx. 1-3 mm 
in length and 1-2 mm in diameter) were maintained as described in 3.1.1. Prior to 
treatment, arteries were equilibrated and washed for 1h in DMEM/F-12 containing 
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200 u/ml penicillin and 0.2 mg/ml streptomycin (Sigma-Aldrich, Dorset, UK) 
(Figure 2.3). 
 
 
Figure 2.3: Preparation of artery for organ culture. (A) Artery size relative to Petri 
dish (9 cm in diameter), with enlarged view of an artery cleared of fat. (B) Artery cut 
into approximately 0.3cm
3
 rings. (C) Explants suspended in control or treatment 
medium (120 μl/well). 
 
 
2.2.4.1 Quantification of Cell and Tissue Vitamin D Synthesis: 1,25(OH)2D3 
Enzyme Immuno Assay (EIA) 
 
HAoSMCs were grown in 12-well plates and maintained in basal culture medium 
with 5% FCS or DMEM/F-12 with 10% normal human serum (A mixture of sera 
collected from healthy individuals, UHCW, UK). Cells, which were grown in basal 
culture medium with 5% FCS were serum starved overnight by replacing the basal 
medium with DMEM/F-12. Cells, which were grown in presence of normal human 
serum, were washed three times with pre-warmed phosphate buffered saline (PBS) 
before treatment. All cells were treated with DMEM/F-12 with or without 100 nM 
25(OH)D3 for 5 h (Sigma-Aldrich, Dorset, UK).  Well volume was 400 μl. Where no 
25(OH)D3 was added, vehicle (0.1% ethanol) treated 5 h controls were set up. 
Supernatants were collected and stored at - 80°C. Cells were harvested on ice using 
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PBS with protease inhibitors (5 mM) (Sigma-Aldrich, Dorset, UK) and three freeze-
thaw cycles, as described later in 2.3.2.1   
 
Arteries from healthy individuals and patients with CKD were placed in 96-well 
plates and maintained in DMEM/F-12 with 200 IU/ml penicillin and 0.2 mg/ml 
streptomycin for one hour. Fresh DMEM/F-12 medium was added with or without 
100 nM 25(OH)D3 for 5 h. All supernatants were collected and stored at -80°C. 
Individual arterial rings were re-suspended in 120 μl of PBS with protease inhibitors 
and also stored at -80°C. 
 
1,25(OH)2D3 production (indirect assessment of 1α-OHase activity) will measured 
by Dr Guerman Molostvov using EIA (IDS, Boldon, UK).  
 
2.2.5 Reagents Used in Experimental Treatments 
 
 
The information on all of the reagents used in experimental treatments is listed in 
Table 2.1.  
Table 2.1: Reagents used in experimental treatments.  
 
Reagent Company, 
Catalogue Number 
 
Treatment Dose/  
Dose Range 
1,25 dihydroxyvitamin D3 Sigma Aldrich, D1530 0.1-100 nM 
25-hydroxyvitamin D3 Sigma  Aldrich, H4014 1-1000 nM 
Interleukin 6 (IL-6) PeproTech, 200-06 100-200 ng/ml 
Interleukin 17A (IL-17A) PeproTech, 200-17 200 ng/ml 
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Tumour Necrosis Factor α 
(TNF-) 
PromoKine C-63721 20 ng/ml, 400 U/ml 
Interferon γ (INF-) Sigma Aldrich, I3265 20 ng/ml, 400 U/ml 
Calcium Chloride 
Dihydrate 
Sigma Aldrich, 223506 1-3 mM 
β-Glycerol Phosphate 
Disodium Salt 
Pentahydrate 
Sigma Aldrich,50020 1-3 mM 
Klotho  R&D systems, 5334-KL 200 pM  
(0.025 µg/ml) 
Heparin Sodium CP Pharmaceuticals Ltd, 10 µg/ml 
Fibroblast Growth Factor 
23 (FGF-23) 
Pepro-tech, 100-52 5-100 ng/ml 
Phorbol 12-myristate 13-
acetate (PMA) 
Sigma Aldrich, P1585 30 μM 
PD98059 (MEK1 Inhibitor) Calbiochem, 513000 60 µM 
Coctail of Protease 
Inhibitors 
Sigma Aldrich, P8340  5 mM 
 
2.3 Western Blot Analysis  
 
2.3.1 Principle 
 
 
Western blotting is a sensitive technique used to identify and semi-quantify proteins 
in complex protein mixtures from cell or tissue samples. After separation of proteins 
by gel electrophoresis (Burnette 1981, Towbin et al. 1979) they are transferred to a 
suitable membrane (e.g. polyvinylidene fluoride- PVDF or nitrocellulose). Due to a 
spatial resolution, this method provides molecular weight information on individual 
proteins. Once proteins have been transferred onto a membrane, they can be stained 
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for visualisation and identified by N-terminal sequencing, mass spectrometry or 
immunodetection.  
 
There are many types of electrophoresis, such as negative gel electrophoresis, 
electrofocusing gel electrophoresis, etc., however the one used in this study was 
sodium dodecyl sulphate polyacrilamide gel electrophoresis (SDS-PAGE). SDS-
PAGE is carried out in the presence of sodium dodecyl sulfate as the primary 
solubilising and charge-conferring agent. SDS binds to linearised proteins, which 
results in even distribution of charge per unit mass, ultimately allowing separation by 
molecular weight during electrophoresis. Therefore SDS-PAGE is used to separate 
proteins accordingly to their electrophoretic mobility, which is a function of the 
charge of the polypeptide chain and its length. The mobility of the ions is pH-
dependent and the higher the pH, the faster the moving boundary (the more the 
system is able to separate low molecular mass proteins, at the expense of the 
separation of high molecular mass proteins). Conversely, the lower the pH, the more 
space is allocated to separate high molecular mass proteins, with the low molecular 
mass ones co-migrating with the ion boundary. The pH in gels is maintained by 
various buffers systems, with Tris-HCl being the most widely used. The first SDS-
PAGE was described by Laemmli over four decades ago (Laemmli 1970). Ever since 
then a variety of 2-D acrylamide gels have been developed, utilizing new polymers, 
such as Duracyl or changing the monomers from acrylamide and bis-acrylamide to 
Bis-acryloyl piperazine and acryloyl morpholine (Artoni et al. 1984, Rabilloud 
2010). A number of permutations in protocols and techniques exist, being constantly 
perfected, each optimised to separation and ultimately – detection of the proteins of 
interest.  
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2.3.2 Preparation of Protein for Western Blot Analysis 
 
2.3.2.1 Protein Isolation from Cells 
 
 
Three protein harvest buffers were tested: RIPA, modified-RIPA (Halford and 
Russell 2009) and PBS, all three with protease inhibitors, in order to subsequently 
achieve the optimal VDR, 1α-OHase and 24-OHase protein detection. Cells were 
placed on ice and washed three times with chilled PBS and any leftover PBS was 
carefully aspirated and discarded. Cells were solubilised in PBS with protease 
inhibitors and triple freeze-thawed by (25°C vs. -80°C) to facilitate the rupture of cell 
membranes. All lysates were centrifuged at 4000 g for 10 minutes to pellet the cell 
debris and the supernatant was collected for subsequent protein concentration 
measurement. Lysates were aliquoted and stored at -80°C.  
Test Buffers’ Constituents (all reagents were purchased from Sigma-Aldrich, Dorset, 
UK):    
  RIPA buffer  (Millipore, Nottingham, UK), constituents: 
 
- 1% Nonidet P-40 (surfactant, non-ionic detergent to extract proteins)  
- 0.25% Sodium Dodecyl Sulphate (surfactant, ionic detergent to extract 
proteins) 
- 50 mM Tris Hydrochloride (buffering agent prevents protein denaturation) 
- 150 mM Sodium Chloride (salt, prevents non-specific protein aggregation) 
- 1 mM Ethylene Glycol Tetraacetic Acid- EGTA (chelating agent) 
- 0.5 M Cocktail of Protease Inhibitors  
- 0.5 M Phosphatase Inhibitors 
- pH 7.4 
 
         Modified RIPA buffer (self-made), constituents: 
- 1% Nonidet P-40 
- 0.1% Sodium Dodecyl Sulphate  
      2. Materials and Methods 
 
 80 
- 0.5% Sodium Deoxycholate (surfactant, ionic detergent to extract proteins) 
- 50 mM Tris-Hydrochloride 
- 150 mM Sodium Chloride  
- 0.5 M Cocktail of Protease Inhibitors  
- 0.5 M Phosphatase Inhibitors 
- pH 8.0 
 
     PBS buffer (self-made), constituents: 
- Phosphate Buffered Saline (Potassium Chloride 2.7 mM, Sodium Chloride 137 
mM, Sodium Phosphate Dihadrate 10 mM, Potassium Phosphate 2mM) 
- 0.5 M cocktail of protease inhibitors 
- pH 7.4 
 
 
PBS with protease inhibitors optimally preserved protein and therefore was used 
routinely in 1α-OHase, 24-OHase and VDR experimental work (Figure 2.4). 
 
 
Figure 2.4: Selection of the optimal protein preparation method. Expression of 1α-
Hydroxylase (1-OHase), 24-Hydroxylase  (24-OHase) and Vitamin D Receptor 
(VDR) protein isolated from HAoSMCs in three different buffers (RIPA, PBS and 
modified RIPA, all with cocktail of protease inhibitors). Three separate cell lysates 
were prepared. Proteins were separated by 10% SDS-PAGE and Western blotted with 
1-OHase, 24-OHase or VDR antibodies. PBS with protease inhibitors appeared to 
be the optimal buffer, with visibly higher expression of protein, compared to other 
two buffers. 10 μg protein per lane, loaded in duplicate.  
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2.3.2.1.1 Protein Isolation from Cells for Subsequent β-Actin, α-Actin, Klotho, 
FGFR1, FGFR3, RUNX-2, ALP, Sclerostin Protein Detection 
 
The protocol was the same as described in 2.3.2.1 except that RIPA buffer containing 
protease inhibitors (5 mM) was used. 
 
2.3.2.2 Protein Isolation from Tissue 
 
 
Approximately 0.3cm
3
 of the required tissue was ground in liquid nitrogen in 0.2 ml 
of PBS containing a complete cocktail of protease inhibitors (5 mM) for the 
characterisation of (VDR, 1α-OHase and 24-OHase) or RIPA buffer with protease 
inhibitors (5 mM) for β-actin, α-actin, Klotho, FGFR1, FGFR3, RUNX-2, ALP and 
sclerostin protein using a homogeniser. The lysates were then freeze-thawed (three 
times, as mentioned previously for VDR, 1α-OHase and 24-OHase only) and 
centrifuged at 300 g for 10 minutes at 4C. The supernatant was collected, aliquoted 
and stored at -80C. 
   
2.3.3 Measurement of Protein Concentration 
 
2.3.3.1 Principle 
 
 
The total soluble protein concentration of cell extracts or tissue homogenates was 
measured using Bio-Rad Protein Determination Kit (Bio-Rad Laboratories, 
Hertfordshire, UK) with a standard curve constructed from BSA (0-1.4 mg/ml in 
either PBS or RIPA buffer). Due to a constant extinction coefficient over a 10-fold 
concentration range, a dye-albumin complex within the linear range could be 
obtained (Bradford 1976).  
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2.3.3.2 Method  
 
 
The reaction was performed in 96-well plate where the protein standard, or the 
samples of cell/tissue protein lysates (5μl/well) were mixed 1:5 with previously 
prepared alkaline copper tartrate solution (4:1, vol./vol. concentrate and buffer). 
Next, 200 μl of folin reagent was added to each well, placed on a plate shaker for 15 
seconds and incubated at 25°C for 10 minutes. Reduction of folin by the copper-
treated protein (tyrosine and tryptophan residues, but also cystine, cysteine, and 
histidine) produced a blue color. Absorbance at 650 nm was measured using a 
MultiScan Ascent plate reader (Thermo Electron Corporation), with background 
values determined by the working dye solution with no protein.  
 
2.3.4 Separation of Protein by Electrophoresis and Protein Transfer 
 
 
Appropriate volumes of protein lysates, containing 10 g of protein were mixed 
with Laemmli Sample Buffer containing 5% -mercapthoethanol (Bio-Rad 
Laboratories, Hertfordshire, UK) in a ratio 1:1. The sample dilution was adjusted 
with water so that an equal volume was loaded per lane. Samples were denatured 
by heating for 5 minutes at 95C, briefly centrifuged and loaded. Gels were run in 
the electrophoresis tanks with 500 ml of electrode buffer. Transfer was achieved 
using a wet or semi-dry system (for details see sections: 2.3.4.1.2-VDR, 2.3.4.1.4-
1α-OHase, 2.3.4.1.6- 24-OHase, 2.3.4.2- all other proteins). 
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2.3.4.1.1 Optimisation of Detection and Quantification of the VDR Protein in 
Cells and Tissues 
 
Pre-cast Nu-PAGE 10% Bis-Tris gel (Invitrogen, Paisley, UK) and pre-cast RunBlue 
10% Bis-Tris gel (Expedeon, Harston, UK), both with buffers recommended by 
manufacturers, were tested.  
Results showed that the optimal protein separation was achieved using the pre-cast 
Nu-PAGE 10% Bis-Tris gel (Figure 2.5).  
 
 
Figure 2.5 The comparison of the Vitamin D Receptor (VDR) protein separation 
and detection by two commercially available pre-cast gels. A) Nu-Page 10% Bis-
Tris Gel, Invitrogen and B) RunBlue 10% Bis-Tris gel, Expedeon. Transfer was 
achieved using nitrocellulose membrane and a wet system (100 V for 1 h). 
Membranes were blocked in Animal Serum Free Block (ASFB) for 1h at 25°C. 
Membranes were probed with primary rabbit polyclonal VDR C-20 antibody (1:500) 
in ASFB overnight at 4°C, washed with PBS-T (0.1%) and probed with secondary 
(horse-raddish-peroxidase-conjugated) antibody (1:4,000) in ASFB.  
 
Further optimisation of the method was required for the comparison of 11 or more 
artery samples on one gel (pre-cast gels were not appropriate, due to a too small 
number of wells). Consequently, four different methods were compared: A) self-
made 10% polyacrylamide gel and a nitrocellulose membrane, B) pre-cast Nu-PAGE 
10% Bis-Tris gel and nitrocellulose membrane, C) self-made 10% polyacrylamide 
gel and a PVDF membrane, D) pre-cast 10% Bis-Tris gel and a PVDF membrane. 
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Transfer was performed at 100 mA for 2 h, with the use of GeneFlow transfer buffer. 
Method C provided the optimal result (Figure 2.6).  
 
 
 
Figure 2.6: Transfer optimisation for the Vitamin D Receptor (VDR) protein 
isolated from human artery. A) Self-made 10% polyacrylamide gel and a 
nitrocellulose membrane B) Pre-cast Nu-PAGE 10% Bis-Tris gel and nitrocellulose 
membrane C) Self-made 10% polyacrylamide gel and a PVDF membrane D) Pre-
cast 10% Nu-Page Bis-Tris gel and a PVDF membrane. Electrophoresis was 
performed at 140 V for 70 minutes, semi-dry transfer at 100 mA for 2 h, blocking in 
Animal Serum Free Blocker (ASFB) for 1 h at 25°C, primary antibody (VDR-C20) 
1:500 in ASFB at 4°C overnight, secondary antibody, HRP-conjugated anti-rabbit 
1:4,000 in ASFB.  
 
It was evident that after longer exposure (15 seconds-1 minute) a second band 
appeared in HAoSMCs and HKC-8 samples (Figure 2.7). 
 
In order to check whether the antibody was binding specifically to VDR, nuclear 
protein from HAoSMCs and HKC-8 (control) were isolated and probed for VDR.  
 
      2. Materials and Methods 
 
 85 
 
Figure 2.7: The Vitamin D Receptor (VDR) protein expression in Human Proximal 
Tubule Cells (HKC-8) and in Human Aortic Smooth Muscle Cells (HAoSMCs) – 
the optimised method. Double bands (approx. 50 and 52 kDa) were detectable in 
both cell types, although the 50 kDa band was hardly visible in HAoSMCs at given 
exposure. There appeared to be an additional band of approx. 53 kDa present in 
HAoSMCs. Electrophoresis was performed at 140 V for 70 minutes, semi-dry transfer 
at 100 mA for 2 h, blocking in Animal Serum Free Block (ASFB) for 1 h at 25°C, 
primary antibody (VDR-C20) 1:500 in ASFB at 4°C overnight, secondary antibody, 
HRP-conjugated anti-rabbit; A) 1:5,000 in ASFB or B) 1:4,000 in ASFB. 
 
 
2.3.4.1.1.1 Preparation of Nuclear Proteins for VDR Western Blot Analysis 
 
 
Nuclear proteins were extracted using an adaptation of the method of Samuels and 
Tsai (Samuels et al. 1974). Cells were lysed in a sucrose/Tris/MgCl buffer 
containing Triton X-100 and the nuclear proteins were released from the nuclei by 
incubation in a KCl lysis buffer. This can only be achieved in presence of protease 
inhibitor, without which a loss of as much as 95% of nuclear protein within 4 
minutes can occur (Paine et al. 1983). 
Cells from each 75 cm
3 
flask were washed with PBS and scraped as normal and 
centrifuged at 4000 g for 5 minutes to pellet. Supernatant was discarded and cells 
were washed with PBS and centrifugation step was repeated. Pellet was resuspended 
in 4 ml of STM buffer (0.25 M sucrose, 20 mM Tris, 1.1 mM MgCl2 with 0.5 mM 
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protease inhibitors) and centrifuged at 900 g for 10 minutes at 4°C, to separate whole 
cells. Pellets were re-suspended in STM buffer with protease inhibitors and 0.5% 
Triton to rupture cell membranes and left on ice for 10 minutes. Subsequently, the 
suspension was centrifuged as previously to separate the nuclei. Pelleted nuclear 
fraction was then re-suspended in STM buffer with protease inhibitors and 0.5% 
Triton, left on ice for 10 minutes and centrifuged as previously. 400 µl of Lysis 
Mixture (STM with 0.5 mM PIs, 5mM DL-dithiothreitol (DTT), 4M KCl, 20% 
vol./vol. glycerol) was added and samples were left agitating for 15 minutes at 4°C. 
Following final centrifugation at 4000 g for 15 minutes at 4°C, supernatant 
containing nuclear proteins was collected, aliquoted and stored at -80°C. 
Results showed that both the whole cell lysates and the nuclear extracts contained the 
VDR protein (Figure 2.8).  
 
Figure 2.8: The Vitamin D Receptor (VDR) protein is expressed in both, whole 
HAoSMCs and the isolated nuclear fraction. Doublet of bands of about 48 and 50 
kDa was detectable in HKC-8 samples, 50 and 52 kDa in HAoSMCs.  
Electrophoresis was performed at 140 V for 70 minutes, semi-dry transfer at 100 mA 
for 2 h, blocking in for 1 h at 25°C, primary antibody (VDR-C20 1:500 in ASFB at 
4°C overnight, secondary antibody, HRP-conjugated anti-rabbit 1:4,000 in ASFB.  
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2.3.4.1.2 FINAL METHOD USED for the VDR Protein Detection and 
Quantification in Cells and Tissues 
 
Denatured samples were loaded into NuPAGE 10% Bis-Tris pre-cast polyacrylamide 
gels using the mini-cell SDS-PAGE system (Invitrogen, Paisley, UK). The running 
buffer was prepared for denaturing electrophoresis using the recommended protocol 
provided with NuPAGE MOPS SDS running buffer (Invitrogen, Paisley, UK). 500 
l of antioxidant (Invitrogen, Paisley, UK) was added to the running buffer and 
electrophoresis was performed at 140V for 70 minutes at room temperature - until 
adequate separation of the molecular marker protein was achieved (Fermentas, York, 
UK). 
 
Following electrophoresis, proteins were transferred onto nitrocellulose membrane. 
Transfer was achieved using wet-blot transfer system (Bio-Rad Laboratories, 
Hertfordshire, UK), after 1 hour at 100 V. Standard transfer buffer containing 00.2 M 
Tris, 0.19 M glycine, 20% (vol./vol.) methanol, pH 8.3 (Geneflow, Stafford, UK) 
was used.  
Membranes were blocked (1 h; 25 °C) in Animal Serum Free Block (ASFB, Vector 
Labs, Peterborough, UK) and rinsed in PBS. Membranes were incubated overnight at 
4 °C with the primary rabbit VDR C-20 antibody diluted 1:500 (Santa Cruz 
Biotechnology, Santa Cruz, USA) in ASFB. After three 10-min washes in PBS-T 
(0.1%), membranes were incubated with the secondary antibody (horseradish 
peroxidase conjugated, Vector Labs, Peterborough, UK) diluted 1:4,000 in ASFB for 
60 minutes at 25 °C and washed for three 10-minute periods in PBS-T (0.1%). 
Proteins were detected by enhanced chemiluminescent assay (ECL, Amersham, 
Buckingham, UK) after exposure of filters to X-ray film for 30 seconds – 3 minutes). 
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Autoradiographs were quantified by densitometry, using Image J software. Signal 
emitted from the peroxidase-conjugated secondary antibodies created darker bands 
on the X-ray film. Optical Density (O.D.) reflects the amount and intensity of pixels 
in the scanned image and can be measured by calculating the surface area under a 
computer-generated curve (proportional to the amount of target protein).  
 
2.3.4.1.3 Optimisation for the Characterisation and Quantification of 1α-OHase 
Protein in Cells and Tissues 
 
The specific method for Western blot analysis for 1α-OHase protein has been 
described previously (Bland et al. 1999).  
This and three other methods were compared in HAoSMCs. All methods were based 
on the original published method, except: Method A: blocking in I-Block 
(Invitrogen, Paisley, UK), Method B: blocking in ASFB, Method C: blocking in non-
fat milk powder 5% (wt/vol.), Method D: blocking in non-fat milk powder 20% 
(wt/vol.). The method D as described by Bland et al. provided the optimal result and 
was used for analyses of 1α-OHase protein isolated from HAoSMCs and tissues, 
(2°Ab. 1:20,000) (Figure 2.9). 
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Figure 2.9: The optimisation of blocking methods for detection of 1α-Hydroxylase 
(1α-OHase) protein. A) I-block B) Animal Serum Free Block (ASFB) C) non-fat milk 
powder 5% (wt/vol.) D) non-fat milk powder 20% (wt/vol.). Proteins were 
transferred from self-made 10% polyacrylamide gels onto polyvinylidene difluoride 
(PVDF) membrane. Membranes were blocked in I-block or ASFB or 5% or 20% 
(wt/vol.) non-fat milk powder for 1h at 25°C. Membranes were incubated overnight 
at 4 °C with the primary mouse 1α-OHase antibody diluted 1:500 in buffers (0.05% 
PBS-T). Secondary antibody (horse radish peroxidase-conjugated) was applied, 
diluted 1:20,000 in PBS-T (0.1%). Membranes were washed with 0.1% PBS-T 
between each step. 
 
In both HAoSMCs cells and kidney, a double band of approximately 54 and 56 kDa, 
was detectable. In tissues, the appearance of the same doublet was even more 
prominent with additional band of approximately 70 kDa, which was absent from the 
HAoSMC protein lysate preparation. The specificity of mouse 1α-OHase antibody 
(The Binding Site, Birmingham, UK) was therefore assessed by antibody pre-
incubation with a 100-fold excess of immunising peptide.  
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Method Development for the 1α-OHase Antibody Neutralisation  
 
 
0.5 μg of custom made 1α-OHase peptide, with the following amino acid sequence: 
RHVELREGEAAMRNQGKPEEDMPS (AltaBioscience, Birmingham, UK) was 
dissolved in 1ml of sterile PBS overnight. 20 µl of dissolved peptide were mixed 
with 8 µl of anti-1α-OHase antibody (100-fold excess of peptide to ensure sufficient 
antibody neutralisation), overnight at 4°C in 2ml of PBS and then added to the same 
volume of PBS-T (0.1%). This resulted in neutralisation of the smaller set of bands 
(54 and 56 kDa) in normal human arteries, HAoSMCs and kidney. The neutralisation 
was not as prominent in kidney, due to significantly higher level of 1α-OHase protein 
expression (Figure 2.10). 
 
 
Figure 2.10: Neutralisation of 1α-Hydroxylase (1α-OHase) protein. Expression of 
1α-OHase in human artery, HAoSMCs and kidney in presence and absence of 
antibody-neutralising peptide. Western blot analysis of protein preparation (10 μg) 
from normal renal arteries (artery 1 and artery 2), HAoSMCs and a normal kidney 
(A) in the presence or (B) absence of 100-fold excess of immunising peptide.  1α-
OHase molecular weight: 56 kDa. 
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2.3.4.1.4 FINAL METHOD USED for Detection and Quantification of 1α-OHase 
Protein in Cells and Tissues 
 
SDS-polyacrylaminde gels for 1α-OHase were self-made and the constituents are 
listed below. 
Constituents for the resolving and stacking gels: 
 
     10% resolving gel:  
 
 4 ml 30% (vol./vol.) Acrylamide 37.5:1 (National Diagnostics, Hessle, UK) 
 3ml of 1.5 M Tris-Glycine Buffer pH 8.8 (Bio-Rad, Herefordshire, UK) 
 120 µl 10% (wt/vol.) Sodium Dodecyl Sulphate (Sigma-Aldrich, Dorset, UK) 
 4.84 ml distilled H2O 
 40 µl 10% (wt/vol.) Ammonium Persulphate (Sigma-Aldrich, Dorset, UK) 
 10 µl TEMED (Bio-Rad, Herefordshire, UK) 
4.5% stacking gel: 
 
 4 ml 40% (vol./vol.) Acrylamide 29:1 (Bio-Rad, Herefordshire, UK) 
 2.5 ml 0.5 M Tris-Glycine Buffer pH 8.8 (Bio-Rad, Herefordshire, UK) 
 100 µl 10% (wt/vol.) Sodium Dodecyl Sulphate (Sigma-Aldrich, Dorset, UK) 
 6 ml distilled H2O 
 100 µl 10% (wt/vol.) Ammonium Persulphate (Sigma-Aldrich, Dorset, UK) 
 15 µl TEMED (Bio-Rad, Herefordshire, UK) 
 
The ingredients of the resolving gel were mixed and the gel solution was poured into 
the gel mould to the required height. The surface was gently overlaid with water and 
the gel was left to polymerise for about 1 hour. When the resolving gel had 
polymerised the water was removed and the stacking gel was mixed and poured over 
the resolving gel. The combs were inserted and the gel was left to polymerise for 1 
hour. Just before the use the combs were removed and the wells were rinsed with 
water. 
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The samples were prepared for loading as described in 2.3.4. Denatured samples 
were loaded into self-made 10% SDS-polyacrylamide gel. The electrode buffer was 
0.02 M Tris with 0.19 M glycine and 3.4
 
M SDS. Electrophoresis was performed at 
200 V for 40 minutes at 4°C, until adequate separation of the molecular weight 
marker protein (Fermentas, York, UK) was achieved.  
 
Following electrophoresis, proteins were transferred onto PVDF membrane – 
Immobilon-P (Millipore, Dundee, UK), which was previously briefly immersed in 
methanol, to wet the membrane (Sigma-Aldrich, Dorset, UK), then water for 1-2 
minutes, to elute the methanol, and equilibrated in transfer buffer for 20 minutes. 
Transfer was achieved using wet-blot transfer system (Bio-Rad, Hertfordshire, UK), 
after 1 hour at 100 V. Transfer buffer was of 0.06 M Tris, 0.48 M Glycine and 20% 
(vol./vol.) methanol. Membranes were blocked (1 h; 25 °C) in PBS-T (0.1% 
containing 20% (wt/vol.) non-fat milk powder (Marvel, Premier Brands, Stafford, 
UK) and rinsed twice in PBS, followed by an additional wash in PBS-T for 15 
minutes. Membranes were incubated overnight at 4 °C with the primary mouse 1α-
OHase antibody diluted 1:500 (The Binding Site, Birmingham, UK) in PBS-T 
(0.05%). After three 10-min washes in PBS-T (0.1%), membranes were incubated 
with the anti-mouse secondary antibody (horseradish peroxidase conjugated, The 
Binding Site) diluted 1:20,000 in PBS-T (0.1%) for 60 minutes at 25 °C and washed 
for three 10-minute periods in PBS-T (0.1%).  
 
Proteins were detected by the ECL after the exposure of filters to X-ray film for 30 
seconds – 3 minutes). Autoradiographs were quantified by densitometry, using 
Image J software as described for VDR. 
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2.3.4.1.5 Optimisation for Characterisation and Quantification of 24-OHase 
Protein in Cells and Tissues 
 
Two different 24-OHase antibodies (custom made sheep polyclonal antibody – The 
Binding Site, Birmingham, UK) and commercially available mouse monoclonal 
antibody, clone 1F8 – Sigma-Aldrich, Dorset, UK) were tested using HAoSMCs 
protein obtained by three different harvest methods (as described in 2.3.2.1.1). Two 
different blocking conditions were used (non-fat milk powder 5% or 20% (wt/vol.) at 
room temperature, for 1 hour.  Application of 1F8 antibody, to the method described 
for 1α-OHase Western analysis (see 2.3.4.1.4) resulted in clear blots and production 
of clear specific bands of 56 kDa (Figure 2.12). 
 
 
 
 
Figure 2.11: The optimisation of 24-Hydroxylase (24-OHase) protein detection in 
Human Aortic Smooth Muscle Cells (HAoSMCs) using two different antibodies. 
(A,B): The Binding Site (C,D): Sigma-Aldrich (A,C): Blocking in 5% (wt/vol.) non-
fat milk powder 1°Ab. 1:500 in PBST 0.05%, 2°Ab. peroxidase conjugated 1:5,000 in 
5% (wt/vol.) non-fat milk powder. (B,D): Blocking in 20% wt/vol.) non-fat milk 
powder, 1°Ab. 1:500 in PBST 0.05%, 2°Ab. peroxidase conjugated 1:5,000  in 5% 
(wt/vol.) non-fat milk powder. Lanes: 1,2: HAoSMCs 10 μg/lane harvested in RIPA 
with protease inhibitors, 3,4: HAoSMCs 10 μg/lane harvested in PBS with protease 
inhibitors, 5,6:  HAoSMCs 10 μg/lane harvested in Modified RIPA with protease 
inhibitors. 
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2.3.4.1.6 FINAL METHOD USED for Detection and Quantification of 24-OHase 
Protein in Cells and Artery 
 
The protocol was identical to one described earlier for 1α-OHase (see 2.3.4.1.4), 
except the membranes were incubated overnight at 4 °C with primary mouse 24-
OHase antibody diluted 1:500 (Sigma-Aldrich, Dorset, UK) in PBS-T (0.05%). After 
three 10-min washes in PBS-T, membranes were incubated with the secondary 
antibody (horseradish peroxidase conjugated) (Vector Labs, Peterborough, UK) 
diluted 1:5,000 in 5% (wt/vol.) non-fat milk powder (Marvel, Premier Brands, 
Stafford, UK) in PBS-T (0.1%) for 60 minutes at 25°C and washed for three 10-
minute periods in PBS-T. Proteins were detected by ECL Filters were exposed to X-
ray film for 2–40 minutes). Autoradiographs were quantified by densitometry, as 
described for VDR. 
 
2.3.4.2 Detection and Quantification of α-Actin, β-Actin, Klotho, FGFR1, 
FGFR3, RUNX-2, ALP, Sclerostin, ERK1/2 and P-ERK Protein 
 
Western analyses of other proteins (α-actin, β-actin, Klotho, FGFR1, FGFR3, 
RUNX-2, ALP, sclerostin, ERK1/2 and P-ERK) were performed using 10% self-made 
gels (as described in 2.3.4.1.4) or (8% for Klotho, for ingredients see below). The 
electrode buffer was identical to the one used for 1α-OHase and 24-OHase 
(2.3.4.1.4). 
Constituents for the resolving gel: 
8% resolving gel: 
 
 6 ml 40% (vol./vol.) Acrylamide (Bio-Rad, Herefordshire, UK) 
 7.5 ml 1.5 M Tris-Glycine Buffer pH 8.8 (Bio-Rad, Herefordshire, UK) 
 300 µl 10% wt/vol. SDS 
 14.1 ml distilled H2O 
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 300 µl 10% (wt./vol.) Ammonium Persulphate (Sigma-Aldrich, Dorset, UK) 
 50 µl TEMED (Bio-Rad, Herefordshire, UK) 
 
All Western blot analyses were performed using the Bio-Rad mini-Protean II gel 
system (Bio-Rad, Herefordshire, UK) or Gene-Flow Omni-Page Wide system (for 
comparison of more than 10 samples: Geneflow, Stafford, UK). Transfer was 
achieved by the use of semi-dry transfer unit at approximately 50 mA per each 48 
cm
2
 membrane, for 2 hours at 25°C. The transfer buffer was identical to the one 
used for 1α-OHase. (For details about type of membrane, blocking reagent and 
antibodies used, for each individual protein, see the summary in Table 2.2). 
2.3.4.2.1 FGF-23 Stimulation of ERK-Signalling in HAoSMCs 
 
HAoSMCs were treated with vehicle (0.1% BSA) or FGF-23 (100ng/ml) for 10, 30 
and 60 minutes. For ERK-signalling control, samples were incubated with PD98059 
(Calbiochem, Damstadt, Germany) (60 μM) 30 minutes before exposure to FGF-23, 
according to previously published data (Perwad et al. 2007). Phorbol 12-myristate 
13-acetate (PMA) (Sigma-Aldrich, Dorset, UK) at 50 μM for 5 minutes was used as 
a positive control of ERK phosphorylation. PMA Cell lysates were prepared in the 
presence of phosphatase inhibitors, and phosphorylated proteins were detected by 
ECL using rabbit anti-phospho-ERK1,2 antibodies (Cell Signal, New England 
Biolabs, Hitchin, UK). Equal protein loading was monitored by detection of total-
ERK1,2 protein, using specific anti-rabbit antibody (Cell Signal, New England 
Biolabs, Hitchin, UK), for details on dilutions see the summary Table 2.2. 
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2.3.5 Protein Loading Control 
 
 
β-actin is one of six actin isoforms. It is a highly conserved cytoskeletal protein 
involved in cell motility and cohesion. It is constitutively expressed, at high levels 
and it is present in most cell types. For all these reasons, β-actin is frequently used as 
a protein loading control in Western blot analysis. At the protein concentrations used 
in my study both β-actin or α-actin are directly proportional to the optical density 
(O.D.) of the band produced on the autoradiograph, as assessed by Image J software 
(Figure 2.12). 
 
 
Figure 2.12: Sample Loading for Protein Isolated from Human Aortic Smooth 
Muscle Cells (HAoSMCs) and Artery. Increasing concentrations of protein were 
loaded onto 10% gels and transferred onto nitrocellulose membranes, which were 
probed for α-actin or β-actin. Individual band optical density (O.D.) was assessed by 
Image J and plotted on a graph as a function of protein concentration (2.5 μg, 5 μg, 
10 μg) (A) HAoSMCs (B) Healthy human artery. 
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2.3.6 Stripping and Re-probing of Membranes 
 
Each filter membrane was stripped and re-probed with anti-β-actin antibody for 
loading control. Membranes were placed in stripping buffer (for ingredients see 
below) and placed in water bath at 60°C for 30 minutes, with occasional agitation. 
Subsequently, membranes were washed twice for 20 minutes in PBS-T and blocked 
in 5% (wt/vol.) non-fat milk powder Marvel for 1h. Then the standard protocol for β-
actin immunoprobing was followed (see Table 2.2).  
 
Constituents of stripping buffer used for the secondary probing of proteins in 
Western blotting: 
 
 0.7% v/v β-mercaptoethanol 
 2 % m/v SDS 
 0.98 % g/v Tris Hydrochloride 
 
2.4 Immunohistochemistry 
 
2.4.1 General Method 
 
 
Tissues were fixed in 10% formaldehyde in water to preserve the general structure of 
the cytoplasm and nucleus by reacting with amino groups of proteins. The tissues 
were then dehydrated by passing through graded series of alcohol solutions (70%, 
95%, 100%) and then placed in a non-aqueous liquid, xylene. Next, the tissues were 
embedded in melted paraffin, left to cool and harden, and 5 µm thick sections were 
cut and placed on charged slides (Superfrost Plus, BDH, Poole, UK) the fixation, 
embedding and cutting of section was performed by Mr Sean James (UHCW, UK).  
For immunohistochemistry, sections were de-parafinised by placing slides in two 
changes of xylene and hydrated by sequentially immersing in 100% ethanol, 90% 
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ethanol and distilled water. Antigen retrieval of sections was achieved using citrate 
pH 6.0 (Dako, Ely, UK) and pressure-cooker, for 2min at 121C (103 kPa).  
 
2.4.2 Immunohistochemical Detection of 1α-OHase Protein in Human 
Artery 
 
 
Immunohistochemistry for 1α-OHase was optimised using commercially available 
Sheep Specific HRP-DAB Tissue Staining Kit (R&D Systems, Abingdon, UK). 
Sections were blocked for endogenous peroxidase activity with hydrogen peroxide 
(3%) in methanol for 10 minutes and the washed with TBS-T, pH 7.6. Sections were 
incubated in 10% donkey serum for 20 minutes. The sections were then incubated 
with avidin blocking reagent for 15 minutes, rinsed with TBS-T and incubated with 
the biotin-blocking reagent for further 15 minutes. 1α-OHase antibody 1:150 (The 
Binding Site, Birmingham, UK) in TBS-T (0.1%) was applied and left overnight at 
4°C. Sections were washed with TBS-T (0.1%) for 5 minutes between each step. 
Sections were incubated with ABC solution and washed with TBS-T (0.1%). The 
localisation of protein was visualised using 3,3-diaminobenzidine (DAB), a 
chromogenic substrate for peroxidase, which allowed observing permanent brown-
coloured deposit at the sight of reaction. The nuclei were counterstained with 
Mayer’s haematoxylin for 5 seconds, washed with distilled water. Section were 
processed through two ethanol washes and xylene and were mounted in the xylene 
based dibutyl polystyrene (DPX, Raymond Lamb, London, UK). Slides were 
scanned and images were captured using Panoramic Viewer software.  
Control sections included omission of primary antibody. Data showing effective 
neutralisation of 1α-OHase mouse antiserum which has been used in our experiments 
has been published previously (Zehnder et al. 1999).   
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2.4.3 Immunohistochemical Detection of 24-OHase, VDR, RUNX-2, ALP 
and Sclerostin Protein in Human Artery 
 
Immunohistochemistry for 24-OHase, VDR, RUNX-2, ALP and sclerostin was 
performed using a Mouse/Rabbit Specific HRP-DAB Novolink Polymer Detection 
Tissue Staining Kit (Leica, Milton Keynes, UK) according to manufacturers 
instructions, for details on specific antibody dilution see Table 2.2. Slides were 
scanned and images were captured using Panoramic Viewer software. RUNX-2 
antibody clone AS110 (Millipore, Dundee, UK) which has previously been 
optimised to detect RUNX-2 protein in tissue sections was used (note: different to 
RUNX-2 antibody used in Western blot analysis, see Table 2.2).  
Control sections included omission of primary antibody. Neutralisation of VDR anti-
serum has been demonstrated in the past (Khadzkou et al. 2006).  
 
2.5 Detailed Summary of Western Blot and Immunohistochemistry 
Protocols 
 
Table 2.2 Detailed summary of Western blot and immunohistochemistry protocols. 
1α-Hydroxylase (1α-OHase), 24-Hydroxlase (24-OHase), Vitamin D Receptor 
(VDR), Alkaline Phosphatase (ALP), FGF Receptor (FGFR), Runt-related 
Transcription Factor 2 (RUNX-2); primary antibody (1°Ab), secondary antibody 
(2°Ab), not-applicable (N/A), Tris-buffered saline with 0.1% tween (TBS-T), Horse 
Radish Peroxidase – 3,3-Diaminobenzidin (HRP-DAB). 
 
ANTIBODY COMPANY WESTERN BLOT –  
dilution and conditions 
IMMUNOHISTO-
CHEMISTRY dilution 
and conditions 
1-OHase 
IgG fraction 
The Binding 
Site, 
Birmingham, 
UK 
 
1 Ab. Sheep polyclonal 1:500 
in PBST 0.05% at 4C overnight 
2 Ab. Donkey anti-sheep 
peroxidase conjugated 1:20,000 
in PBST 0.05%, at 25°C for 1 
hour  
PVDF membrane 
1Ab. 1:150 in PBS 
 
Cell and Tissue Staining 
Kit, Sheep, HRP-DAB, 
(R&D Systems, UK) 
 
24-OHase  Sigma- 1Ab. Mouse monoclonal 1:500 1Ab. 1:200 in PBS 
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clone 1F8 Aldrich, 
Dorset, UK 
in PBST 0.05% at 4C overnight 
2Ab. Anti-mouse, 1:5,000 in 
PBST 0.05%, 5% milk at 25°C 
for 1 hour 
PVDF membrane 
 
Novolink Polymer 
Detection HRP-DAB 
System, (Leica, Milton 
Keynes, UK) 
VDR  
clone C-20 
Santa Cruz, 
Wembley, 
UK 
1Ab. Rabbit polyclonal 1:500 
in Animal Serum Free Blocker 
(ASFB) at 4C overnight 
2Ab. Anti-rabbit, 1:5,000 in 
ASFB at 25°C for 1 hour 
Nitrocellulose membrane 
 1Ab. 1:200 in PBS 
 
Novolink Polymer 
Detection HRP-DAB 
System, Leica 
RUNX-2 Santa Cruz 
Biotechnolog
y Inc., Santa 
Cruz, USA  
1Ab. Mouse monoclonal 
1:1,000 in 5% milk at 4C 
overnight 
2Ab. Anti-mouse 1:5,000 in 
5% milk at 25°C for 1hour 
Nitrocellulose membrane 
N/A 
RUNX-2  
clone AS110  
Millipore, 
Dundee, UK 
 
N/A 
 
1Ab. 1:200 in TBS-T 
Novolink Polymer 
Detection HRP-DAB 
System, (Leica, Milton 
Keynes, UK) 
Klotho  
 
ABcam, 
Cambridge, 
UK 
1Ab. Rabbit polyclonal 1:1,000 
in 1% milk at 4°C overnight. 
2Ab. Anti-mouse 1:5000 in 5% 
milk at 25°C for 1hour 
Nitrocellulose membrane 
N/A 
α-Actin 
clone 1A4 
Sigma 
Aldrich, 
Dorset, UK 
1°Ab. Mouse monoclonal 
1:2,000 in 5% BSA 0.1% PBST 
at 4C overnight 
Nitrocellulose membrane 
N/A 
β-actin – 
loading 
control 
Cell Signal, 
New 
England 
Biolabs, 
Hitchin, UK  
1Ab. Rabbit polyclonal 1:1,000 
in 5% BSA 0.1% PBST at 4C 
overnight 
2Ab. Anti-rabbit 1:5000 in 5% 
milk at 25°C for 1 hour 
Any membrane 
N/A 
ERK-1/2 Cell Signal, 
New 
England 
Biolabs, 
Hitchin, UK 
1Ab. Rabbit polyclonal 1:2,000 
in 5% BSA 0.1% PBST at 4C 
overnight 
2Ab. Anti-rabbit 1:5,000 in 5% 
milk at 25°C for 1 hour 
Nitrocellulose membrane 
N/A 
p-ERK-1/2 Cell Signal, 
New 
1Ab. Rabbit polyclonal 1:1,000 
in 5% BSA 0.1% PBST at 4C 
N/A 
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England 
Biolabs, 
Hitchin, UK 
overnight 
2Ab. Anti-rabbit 1:5000 in 5% 
milk at 25°C for 1 hour 
Nitrocellulose membrane 
Sclerostin  Santa-Cruz 
Biotechnolog
y Inc., Santa 
Cruz, USA 
N/A 1Ab. 1:40 in TBS-T 
Novolink Polymer 
Detection HRP-DAB 
System, (Leica, Milton 
Keynes, UK) 
ALP ABcam, 
Cambridge, 
UK 
 
 
1Ab. Rabbit polyclonal 1:500 
in 1% milk at 4°C overnight. 
2Ab. Anti-mouse 1:5,000 in 
5% milk at 25°C for 1hour 
PVDF membrane 
1Ab. 1:50 in TBS-T 
Novolink Polymer 
Detection HRP-DAB 
System, (Leica, Milton 
Keynes, UK) 
FGFR-1 (Fgl) 
clone C15 
 
Santa Cruz 
Biotechnolog
y Inc., Santa 
Cruz, USA 
1Ab. Rabbit polyclonal 1:1,000 
in 5% BSA 0.1% PBST at 4C 
overnight 
2Ab. Anti-rabbit 1:5000 in 5% 
milk at 25°C for 1 hour 
Nitrocellulose membrane 
N/A 
FGFR-3  
clone C15 
 
Santa Cruz 
Biotechnolog
y Inc., Santa 
Cruz, USA 
1Ab. Rabbit polyclonal 1:1,000 
in 5% BSA 0.1% PBST at 4C 
overnight 
2Ab. Anti-rabbit 1:5000 in 5% 
milk at 25°C for 1 hour 
Nitrocellulose membrane 
N/A 
 
 
2.6 Assessment of Calcium Deposition in Arterial Sections using 
Alizarin Red Staining 
 
Immunohistochemistry sections were de-parafinised as described before (2.4.1). 2% 
Alizarin Red S (Sigma-Aldrich, Dorset, UK) pH 4.2. The tissue sections were stained 
for 2 minutes and washed with distilled water. Sections were dehydrated in 100% 
acetone (20 dips) and in acetone-xylene (1:1) solution (20 dips), followed by 5 
minutes in xylene solution prior to mounting. Areas of calcium deposition stained 
red. Slides were scanned and images were captured using Panoramic Viewer 
software.   
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2.7 RNA Isolation and Analysis 
 
2.7.1 Principle 
 
 
The principle of extracting total mRNA based on the one step-acid guanidinium 
method was first described by Chomczynski and Sacchi (Chomczynski and Sacchi 
1987). In this study, total RNA was extracted from cells using the QiagenRNeasy kit 
(Qiagen, Crawley, UK), and procedure was carried out according to a modified 
protocol provided by the manufacturer.  
2.7.2 RNA Extraction Procedure 
 
 
Cells were washed twice in PBS and 2 ml of RNA lysis buffer was added per 73 cm
3
 
flask, with all steps performed on ice as follows. Cells were then gently scraped and 
lysate was transferred to microfuge tubes. Arterial rings (0.2-0.3 cm
3
) were placed in 
large Eppendorfs, kept on ice and 150-200 μl of RNA lysis buffer was added. Small 
plastic pestles were used to manually grind the tissue. 
1 volume of 70% vol./vol. molecular grade ethanol (Sigma-Aldrich, Dorset, UK) was 
added and sample was transferred to RNeasy column, and then centrifuged for 15 
seconds at 9000 g. RNA remained bound to the filter (silica-based membrane with 
selective binding properties allows isolation of up to 100 µg of RNA longer than 200 
bases) and the flow-through was discarded. Subsequently, two different buffers: 
RW1 (containing guanidine thiocyanate) and RPE (high salt buffer) were used to 
wash and purify the RNA fraction bound to the filter. RNA was eluted by the 
addition of 30 µl of RNase free water to the filter and centrifuging the sample for 1 
minute at 9000 g. Samples were stored at -20 °C.  
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The concentration of the isolated RNA was assessed by measuring 
spectrophotometric absorbance at 260 nm (ND-1000 Spectrophotometer) and 
calculated against 1 optical density (OD) unit at 260 nm being equivalent to 40 µg of 
RNA in 1 ml. The ratio of absorbance at 260 nm to 280 nm (260/280) above 1.8 was 
considered as an RNA sample pure of DNA contamination. The usual RNA 
concentration from HAoSMCs was 200 ng/μl and for tissues, 400 ng/μl. 
 
2.7.3 RNA Reverse Transcription (RT-PCR) 
 
 
Reactions were set up in a final volume of 20 l. 500 ng of total RNA, 50 ng/ml 
random primers, 0.1 mM dNTP mix was combined and the reaction brought to 13 l 
with nuclease-free H2O. Samples were heated at 65C for 5 minutes, and then placed 
on ice. Subsequently, a RT master-mix was made-up containing 1x buffer, 0.1M 
DTT, 40 u/l RNAse inhibitor and 200 u/l of Superscript Reverse Transcriptase III. 
7 l of the master mix was added to each sample to bring the total volume to 20l. 
Samples were mixed and incubated at 25C for 5 minutes, 50C for 1 hour, 70C for 
15 minutes and cooled to 4C. cDNA was stored at -20°C.  
 
2.7.4 Polymerase Chain Reaction 
 
2.7.4.1 Principle 
 
 
The polymerase chain reaction is a process in which a product from one cycle of 
amplification serves as a substrate in the following cycle. The amount of product 
increases exponentially, and provided ideal theoretical conditions unrestricted by the 
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substrate limitation, the amount of product doubles during each cycle according to 
the equation:  
N = N02
n 
Equation 1: Product formation in PCR reaction.  Where N is a number of amplified  
molecules; N0 is an initial number of molecules and n is a number of amplification 
cycles.  
 
PCR was carried out using the cDNA obtained by reverse transcription at an 
appropriate dilution with the appropriate primers (Zehnder et al. 2008) (Table 2.3).  
 
Table 2.3: Primers for RNA detection and quantification. Forward and reverse 
PCR primer sequences for 24-hydroxylase (24-OHase), 1α-hydroxylase (1α-OHase) 
and vitamin D receptor (VDR); F-forward, R-reverse. 
 
PRIMER Sequence (5’3’) Product Size (bp) 
24-OHase (F) 
24-OHase (R) 
CCCACTAGCACCTCGTACCAAC 
CGTAGCCTTCTTTGCGGTAGTC 
485 
1α-OHase (F) 
1α-OHase (R) 
ACGCTGTTGACCATGGC 
GTGACACAGAGTGACCAGCATAT 
542 
VDR (F) 
VDR (R) 
CGCTCCAATGAGTCCTTCACC 
GCTTCATGCTGCACTCAGGC 
421 
 
 
A 40l PCR reaction was set up with 1x PCR buffer, 1.5 mM MgCl2, 0.2mM dNTPs, 
0.2 pM forward and reverse primers, 1 u Taq DNA polymerase and 2 l cDNA. The 
reactions were made up to 40 l with nuclease free water and PCR was performed in 
a thermal cycler. HKC-8 or kidney cDNA were used as controls (VDR, 1α-OHase 
and 24-OHase) (Bland et al. 1999), water was used as a negative control.  
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Table 2.4: RT-PCR cycling conditions. 
 
TEMPERATURE TIME STEP CYCLES 
95C 5 minutes Initial denaturation 
 
95C 1 minute Denaturation 
59C 
 
1 minute Annealing 35 cycles 
 
72C 1 minute Extension 
72C 5 minutes Extension 
 
4C Hold Cooling 
 
 
2.7.5 DNA Gel Electrophoresis 
 
 
DNA separation was achieved using agarose gel electrophoresis. 1.5% (wt/vol.) gel 
was made up with TBE buffer containing ethidium bromide at 0.2g/ml. 5xDNA 
loading buffer (Bioline, London, UK) was added to a final concentration of 1x to 
each sample. DNA Hyperladder I (Bioline, London, UK) was used as a size marker 
(5 μl). PCR bands were visualised under UV light and images captured using gel doc 
system.  
 
2.7.6 Real Time RT-PCR  
 
2.7.6.1 Principle 
 
The main difference between standard RT-PCR and Real-Time RT-PCR is that the 
latter allows quantification of the product in each individual cycle as the reaction 
progresses. It takes advantage of the 5’ nuclease activity of AmpliTaq Gold DNA 
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polymerase, which removes any double stranded DNA and cleaves the TaqMan gene 
specific probe, which is hybridised with the target cDNA that is amplified. The probe 
contains a reporter dye at its 5’ end and a quencher at its 3’ end. The quencher 
suppresses fluorescence emitted by the dye. As the complementary strand is 
synthesised, cleavage of the probe separates the reporter dye from the quencher, 
resulting in increased fluorescence of the reporter (Livak et al. 1995). The probe 
fragments are blocked at 3’ ends and removed from the target and the polymerisation 
of the strand continues.  
As amplification proceeds, the fluorescence accumulation is captured by the 
instrument after every cycle, and is translated into a Real-Time RT-PCR graph. 
There are three amplification stages: exponential, linear and plateau. In the 
exponential phase the reagents are in the abundance, which allows the most precise 
and accurate data for quantitation (Figure 2.14A). 
 
The Comparative Ct Method was used to analyse the results. In the exponential 
phase two values are calculated: the Threshold line (which is the level of detection at 
which the reaction reaches the level of fluorescent intensity above background) and 
the Ct (threshold cycle for amplification, which is the PCR cycle at which the sample 
reaches the Threshold line; it is a relative measure of concentration of target in the 
Real-Time PCR reaction) (Figure 2.14B). 
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Figure 2.13: The Real-Time RT-PCR curve. A) There are three amplification stages: 
1-Exponential, 2-Linear, 3-Plateau. B) The PCR cycle at which the sample reaches 
the threshold level is called the cycle threshold, Ct and is used in downstream 
quantitation. Adapted from http://www.appliedbiosystems.com. 
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Arithmetic Formulae: 
 
ΔCt = Ct of the target gene minus Ct of the housekeeping gene 
ΔΔCt = ΔCt of the target amplification minus ΔCt of the reference 
amplification. 
 
The amount of target, normalised to an endogenous reference is given by the 
Equation 2: 
  
2
-ΔΔCt 
Equation 2: The amount of target normalized to endogenous reference. Where ΔCt 
= Ct of the target gene - Ct of the housekeeping gene; ΔΔCt = ΔCt of the target 
amplification - ΔCt of the reference amplification. 
 
This means that the amount of target mRNA is two times (each cycle one copy from 
one template) the power relative to cycle number compared to the housekeeping gene 
and to the reference. This formula expresses the fold increase or decrease of target 
(mRNA) compared to the reference. In this study, all experiments were multiplexed 
(multiple cDNA targets were simultaneously amplified using a single sample) and 
the mRNA of interest were normalised to 18S rRNA.  
 
2.7.6.2 Method for Real-Time RT-PCR Analysis 
 
 
Samples were prepared in 96-well micro-plates, in the total volume of 25 l, that 
included 23 l of mastermix (12.5 µl TaqMan buffer, 1.25 µl gene specific TaqMan 
probe, 1.25 µl of 18S probe, 8 µl H2O) and 2 l of sample cDNA. The plate was 
sealed using MicroAmo optical adhesive film (Applied Biosystems, Bedford, UK) 
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and centrifuged at 600 g for 30 seconds. 7500 Systems software (Applied 
Biosystems, Bedford, UK) was used for detection of the fluorescence signal.  
2.7.6.3 The TaqMan Probe Information: 
 
 
The primers have been designed previously by (Zehnder et al. 2008). 
 
CYP27B1(1α-Hydroxylase, Hs00168017_m1) 
 Primer sequence: 
FAM reporter 5’ [bp]-TTGCAATTCAAGCTCTGCCAGGCG-[bp] 3’ quencher  
CYP24A1 (24-Hydroxylase, Hs00989013_g1)  
 Primer sequence: 
FAM reporter 5’[bp]-ACTACCGCAAAGAAGGCTACGGGCTG-[bp] 3’ 
quencher  
 
VDR (Vitamin D Receptor, Hs01045847_m1) 
 Primer sequence: 
FAM reporter 5’[bp]-AAGGCACTATTCACCTGCCCCTTCAA-[bp] 3’ 
quencher  
 
18S 
 Reporter dye: VIC 
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2.8 Statistical Analysis 
 
The data were presented graphically and analysed statistically using Microsoft 
Excel 2010, Prism 7.0 and SPSS 19 software. 
 
2.8.1 The Two Sample (Unpaired) Student’s t-Test 
 
 
In this study all data were tested for normality and the non-normally distributed 
data were normalised by logarithmic transformation (Ln). The unpaired parametric 
Student’s t-test was used to analyse the samples from normally distributed 
populations with the same variances, in order to assess whether the means of two 
different groups were greater than what can be attributed to random sampling 
variation. In graphical representation, dot plots were used, where each dot 
depicted individual patient sample (the optimal and informative approach to show 
the variation among the values) and its distance from the mean (where mean was 
depicted by a bar).  
 
2.8.2 One-way Analysis of Variance (ANOVA) and Tukey-Kramer 
Testing  
 
 
Statistical analysis of more than two experimental groups from normally 
distributed populations was performed using one-way ANOVA (parametric), with 
post-hoc testing using Tukey-Kramer multiple comparison post-test. Tukey-
Kramer testing was important to confirm the results of ANOVA, as no single 
study can support a whole series of hypotheses.  
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2.8.3 Probability 
 
 
p values (meaning the probability of observing the data when the null hypothesis 
is true) were calculated, where  p < 0.05 was considered as statistically significant.  
 
2.8.4 Standard Deviation and Standard Error of the Mean 
 
 
Standard Deviation (SD) describes the average spread of observations around the 
mean. The Standard Error of the Mean (SEM) is the standard deviation of the 
error in the sample mean relative to the true mean. SEM can be calculated by the 
sample estimate of the population SD divided by the square root of the sample 
size, assuming statistical independence of the values in the sample.  
 
2.8.5 Real-Time RT-PCR Statistical Analysis 
 
 
Real-Time RT-PCR data were depicted as fold changes, which were calculated 
using ΔΔCt method (2.7.6). The experimental values were expressed as relative to 
the control value of 1. It is important to note, that the error bars (SEM) were 
omitted from all Real-Time RT-PCR graphs, as the representation of data with 
ΔΔCt method implies an exponential transformation (2-ΔΔCt) and since the error 
bars originated at the ΔΔCt step, they would be asymmetrical. Consequently, ΔCt 
values were used for statistical analysis (one-way ANOVA with Tukey-Kramer 
post-tests).  
2.8.6 Product moment correlation coefficient: r 
 
 
The product moment correlation coefficient (Pearson’s r) test assesses the strength 
of the straight line between the continuous variables. Pearson's r between variables 
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is defined as the covariance of the variables divided by the product of their SDs 
Strength of correlation can be interpreted as negative: -1.0 to -0.1 and positive 0.1-
1.0; 0 indicates no correlation (Belle 2004).  
 
2.8.7 Coefficient of determination: R
2
 
 
 
R
2
 is the square of the correlation coefficient and describes the fraction of variance 
between the two dependent variables. It informs how good is one variable in 
predicting another, if R
2
=1, then if one value is given, another value can be 
perfectly predicted. If R
2
=0, then even if both values are given, the prediction of 
any value is impossible.  
 
2.9 Web-based Resources  
 
The gene DNA sequence searches for primer design were performed using Blast 
engine, www.ncbi.nlm.nih.gov. The U.S. National Library of Medicine (PubMed), 
at www.ncbi.nlm.nih.gov/pubmed and MEDLINE, at http://ovidsp.tx.ovid.com 
were the main sources of literature.  
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Chapter 3  
 
Expression of the Vitamin D System 
in Human Artery 
 
 
 
 
 
 
3.1 Background 
 
 
The discovery of the VDR in 1969 was followed by the emergence of multiple 
reports demonstrating the presence of the receptor in over 30 tissues/organs of 
human body (Freake et al. 1981, Holick et al. 1987, Karmali et al. 1989, Kuroki 
1985, Norman A. W. 2006, Ohta et al. 1985, Reitsma et al. 1983, Simpson et al. 
1987). VDR protein and mRNA was also shown to be present in human vasculature, 
in endothelial cells, smooth muscle cells and in cardiomyocytes (Zehnder, 
Lubczanska 2012 – unpublished, part of other research project, Wu-Wong et al. 
2006a).  
Recent studies suggest that conversion of 25(OH)D to 1,25(OH)2D in a number of 
tissues, independent of renal conversion may play a role in survival. Observational 
studies demonstrated that survival rate in patients on dialysis is higher in patients on 
VDR activation therapy (Kalantar-Zadeh et al. 2006, Teng et al. 2005, Tentori et al. 
2006, Wolf and Thadhani 2007). Further, comparison of survival in patients where 
two different VDRA therapeutic regimes were used: paricalcitol and calcitriol 
demonstrated that the mortality rate was 16% lower using paricalcitol versus 
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calcitriol (Teng et al. 2003). VDR activators have also been associated with 
beneficial cardiovascular outcomes in patients with CKD (Shroff R. C. et al. 2008).  
Previous reports suggest that VDR binding in heart may have beneficial 
antihypertrophic effects (Zittermann et al. 2005). This was confirmed in a global 
VDR-knockout mouse model, where mice with deleted VDR exhibited cardiac 
hypertrophy (Rahman et al. 2007). A recent study by Chen and colleagues 
investigated the effect of targeted deletion of VDR gene in rat cardiomyocytes and 
compared the effects to the ones previously described in full VDR-knockout mice 
(Chen S. et al. 2011, Rahman et al. 2007, Xiang et al. 2005). All studies reported an 
increased mRNA and protein levels of modulatory calcineurin inhibitory protein 1 
(MCIP1) in all VDR-knock out animals. Expression of MCIP1 was shown to 
correlate with calcineurin/nuclear factor of activated T cells (NFAT) signalling in the 
heart and its knockout in mice resulted in reduction in cardiac hypertrophy (Sanna et 
al. 2006, Vega et al. 2003), suggesting that there are vasculature-specific vitamin D 
dependent regulatory pathways. 
Recent studies in vasculature demonstrated that VSMC vitamin D hormonal system 
can be regulated by PTH and estrogenic compounds (Somjen et al. 2005).  VDR-
signalling in vascular endothelial cells was shown to be regulated also by 
inflammatory cytokines (Zehnder et al. 2002b). Irrespectively of all evidence, some 
still argue that vitamin D hormonal system is not present in extra-renal tissues 
(Vanhooke et al. 2006).  
Evidence suggests expression and activation of the VDR is protective/maybe 
beneficial and prevent CVD and CV calcification in renal patients. Despite this 
people still dispute whether the vitamin D signalling system exists in vascular tissue.  
I therefore wanted to investigate the expression of components of the vitamin D 
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system in healthy and diseased human arteries and more specifically in VSMC. This 
would also allow me to determine the suitability of VSMC as a model system in 
which to further investigate the regulation of vitamin D signalling in the artery. 
Human healthy and CKD epigastric and renal arteries were obtained as described in 
chapter 2.1. mRNA expression was assessed by real-time RT-PCR, proteins 
identification and level of expression were determined by Western blot analyses, and 
localized by immunohistochemistry in tissues sections. 
 
 
 
 
3.2 Results 
 
3.2.1 Expression of the Vitamin D system in Healthy Human Artery and 
Vascular Smooth Muscle Cells 
 
3.2.1.1  Expression of the Vitamin D Receptor (VDR) 
 
RT-PCR analyses revealed that VDR mRNA was detected in HAoSMCs and that it 
was a similar size transcript to that seen in HKC-8 (human kidney proximal tubule 
cells were used as control) (Figure 3.1A). Western analyses were carried out using 
proteins isolated from HAoSMCs and normal human artery (HKC-8 and normal 
human kidney were used as controls). In both, HAoSMCs and HKC-8 cells a doublet 
was detected (approximately 48 kDa and 50 kDa in HAoSMCs and 50 kDa and 52 
kDa in HKC-8) (Figure 3.1B, as discussed in more detail in 2.3.4.1.1). Western blot 
analysis of protein isolated from normal human artery demonstrated presence of one 
strong band of about 50 kDa (Figure 3.1C). The higher molecular band (52 kDa) 
appeared in all tested cells. Although expression in HAoSMCs was lower and longer 
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exposure times were required. Similar size bands were observed in normal human 
kidney.  
 
 
 
 
Figure 3.1: The expression of Vitamin D Receptor (VDR) mRNA and protein in 
Human Aortic Smooth Muscle Cells (HAoSMCs) and normal human artery. (A) 
RT-PCR analyses using primers specific for VDR mRNA, in both HAoSMCs from 
three (1,2,3) different donors; water (H20) negative control.  Human kidney proximal 
tubule cells (HKC-8) as a positive control. The expected PCR product of 421 bp was 
observed. (B) Western blot analysis of HAoSMC protein (10 μg/lane and 20 μg/lane) 
and HKC-8 protein (5 μg/lane and 10 μg/lane) (C) and normal human artery protein 
(10 μg/lane); kidney as control, using rabbit polyclonal antibody specific for VDR 
(C-20)).  
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3.2.1.2  Expression of the 25-Hydroxyvitamin D 1α-Hydroxylase (1α-OHase, 
CYP27B1)  
 
 
HKC-8 cells and cortical region of healthy human kidney tissue have been shown 
previously to express 1α-OHase (Bland et al. 1999, Zehnder et al. 1999) and I have 
used them as positive controls. RT-PCR analyses confirmed the presence of 
CYP27B1 mRNA in HAoSMCs revealing similar size transcripts to those seen in 
HKC-8 (Figure 3.2A). Western blot analysis of protein isolated from HAoSMCs 
demonstrated the presence of two bands of approximately 54 and 56 kDa (where the 
56 kDa band always appeared fainter than the 54 kDa band). Protein isolated form 
HKC-8 were used as positive control previously shown to express 1α-OHase (Bland 
et al. 1999) (only 54 kDa band was detected) (Figure 3.2B). In artery, the appearance 
of the doublet was even more prominent and bands were similar in size to the ones 
detected in kidney (Figure 3.2C). As shown in the methods section, the specificity of 
antiserum was assessed by its pre-incubation with a 100-fold excess of immunising 
peptide. This resulted in neutralisation of all bands in HAoSMCs, artery, and 
significant reduction in the kidney (Figure 2.11). 
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Figure 3.2: The expression of 1α-Hydroxylase mRNA (CYP27B1) and protein (1α-
OHase) in Human Aortic Smooth Muscle Cells (HAoSMCs) and normal human 
artery. (A) RT-PCR analyses using primers specific for CYP27B1 mRNA, in both 
HAoSMCs from three (1,2,3) different donors; water (H20) negative control; human 
kidney proximal tubule cells (HKC-8) as control. The expected PCR product of 542 
bp was observed (B) Western blot analysis of HAoSMC protein (10 μg/lane and 20 
μg/lane) and HKC-8 protein (5 μg/lane and 10 μg/lane) (C) and normal human 
artery protein (10 μg/lane); kidney as positive control using antibody specific for 1α-
OHase, confirmed the presence of 1α-OHase protein both in HAoSMCs and normal 
human artery (band detected: approximately 56 kDa).   
 
 
3.2.1.3 Expression of the 24-Hydroxylase (24-OHase, CYP24A1) 
 
 
The presence of 24-OHase protein and mRNA has been shown throughout the 
kidney and in other non-renal vitamin D responsive tissue (Akeno et al. 1997, Kumar 
et al. 1994, Lechner et al. 2007, Schuster et al. 2001), but not in human vasculature 
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My results have demonstrated for the first time that both HAoSMCs and healthy 
human artery express 24-OHase. RT-PCR analyses confirmed the presence of 
CYP24A1 mRNA in HAoSMCs, where the PCR product was the same size as the 
one seen in HKC-8 (Figure 3.3A). Western blot analyses carried out using proteins 
isolated from HAoSMCs and normal human artery, demonstrated the presence of a 
single band of approximately 56 kDa. A similar size band was also observed in 
HKC-8 and human kidney (Figure 3.3B and 3.3C). In tissues, protein expression 
appeared to be at similar level. Conversely, protein expression of 24-OHase appeared 
to be at a lower level in HAoSMCs compared to expression in HKC-8. Human artery 
appeared to express 24-OHase protein at a level similar to that seen in the kidney, but 
HAoSMC expression was lower than that seen in HKC-8 cells (Figure 3.3C). 
 
 
Figure 3.3: Expression of the 24-Hydroxylase mRNA (CYP24A1) and protein (24-
OHase) in Human Aortic Smooth Muscle Cells (HAoSMCs) and human artery 
from healthy individuals. (A) RT-PCR analyses using primers specific for 24-OHase 
mRNA, in both HAoSMCs from three (1,2,3) different donors; water (H20) negative 
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control; human kidney proximal tubule cells (HKC-8) as positive control. The 
expected PCR product of 485 bp was observed. (B) Western blot analysis of 
HAoSMC protein (10 μg/lane and 20 μg/lane) and HKC-8 protein (5 μg/lane and 10 
μg/lane) (C) and normal human artery protein (10 μg/lane); kidney as control, using 
mouse monoclonal antibody specific for 24-OHase (1F8), confirmed the presence of 
24-hydroxylase protein both in HAoSMCs and normal human artery (band detected: 
approximately 56 kDa).  
 
 
The vascular distribution and cellular abundance of VDR, 1α-OHase and 24-OHase 
protein in human kidney and human arteries from healthy individuals donating a 
kidney were assessed by immunohistochemistry of formalin fixed and paraffin 
embedded sections. Strong immunoreactivity was observed for both VDR and 1α-
OHase, with relatively low staining for 24-OHase (positive staining brown) in the 
medial layer of the artery, with visible staining of individual SMCs (Figure 3.4). 
Consistent with previous findings in kidney (Kumar et al. 1994, Zehnder et al. 
1999), staining for 1α-OHase and 24-OHase in VSMCs was cytoplasmic. The VDR 
appeared to be present both in the cytoplasm and in the nuclei. Further, VDR, 1α-
OHase and 24-OHase staining was also present in the endothelium (single-cell layer 
on the inner periphery of the artery, 200X Figure 3.4). Endothelial presence of 1α-
OHase and VDR protein and synthesis of 1,25(OH)2D has been described previously 
in human vascular endothelial cells (Zehnder et al. 2002b). 
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Figure 3.4: Expression and localisation of the Vitamin D Receptor (VDR), 1α-Hydroxylase (1α-OHase) and 24-Hydroxylase (24-OHase) proteins by 
immunohistochemistry in sections of human artery from healthy individuals. Strong positive staining (brown) for all three proteins was observed in the 
medial (M) layer of the artery. Negative control: the primary antibody was omitted. Positive control: human kidney, cortex. Magnification: 50X, 200X and 
400X. L-lumen, A-adventitia
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3.2.2 Comparison of Expression of the Vitamin D System in Artery from 
Healthy Individuals and in Patients with CKD 
 
3.2.2.1 Quantification of mRNA Expression by Real-Time RT-PCR Analyses 
 
 
RNA was extracted from 11 healthy and 17 CKD arteries (see 2.1), transcribed and 
real-time PCR analyses were performed using VDR, CYP27B1, CYP24A1 or RUNX-
2-specific probes. The patient details including age, gender, blood pressure, 
hypertension, diabetes, CKD stage, renal diagnosis, blood haemoglobin, serum 
creatinine, serum calcium, phosphate and eGFR are outlined in Table 3.1. 
 
Table 3.1 Summary of Demographic and Clinical Data of Patients Included in 
mRNA Expression Analyses (Real Time RT-PCR). Chronic Kidney Disease (CKD), 
Haemodialysis (H), Body Mass Index (BMI), Autosomal Dominant Polycystic Kidney 
Disease (ADPKD). 
 
Patient Characteristics Healthy CKD P 
Age (median, range; years) 50 (23-70) 54 (23-67) NS 
Male (%) 6 (60%) 10 (63%)  
BMI (mean ± SD; kg/m
2
)  24.2 ± 5.3 25.7 ± 2.8 NS 
Nicotine (n) 4 (40%) 9 (56%)  
Blood Pressure (mean ± SD; mmHg) 
  Systolic 
  Diastolic 
 
124 ±16.8 
74 ±15.9 
 
132 ± 18.0 
75 ± 10.5 
 
NS 
NS 
Hypertension (%) 
Diabetes (%) 
1 (10%) 
0 
14 (88%) 
2 (13%) 
 
CKD Stage (n) 
  5 
  5D 
 
0 
0 
 
4 
12 
 
Renal diagnosis (n) 
  ADPKD 
  Glomerulonephritis 
  Diabetes 
  Other 
 
- 
- 
- 
- 
 
5 
5 
2 
4 
 
Laboratory (mean ± SD) 
  Haemoglobin blood (g/dL) 
  Creatinine serum (μM) 
  Calcium (mM) 
  Phosphate (mM) 
  eGFR (ml/min/1.73m
2
) 
 
12.0 ± 1.6 
87 ± 32.3 
2.09 ± 0.12 
1.2 ± 0.15 
84.7 ± 22.9 
 
11.6 ± 1.6 
674 ± 296.9 
2.3 ± 0.12 
1.6 ± 0.47 
9.4 ± 5.0 
 
NS 
<0.0001 
<0.01 
<0.05 
<0.0001 
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mRNA expression was corrected by 18S rRNA expression levels and presented 
graphically as a percentage, relative to normal untreated control (100%). Expression 
of VDR mRNA in CKD arteries was significantly reduced by 68%, compared to 
healthy control arteries (p < 0.001). Conversely, CYP27B1 and RUNX-2 mRNA was 
significantly increased by 94% and by 172% in CKD arteries, respectively (p < 
0.001, p < 0.0001).  CYP24A1 mRNA levels in CKD arteries, compared to those in 
healthy arteries were not significantly different (p = 0.20) (Figure 3.5, data provided 
by Dr Guerman Molostvov).  
 
 
 
Figure 3.5: Relative expression of Vitamin D Receptor (VDR), 24-Hydroxylase 
(CYP24A1), 1α-Hydroxylase (CYP27B1) and Runt-related Protein 2 (RUNX-2) 
mRNA in normal and Chronic Kidney Disease (CKD) arteries. Results 
demonstrated by real-time RT-PCR. Values were corrected to 18S rRNA expression 
levels.  *** p < 0.001, as calculated by one-way ANOVA; (n=11-17). 
 
 
3.2.2.2 Protein Expression of the Receptor and the Enzymes of the Vitamin D 
Hormonal System in HAoSMCs and Human Artery 
 
 
Arterial explant samples from a group of nine healthy individuals and nine CKD 
patients (all undergoing haemodialysis) were obtained with an informed consent. The 
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patient details including age, gender, blood pressure, hypertension, diabetes, CKD 
stage, renal diagnosis, blood haemoglobin, serum creatinine, serum calcium, 
phosphate and eGFR are outlined in Table 3.2. 
 
Table 3.2 Summary of Demographic and Clinical Data of Patients Included in 
Protein Expression Analyses (Western Blot). Chronic Kidney Disease (CKD), 
Haemodialysis (H), Body Mass Index (BMI), Autosomal Dominant Polycystic Kidney 
Disease (ADPKD). 
 
Patient Characteristics Healthy CKD P 
Age (median, range) 55 (23-79) 53 (26-64) NS 
Male (n,%) 8 (80%) 7 (70%) NS 
BMI (mean ± SD; kg/m
2
) 24.6 ± 4.6 23.7 ± 4.0 NS 
Nicotine (n,%) 3 (30%) 6 (60%)  
Blood Pressure (mean ± SD; mmHg) 
  Systolic 
  Diastolic 
 
121 ± 10.6  
66 ± 16.7 
 
137 ± 29.70 
79 ± 13.7 
 
NS 
NS 
Hypertension (n,%) 
Diabetes (n,%) 
1 (10%) 
0 
9 (90%) 
0 
 
CKD Stage (n) 
  5 
  5D 
 
0 
0 
 
1 
9 
 
Renal diagnosis (n) 
  ADPKD 
  Glomerulonephritis 
  Obstructive uropathy 
  Other 
 
- 
- 
- 
- 
 
1 
5 
2 
2 
 
Laboratory (mean ± SD) 
  Haemoglobin blood (g/dL) 
  Creatinine serum (μM) 
  Calcium (mM) 
  Phosphate (mM) 
  eGFR (ml/min/1.73m
2
) 
 
12.2 ± 1.1 
98 ± 19.4 
2.2 ± 0.22 
1.2 ± 0.22 
75 ± 12 
 
11.6 ± 1.5 
    704 ± 121.9 
2.1 ± 0.19 
1.8 ± 0.52 
7.2  ± 1.9 
 
NS 
<0.0001 
NS 
<0.01 
<0.0001 
 
 
Western blot analyses were performed as described previously and expression was 
normalised to β-actin. On the following figures data are presented in a numbers of 
formats. A representative Western blots are shown and data are represented 
graphically. B for better visualisation, data were also presented in a form of a dot 
plot, where positioning from the mean was illustrated graphically for each individual 
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data point (mean was depicted by bars), for both groups. Data sets, in which data 
were non-normally distributed, were transformed by means of natural logarithm (ln) 
and then presented in a form of a dot plot.  
Western blot analyses indicated that expression of the VDR, 1α-OHase and 24-
OHase proteins was altered in CKD. VDR protein expression was not statistically 
different in CKD (Figure 3.6). 1α-OHase protein expression in CKD arteries was 
significantly reduced by 27% compared to the control group (p=0.048, as determined 
by an unpaired Student’s t-test) (Figure 3.7). 24-OHase protein was not significantly 
changed (p= 0.15 and p = 0.12, respectively) (Figure 3.8), a larger patient group 
may be needed to reduce the observed variability and confirm these findings. 
Interestingly, when relative 24-OHase protein were plotted as a function of relative 
1α-OHase protein levels for all nine normal patients, a line showing almost a directly 
proportional relationship was observed (R
2
=0.18) (p < 0.0001) (Figure 3.9A). This 
relationship appeared lost in CKD arteries, represented by almost a flat line  
(R
2
=0.002) (p < 0.0001) (Figure 3.9B). This may suggests an increased 24-OHase 
catabolism in CKD, although this would have to be confirmed by measuring 24-
OHase activity. 
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Figure 3.6: The Vitamin D Receptor (VDR) protein expression in arteries from healthy individuals (Control Artery) and patients with advanced Chronic 
Kidney Disease (CKD). (A) VDR protein expression in the arteries from patients with CKD was decreased (31%), compared to expression in control arteries, 
as demonstrated by Western blot analysis. (B) The same data presented in the form of a dot plot, where the distance from the mean (mean represented by a 
bar) is presented graphically for each individual data point; n=9 for each group. Reduced VDR protein expression in CKD compared to control artery was not 
statistically significant (NS), p=0.15, p value calculated by Student’s t-test (data were normalised by logarithmic (ln) transformation prior to statistical 
analysis). 
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Figure 3.7: The 1α-Hydroxylase (1α-OHase) protein expression in arteries of healthy individuals (Control Artery) and arteries of patients with advanced 
Chronic Kidney Disease (CKD). (A) 1α-OHase protein expression is significantly decreased (27%) in the arteries from patients with CKD, compared to 
control arteries, as demonstrated by Western blot analysis. (B) The same data presented in the form of a dot plot, where the distance from the mean (mean 
depicted by a bar) is presented graphically for each individual data point, n=9 for each group, p=0.048, p value calculated by Student’s t-test (data were 
normalised by logarithmic (ln) transformation prior to statistical analysis). 
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Figure 3.8: The 24-Hydroxylase (24-OHase) protein expression in arteries from healthy individuals (Control Artery) and arteries from patients with 
advanced Chronic Kidney Disease (CKD). (A) 24-OHase protein expression in the arteries from patients with advanced CKD was increased (49%), compared 
to expression in control arteries, as demonstrated by Western blot analysis. (B) The same data presented in the form of a dot plot, where distance from the mean 
(mean depicted by a bar) is presented graphically for each individual data point, n=9 for each group. Increased 24-OHase protein expression in CKD 
compared to control artery was not statistically significant (NS), p=0.12, p value calculated by Student’s t-test (data were normalised by logarithmic (ln) 
transformation prior to statistical analysis). 
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Figure 3.9: Linear correlation between 24-Hydroxylase (24-OHase) protein level 
and 1α-Hydroxylase (1α-OHase) protein level, in healthy and Chronic Kidney 
Disease (CKD) arteries. Values expressed as natural log Ln of optical density (O.D.), 
corrected by β-actin A) Normal arteries, negative correlation R2=0.186, r=-0.31, p< 
0.0001 (n=8) B) CKD arteries, positive correlation R
2
=0.003, r=0.49 (n=9).  
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 Expression of RUNX-2, ALP and sclerostin in arteries, was used to indicate the 
stage of osteoblastic differentiation of VSMCs in the artery. High levels of α-actin 
were indicative of contractile, VSMC-like phenotype.  
 α-Actin (Figure 3.10 , RUNX-2 (Figure 3.11).  and ALP (Figure 3.12) protein 
levels were not significantly different between control and CKD group, as 
demonstrated by Western blot analyses. Protein expression of α-actin was fairly 
uniform across both groups, as indicated by similar means (0.63 and 0.60) (Figure 
3.10).   
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Figure 3.10: The α-Actin protein expression in arteries from healthy individuals (Control Artery) and arteries from patients with advanced Chronic 
Kidney Disease (CKD). (A) α-Actin protein expression in the arteries from normal patients and those with advanced CKD appears to be fairly uniform, with 
no significant changes observed, as demonstrated by Western blot analysis. (B) The same data presented in the form of a dot plot, where distance from the 
mean (mean depicted by a bar) is presented graphically for each individual data point, n=9 for each group. Not statistically significant (NS), p=0.93, p value 
calculated by Student’s t test.  
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Figure 3.11: The Runt-related transcription factor 2 (RUNX-2) expression in arteries from healthy individuals (Control Artery) and arteries from patients 
with advanced Chronic Kidney Disease (CKD). (A) RUNX-2 protein expression in the arteries from normal patients appeared similar, if not slightly increased, 
compared to the expression in those with advanced CKD, as demonstrated by Western blot analysis. (B) The same data presented in the form of a dot plot, where 
distance from the mean (mean depicted by a bar) is presented graphically for each individual data point, n=9 for each group. Not statistically significant (NS) 
change, p=0.27, p value calculated by Student’s t-test.  
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Figure 3.12: The Alkaline Phosphatase (ALP) protein expression in arteries from healthy individuals (Control Artery) and arteries from patients with 
advanced Chronic Kidney Disease (CKD). (A) ALP protein expression in the arteries from normal patients appeared to be elevated, as demonstrated by 
Western blot analysis. (B) The same data presented in the form of a dot plot, where distance from the mean (mean depicted by a bar) is presented graphically for 
each individual data point, n=9 for each group. Not statistically significant change (NS), p=0.06, p value calculated by Student’s t test.  
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Figure 3.13 is a summary of all arterial Western blot analyses to allow for easy 
characterization of the protein expression profile of an individual patient.     
 
 
 
 
Figure 3.13: Protein expression of the Vitamin D Receptor (VDR), 1α-
Hydroxylase (1α-OHase) and 24-Hydroxylase (24-OHase) in normal human 
artery and chronic kidney disease (CKD), artery together with the 
corresponding protein expression of the Runt-related transcription factor 2 
(RUNX-2), Alkaline Phosphatase (ALP) and α-Actin. Representative Western 
blots. β-actin was used as a loading control, numbers 1-17 indicate arteries from 
individual patients.  
 
3.2.2.3 Localisation of the VDR, 1α-OHase, 24-OHase and Bone-Specific 
Proteins in Human Artery using Immunohistochemistry 
 
 
To further analyse expression and localisation of the vitamin D signalling elements, 
sections of artery were examined by immunohistochemistry. 15 healthy and 15 CKD 
arteries were obtained as described in 2.1. Sections were prepared and stained for 
VDR, 1α-OHase, 24-OHase, as well as RUNX-2, ALP, sclerostin and calcium 
(Alizarin Red), as described in 2.4.  
The intensity of the positive staining (brown for protein expression; red for calcium) 
of each individual section was assessed using a microscope. Random areas were 
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chosen on separate occasions and. Relative staining intensity was ranked from 0 (no 
staining) through 1 (very weak), 2 (medium) and 3 (strong), data were averaged and 
summarized in Table 3.1. Figures representative of staining for each of the proteins, 
in arteries from healthy individuals and from people with CKD are shown (Figures 
3.14-3.19). 
Immunochistochemical staining for VDR and 1α-OHase in CKD was weaker than 
the staining in normal arteries (Figure 3.15 and 3.16). This was consistent with the 
previous results from Western blot analyses (Figure 3.5 and 3.6). Again, consistent 
with my earlier findings, 24-OHase protein expression in CKD arteries appeared to 
be elevated, compared to healthy arteries (Figure 3.17). Calcification in all sections 
was assessed by Alizarin red (positive staining is red). No calcification was detected 
in any of the 15 healthy arteries. Of the 15 CKD arteries, moderate calcification was 
present in 3 and severe calcification was detected in another 3 arteries, the remaining 
9 arteries did not appear to have any calcium deposits. Interestingly, it was observed 
that areas of calcification co-localised with the decreased expression of VDR (Figure 
3.13) and 1α-OHase (Figure 3.14) and elevated expression of 24-OHase protein 
(Figure 3.15) in CKD, compared to healthy arteries. RUNX-2 protein was increased 
in CKD arteries, compared to expression in normal vessels (Figure 3.17). This 
finding was more convincing, than the data from Western blot analyses and 
consistent with the published findings (Moe et al. 2002, Tyson et al. 2003, Zhu et al. 
2011). Similarly, low sclerostin expression seemed to be associated with high 
RUNX-2 protein levels or high calcium content in the medial layer (Table 3.4 and 
Figure 3.19). Immunohistochemistry results for ALP were similar to the data from 
Western blot analyses, where healthy arteries appeared to have higher levels of ALP, 
compared with healthy controls (Figure 3.18).  
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Figure 3.14: The Vitamin D Receptor (VDR) protein expression and localisation in healthy (normal) human artery and in Chronic Kidney Disease (CKD) 
artery. The same arterial sections stained with Alizarin Red for calcium. VDR positive staining (brown), calcium (red). VDR staining in the media (M) of CKD 
artery was weaker than the staining in the media of normal artery, as demonstrated by immunohistochemistry. Decreased VDR staining appeared to be linked 
to the presence of calcium deposits in the medial layer of the CKD artery. Magnifications: 50X, 100X, 400X. L-lumen, A-adventitia. Kidney cortex was used as 
positive control.  
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Figure 3.15: The 1α-Hydroxylase (1α-OHase) protein expression and localisation in healthy (normal) human artery and in Chronic Kidney Disease (CKD) 
artery. The same arterial sections stained with Alizarin Red for calcium. 1α-OHase positive staining (brown), calcium (red). 1α-hydroxylase staining in the media 
(M) of CKD artery was weaker than the staining in the media of normal artery, as demonstrated by immunohistochemistry. Decreased 1α-OHase staining 
appeared to be linked to the presence of calcium deposits in the medial layer of CKD artery. Magnifications: 50X, 100X, 400X. L-lumen, A-adventitia. Kidney 
cortex was used as positive control.  
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Figure 3.16: The 24-Hydroxylase (24-OHase) protein expression and localisation in healthy (normal) human artery and in Chronic Kidney Disease (CKD) 
artery. The same arterial sections stained with Alizarin Red for calcium. 24-OHase positive staining (brown), calcium (red). 24-OHase staining in the media 
(M) of CKD artery was stronger than the staining in the media of normal artery, as demonstrated by immunohistochemistry. Increased 24-OHase staining 
appeared to be linked to the presence of calcium deposits in the medial layer of CKD artery. Magnifications: 50X, 100X, 400X. L-lumen, A-adventitia. Kidney 
cortex was used as positive control. 
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Figure 3.17: The Runt-related Transcription Factor 2 (RUNX-2) protein expression and localisation in healthy (normal) artery and in Chronic Kidney 
Disease (CKD) artery. The same arterial sections stained with Alizarin Red for calcium. RUNX-2 positive staining (brown), calcium (red). RUNX-2 staining in 
the media (M) of CKD artery was stronger than the staining in the media of normal artery, as demonstrated by immunohistochemistry. Increased RUNX-2 
staining appeared to be linked to the presence of calcium deposits in the medial layer of the CKD artery. Magnifications: 50X, 400X. L-lumen, A-adventitia. 
  140 
 
 
Figure 3.18: The Alkaline Phosphatase (ALP) protein expression and localisation in healthy (normal) human artery and in Chronic Kidney Disease 
(CKD) artery. The same arterial sections stained with Alizarin Red for calcium. ALP positive staining (brown), calcium (red). RUNX-2 staining in the media 
(M) of normal artery was stronger than the staining in the media of a CKD artery, as demonstrated by immunohistochemistry. ALP staining (individual cells) 
appeared to co-localise with calcium in the medial layer of CKD artery. Magnifications: 50X, 400X. L-lumen, A-adventitia 
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Figure 3.19: The Sclerostin protein expression and localisation in healthy (normal) human artery and in Chronic Kidney Disease (CKD) artery. The same 
arterial sections stained with Alizarin Red for calcium. Sclerostin positive staining (brown), calcium (red). RUNX-2 staining in the media (M) of normal artery 
was stronger than the staining in the media of a CKD artery, as demonstrated by immunohistochemistry. Sclerostin staining (individual cells) appeared to co-
localise with calcium in the medial layer of CKD artery. Magnifications: 50X, 400X. L-lumen, A-adventitia. 
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Table 3.3: Estimation of the Vitamin D Receptor (VDR), 1α-Hydroxylase (1α-
OHase), 24-Hydroxylase (24-OHase), Runt Related Transcription Factor 2 
(RUNX-2), Alkaline Phosphatase (ALP), Sclerostin and calcium staining intensity 
in the arterial sections from healthy and Chronic Kidney Disease (CKD) patients. 
Staining intensity (% intensity of brownness in the medial layer) was assessed by eye. 
Three random areas were chosen on 3 separate occasions (n=15 healthy, n=15 
CKD) Staining was scored subjectively as: 0 (no staining) through 1 (very weak 
staining), 2 (medium staining) and 3 (strong staining). Data represent median scores 
from 15 sections. Presence of calcification scores - in red and highlighted. Mode, 
range and average were calculated.  
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3.3 Discussion 
 
Current research in the area of vascular calcification and vitamin D has focused 
primarily around endocrine hormonal system, the importance of which, categorically, 
cannot be underestimated. However, vitamin D metabolites, particularly 
1,25(OH)2D3, are able to act on a range of not only systemic but also local processes 
in vascular cells. The recent result of PRIMO study (Thadhani 2011), which failed to 
show the long term effect of the paricalcitol administration on cardiac structure and 
function in cardiac haemodialysis patients with left ventricular hypertrophy 
confirmed the need for more in-depth understanding of the complex interrelationship 
between vitamin D system and vasculature.  
This study demonstrated presence of VDR mRNA and protein in human VSMC and 
in human artery. RT-PCR analyses showed that VDR PCR product was detectable in 
VSMCS and that it was similar in size to the transcript detected in HKC-8 cells. The 
method for VDR protein detection was carefully validated and is described in 
Chapter 2. Presence of VDR protein in VSMCs and human artery was conformed 
where a dublet of bands was detected (approximately 50 kDa and 52 kDa).  48 kDa 
protein has been previously detected in human intestinal semian virus (CV-1) cells 
engineered to over express VDR, whereas 50 kDa protein has been detected in the 
membrane fraction of the same cells (Bula et al. 2005). Literature suggests that the 
48 kDa protein is likely to be a product of transcription starting at the first ATG 
codon in exon 2, methionine 4 (Bula et al. 2005). It has also been suggested that both 
48 and 52 kDa may be other nuclear matrix proteins with C-terminal homologous to 
that of VDR (Nangia et al. 1998). The nature of higher molecular mass protein cross-
reacting with VDR antibody, which has been observed by others is not known (Bula 
et al. 2005, Krishnan and Feldman 1992, Kumar et al. 1994), it may also be a 
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different VDR isoform or a result of posttranslational modifications, such as 
phosphorylation or glycosylation.  
Despite multiple publications demonstrating the presence of VDR in smooth muscle 
tissues other groups strongly argue that the receptor is not there (Wang Y. and 
DeLuca 2011). The primary argument dismissing the validity of previous research is 
the lack of specificity of antibodies used in the previous studies (allegedly non-
specific C-20 and 9A7, as opposed to specific D-6). As it is harder to disagree with 
research showing variety of effects that 1,25(OH)2D exerts on SMCs, it is argued by 
the authors that these effects are indirect. Further, the same authors state that 
according to the unpublished results, mRNA expression levels in intestinal SMCs are 
extremely low, which may explain why VDR protein expression is negligible to non-
existent.  
Further, mRNA and protein expression of two essential enzymes of the vitamin D 
system, 1α-OHase and 24-OHase (the latter for the first time) was shown by us in 
VSMCs and human artery, which suggests that vascular VDR-1,25(OH)2D exerts its 
actions through the genomic pathway. 24-OHase protein of approximately 56 kDa, 
the same size as detected by us has been previously shown to be present in kidney 
proximal tubule cells, breast cells, keratinocytes and other tissues (more on 24-
OHase expression and regulation see chapter 1.3.3.3). Interestingly, in malignant 
breast tissues a band of 40 kDa is also present and it may be a result of alternative 
splicing of CYP24A1 mRNA (Fischer et al. 2009). In our study no isoforms of 24-
OHase were detected neither in VSMCs, healthy nor in CKD arteries suggesting that 
alternatively spliced CYP24A1 mRNA is not necessarily an indication of a disease 
process per se, but may be more specifically associated with cancerous processes. 
First report of CYP27B1 mRNA in human VSMC was by Somjen almost a decade 
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ago (Somjen et al. 2005), however to date there have been no reports demonstrating 
the expression of 1α-OHase protein in human VSMCs.  
Importantly, the results from this study proved that there are differences in 
expression of the vitamin D system elements, in mRNAs and proteins between 
healthy and CKD arteries. The altered expression of both VDR mRNA (decreased) 
and CYP27B1 mRNA (increased) was consistent with previous observations by 
others. Altered expression of renal VDR, 1α-OHase and 24-OHase in CKD has been 
previously shown both in humans and rats and has been addressed in Chapter 1 
(Cozzolino et al. 2006, Dusso and Rodriguez 2012, Helvig et al. 2010). According to 
real-time RT-PCR analyses, CYP27B1 mRNA levels were significantly higher in 
CKD arteries, by 94% compared to those in normal arteries. This finding was not 
reflected on the protein level, as according to Western blot analysis, 1α-OHase 
protein in CKD arteries was down by 27% compared to normal controls. This is a 
very interesting finding, which potentially could be explained by observations made 
by others in THP1 (human acute monocytic leukemia cell line) and human 
monocytes. It appears that monocytic baseline CYP27B1 mRNA expression is 
increased in uraemia, possibly reflecting the low-grade inflammation present in CKD 
(Viaene et al. 2012). Interestingly, when cells were stimulated with pro-
inflammatory cytokines (IL-6 or TNF-α or IL-1) in presence of uraemic serum, the 
induction of CYP27B1 mRNA was impaired. Further, uraemic toxins such as indoxyl 
sulphate or p-cresyl sulphate were shown not to have any impact on CYP27B1 levels. 
Taken together these findings may explain the high CYP27B1 mRNA levels in CKD 
arteries and low 1α-OHase protein levels. Further, despite no interference with 
mRNA, uraemic toxins may interfere and ultimately reduce 1α-OHase protein 
translation. Further studies are needed to confirm this theory. Another potential 
explanation may be presence of small non-coding RNAs - micro RNA (miRNA) 
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species, which are responsible for the regulation of up to 30% of human genes, with 
capabilities to influence almost all cellular pathways (Sioud and Cekaite 2010). 
Recent evidence from studies on HKC-8 and THP-1 monocytic cells confirmed the 
existence of regulatory noncoding CYP27B1 splice variants, which may have great 
impact on 1,25(OH)2D synthesis in normal physiology (Wu et al. 2007). miRNAs 
are known to be dysregulated in cancer (Sioud and Cekaite 2010), it is therefore not 
unreasonable to speculate that CKD may also be a state of altered  expression of 
certain miRNAs. 
Decrease in VDR mRNA and protein in CKD arteries, although not significant 
(protein), may suggest that regulation of 1α-OHase may not only be exerted via a 
downstream action of VDR, but that it may be strongly dependent on the levels of 
24-OHase, which in turn, may be regulated by some other indirect mechanism. In 
CKD arteries, levels of CYP24A1 mRNA were similar to those in normal arteries, 
whereas levels of CYP27B1 mRNA were significantly increased. Conversely, in 
CKD levels of 24-OHase protein, albeit non-significantly, were increased, as 
opposed to significantly reduced 1α-OHase protein levels. The question that remains 
to be answered is what exactly causes this dramatic shift post-transcription or 
pre/during translation. 
 
Overall, only four out of 15 examined arteries were calcified (one was calcified 
moderately and there was no apparent calcification in the remaining 9, as indicated 
by alizarin red staining).  Similar observations have been made in the past (Moe et 
al. 2002), where less than a half of the arteries from ESRD patients undergoing renal 
transplantation were calcified (out of 39 vessels, 12 were calcified and 27 showed no 
evidence of calcification). Interestingly, in this study, in the four severely calcified 
sections, the immunoreactivity for 24-OHase was very strong in two vessels and very 
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weak in the other two. Consequently, the expression of 1α-OHase in the severely 
calcified vessels followed the exact opposite pattern, suggesting that neither a 
decrease in 1α-OHase nor an increase in 24-OHase protein is a single determinant of 
a medial calcification. The VDR immunoreactivity in severely calcified arteries was 
consistently decreased compared with non-calcified arteries from patients 
undergoing haemodialysis. This may suggest that the VDR signalling is hampered in 
calcified vessel, but not the reciprocal regulation of 1α-OHase and 24-OHase. 
Further, the differences in expression of vitamin D system elements in calcified 
arteries may be attributed to status of 1,25(OH)2D of an individual patient as well as 
the plausible VDRA treatment they might have been undergoing, also age of a 
patient may have an impact.  
Western analyses of early (ALP, RUNX-2) and late osteoblastic markers (sclerostin) 
in CKD and the control group have not shown any significant sign in phenotypic 
transdifferentiation of VSMCs. Interestingly, it appeared that ALP protein levels 
were higher in healthy than in CKD arteries. This is in conflict with previous reports, 
which suggested elevated ALP in serum of CKD patients (Shantouf et al. 2009) and 
in calcified CKD arteries (Moe et al. 2002). Perhaps, if the test group was larger, 
clearer association would become more apparent. On the other hand, the 
immunohistochemistry studies showed an increase in RUNX-2 staining in CKD 
group (6 out of 15 very strong staining in CKD, as opposed to 5 out of 15 with weak 
to moderate staining in normal arteries). The staining appeared highest in arteries, 
which stained very weakly with alizarin red, confirming that increase in RUNX-2 
occurs at an early stage of osteoblastic transdifferentiation. On the basis of recently 
published findings showing contradictory result (Moe et al. 2002, Tyson et al. 2003, 
Zhu et al. 2011) – perhaps increasing the patient number would decrease the 
variability ultimately impacting the result.   
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More evidence in the following chapters shows direct involvement of VDR in 
vitamin D system regulation within the VSMCs.  Direct involvement of VDR in 
regulation of VSMC function was demonstrated few years ago through performing a 
DNA microarray study in human coronary artery SMCs (Wu-Wong et al. 2007b).  
VDR DNA was not only shown to be expressed at high levels, but also to be 
significantly upregulated (together with CYP24A1) as a result of 1,25(OH)2D3 
treatment. To date, the enzymatically functional 1α-OHase system in VSMCs was 
characterised, however the context of VDR and 24-OHase involvement was not 
addressed (Somjen et al. 2005).  Due to the lack of published data in the area of 
vascular vitamin D system regulation, it is still not known whether VDR-24-OHase-
1α-OHase feedback regulation is principally the same as described in kidney (Bland 
et al. 1999, Bland et al. 2001, Zehnder and Hewison 1999, Zehnder et al. 1999).  
 
 
Figure 3.20: Schematic Representation of the Changes in the Expression of 
Vitamin D Receptor (VDR), 1α-Hydroxylase (1α-OHase), 24-Hydroxylase (24-
OHase) mRNA and Protein in Normal Vascular Smooth Muscle Cell (VSMC) and 
in Chronic Kidney Disease (CKD) VSMC, with accompanying osteoblastic 
changes. Runt related Transcription Factor (RUNX-2), Hydroxyapatite crystals 
Ca10(PO4)6(OH)2 (HAT). 
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Overall, 1α-OHase activity studies are needed to understand how relevant the 
observed 1α-OHase-24-OHase-VDR disconnection in CKD really is. On the basis of 
previous research, it is not unreasonable to assume that local vitamin D system in 
artery may be regulated similarly to the one described in human monocytes, i.e. by 
stimuli such as calcium, phosphate, proinflammatory cytokines or other important 
factors in CKD, such as FGF-23 or Klotho. Another important stimulus may be 
1,25(OH)2D itself and therefore the content of the next chapter has been dedicated to 
elucidation of that aspect entirely.  
 
To summarise, the expression of 24-OHase protein and mRNA in human vasculature 
and primary cultures of HAoSMCs was demonstrated for the first time. Further, 
presence of VDR and 1α-OHase mRNA and protein was shown, which suggested a 
role for a local, arterial VDR activation. Also, the expression of 1α-OHase, 24-
OHase and VDR protein and mRNA in normal and CKD arteries was compared. 
This led to the discovery that expression of 1α-OHase protein was decreased in CKD 
arteries compared to control, whereas VDR and 24-OHase protein expression was 
not statistically changed. Altered expression of the aforementioned elements in CKD 
arteries appeared to co-localise with medial calcification and increased levels of 
RUNX-2 and sclerostin. 
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Chapter 4  
 
Regulation of the Vascular  
Vitamin D System by 1,25(OH)2D3 
 
 
 
 
 
 
4.1 Background 
 
The importance of selective vascular VDR activation can be appreciated by 
understanding of the differences between the endocrine and an auto/paracrine 
vitamin D system.  Treatment of vitamin D deficient patients with non-selective 
1,25(OH)2D3 as discussed in general introduction, leads to the correction of 
1,25(OH)2D3, where 1,25(OH)2D3 acts systemically on intestinal calcium and 
phosphate absorption, bone metabolism, renal calcium absorption and parathyroid 
function. Evidence shows that mortality risk in haemodialysis patients undergoing 
VDR activation therapy is associated with increased level of serum calcium, 
phosphate and PTH (Teng et al. 2005). Although there is currently no scientific 
consensus on the detailed molecular understanding of selectivity of VDR activation, 
it is thought that it is attributed to selective interaction with different components of a 
transcriptional complex. In this notion, locally produced 1,25(OH)2D in vascular 
cells could be compared to molecularly engineered selective VDR activator. 
However as good as it sounds in theory evidence shows that such pharmacological 
therapy mimics the endocrine system and therefore is not free of the aforementioned 
side effects. Even though a selective VDR activation by an active VDR activator - for 
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instance paricalcitol suppresses PTH and is manifested clinically by reduced 
hypercalcaemia and reduced hyperphosphotaemia (Sprague et al. 2003), the overall 
effect on progression of LVH and consequently morbidity in CKD is unchanged 
(Thadhani et al. 2012). Therefore, in principle the main benefit of auto/paracrine 
vitamin D system would be the reduced activity of locally produced 1,25(OH)2D3 on 
gastro-intestinal tract, kidney and bone. To date, the para/aurocrine vitamin D system 
in vasculature has not been studied in detail, nonetheless it has been postulated by 
some that the robustness of such system would be insufficient to support, mimic the 
endocrine system nor to maintain cellular health. 
Synthesis of 1,25(OH)2D in kidney fulfills both endocrine and autocrine actions. The 
thick ascending loop of Henle is an example of differentially controlled vitamin D 
system within a kidney. Firstly, the direct effects include control of calcium secretion 
by acting on CaSR, Na-Pi co-transporters, cell differentiation (Brown et al. 1996, 
Custer et al. 1994, Schwarz et al. 1998) and secondly vitamin D deficiency or low 
serum calcium do not result in decrease in VDR and CYP24A1 mRNA, as opposed to 
for instance proximal convoluted tubule (Iida et al. 1995). In other tissues, such as 
the heart selective VDR activation in a rat CKD model was shown to decrease 
cardiomyocyte hypertrophy and cardiac dysfunction (Bodyak et al. 2007), where the 
pharmacological therapy also seemed to mimic the endocrine system. Although it is 
known that VDR activation in vasculature provides survival benefit, which is 
associated with a decrease in cardiovascular-related events (Shoji et al. 2004), 
existing data highlights further need to elucidate the mechanism of action of VDR 
signalling in vasculature. Figure 4.1 depicts possible local hydroxylation of 
25(OH)D3 to 1,25(OH)2D3 and subsequent effects of 1,25(OH)2D3 on downstream 
actions of VDR, 1α-OHase and 24-OHase. Previous evidence from in vitro studies 
showed that VDR activation in VSMCs plays an important role in cardiovascular 
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diseases. Gene chip microarray analysis provided a broad profile of the modulatory 
effects of 1,25(OH)2D3 on human coronary artery SMCs. VDR activation by 
1,25(OH)2D3 was shown to downregulate mRNA and protein of atherotrombotic 
factors, such as plasminogen activator inhibitor-1 (an established marker of coronary 
heart disease) and thrombospondin-1 (Wu-Wong et al. 2007a).  
 
  
Figure 4.1: Schematic Representation of Possible Local Hydroxylation of 
25(OH)D3 to 1,25(OH)2D3 and the subsequent effects of 1,25(OH)2D3 on the 
downstream actions of the Vitamin D Receptor (VDR), 1α-Hydroxylase (1α-
OHase) and 24-Hydroxylase (24-OHase) in Vascular Smooth Muscle Cell (VSMC). 
mb- membrane bound, MARRS- membrane associated rapid response steroid binding 
receptor, grey arrows – alternative mechanism of action, (-) inhibition, (+) 
upregulation.   
 
 
 
In the previous chapter I demonstrated that VDR, 1α-OHase and 24-OHase are all 
expressed in primary cultures of HAoSMCs and in human arteries, which confirmed 
that vasculature is a target tissue for 1,25(OH)2D3, but also raised a question as to the 
role of the local vitamin D metabolism in maintaining vascular health, especially 
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taking into consideration my results which demonstrate that the expression of the 
vitamin D system is altered in the vessels of patients with CKD. Synthesis of 
1,25(OH)2D3 from 25(OH)D3 has been shown in human endothelial cells (Zehnder et 
al. 2002b), collecting duct cells of human nephron (Bland et al. 2001, Zehnder et al. 
1999), prostate (Schwartz G. G. et al. 1998), parathyroid (Kawahara et al. 2008, 
Ritter et al. 2006) also in VSMCs (Somjen et al. 2005). The importance of 
25(OH)D3 as a substrate for a local activation in VSMCs requires further 
investigation. It has been suggested, that subclinical vitamin D insufficiency (i.e. low 
25(OH)D in the serum; 50-100 nM) is most likely to affect the extra-renal 1α-OHase 
activity, which is regulated differently to the renal enzyme (Hewison M. 2011).  
 
In this chapter, the regulation of the vitamin D system by 1,25(OH)2D3 in 
HAoSMCs, healthy and CKD human arteries was examined. Furthermore local 1α-
OHase activity was analysed by quantifying local synthesis of 1,25(OH)2D3 from 
25(OH)D3 in HAoSMCs, healthy and CKD arteries (ongoing). 
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4.2 Results 
 
4.2.1 Functional Vitamin D Signalling in HAoSMCs 
 
VDR is a Target for 1,25(OH)2D3: Regulation of VDR, 1α-OHase and 24-
OHase by 1,25(OH)2D3 – Time Dependence 
 
 
HAoSMCs were treated with vehicle (0.1% ethanol) or 1,25(OH)2D3 (10 nM) for 2, 
4, 6 and 24 hours and mRNA expression was analysed by real-time RT-PCR. VDR 
mRNA was significantly upregulated 3.5-fold at 2 hours (p=0.013), 1.9-fold at 4 
hours (p=0.004) and 1.8-fold at 6 hours (p=0.04)  (Figure 4.2A). 
CYP27B1 mRNA expression was slightly, albeit significantly reduced at 6 hours 
(p=0.045) (Figure 4.2B). CYP24A1 mRNA was increased by 30-fold at 2 hours 
(p=0.01) and 95-fold at 4 hours (p=0.004); at 6 hours the induction in CYP24A1 
mRNA was 214-fold higher than in vehicle treated 6-hour control (p=0.008) (Figure 
4.2C).  At 24 hours CYP24A1 mRNA level was almost back to the base level, 
possibly due to the complementation of the catabolic removal of 1,25(OH)2D3. 
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Figure 4.2:  The effect of 1,25(OH)2D3 on Vitamin D Receptor (VDR), 1α-Hydroxyalse 
(1α-OHase) and 24-Hydroxylase (24-OHase) mRNA expression in human aortic 
smooth muscle cells (HAoSMCs). Cells were incubated with vehicle (0.1% ethanol) or 
10nM 1,25(OH)2D3 for 2, 4, 6 and 24 hours. (A) VDR mRNA expression (B) 1α-OHase 
mRNA expression (C) 24-OHase mRNA expression, as demonstrated by real-time RT- 
PCR. VDR, 1α-OHase, 24-OHase mRNA levels were normalised to 18S rRNA. Results 
represent mean of relative mRNA levels, n=4-5; * p < 0.05; vs. 6h control, as determined 
by one-way ANOVA.  
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To confirm that VDR, 1α-OHase and 24-OHase protein expression did not change 
over time when treated with vehicle, cells were cultured for 2, 4, 6, 24, 48 hours. 
(Figure 4.3). 6h treatment with vehicle (0.1% ethanol) was therefore used as control. 
 
 
Figure 4.3: Vitamin D Receptor (VDR), 1α-Hydroxyalse (1α-OHase) and 24-
Hydroxyalse (24-OHase) protein expression in vehicle treated Human Aortic 
Smooth Muscle Cells (HAoSMC) over time. Representative Western blots. Cells 
were incubated with vehicle (0.1% ethanol) for 2, 4, 6, 24 and 48 hours – no obvious 
changes in protein levels, over time, were observed.    
 
Western blot analyses of protein expression in HAoSMCs exposed to 1,25(OH)2D3 
(10 nM) for 6, 24 and 48 hours demonstrated that VDR protein was significantly 
elevated (1.8-fold) at 6 hours (p=0.015),  compared to 6 hour vehicle treated control, 
confirming that VDR is a target for 1,25(OH)2D3 (Figure 4.4A). 1α-OHase protein 
was significantly inhibited (0.2-fold) at 6 hours (p=0.044) after exposure to 
1,25(OH)2D3 (10 nM)  (Figure 4.4B). 
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Figure 4.4: The effect of 1,25(OH)2D3 on the Vitamin D receptor (VDR), 1α-
Hydroxylase (1α-OHase) and 24-Hydroxyalse (24-OHase) protein expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs) over time. Cells were incubated 
with vehicle (0.1% ethanol) or 10 nM 1,25(OH)2D3 for 6, 24 and 48 hours. (A) VDR 
protein expression (B) 1α-OHase protein expression (C) 24-OHase protein 
expression, as demonstrated by Western blot analyses. Results represent mean of 
relative protein levels ± SEM, n=4-8; * p < 0.05; vs. control, as determined by one-
way ANOVA. Results were normalised to β-actin levels. Next to each graph are the 
representative Western blots. 
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24-OHase protein was significantly upregulated at 6 hours (p=0.01), just like 1α-
OHase and VDR (Figure 4.4C).  
 
In summary, 1,25(OH)2D3 (10 nM) activated VDR gene transcription by 2 hours and 
VDR protein synthesis by 6 hours, which consequently modulated the expression of 
the downstream genes – CYP27B1 (by 6 hours) and CYP24A1 (by 2 hours, 6 hours 
and 24 hours).  VDR and CYP27B1 mRNA induction appeared to be tightly 
controlled by increase in CYP24A1 mRNA, via a negative feedback. Changes in 
VDR, 1α-OHase and 24-OHase protein expression by 6 hours reflected changes in 
mRNA. By 24 hours, no significant changes in protein expression were recorded, 
although the protein expression appeared to follow the trend described for mRNA 
(initial increase in VDR early after 1,25(OH)2D3 stimulation, increase in 24-OHase 
and drop in 1α-OHase, further increase in 24-OHase, VDR and 1α-OHase back to 
control levels).  
 
 The VDR is a Target for 1,25(OH)2D3: Regulation of the VDR, 1α-OHase 
and 24-OHase by 1,25(OH)2D3 – Dose Dependence 
 
In order to obtain a broader picture of the dynamics of VDR activation, the effect of 
increasing concentrations of 1,25(OH)2D3  (0.1, 1, 10, 100 nM; 6 hours was chosen 
based on my earlier results where 10 nM 1,25(OH)2D3 significantly altered 
expression of VDR, 1α-OHase and 24-OHase protein at 6 hours, see Figure 4.2) on 
expression of VDR, CYP27B1 and CYP24A1 mRNA and protein was examined in 
HAoSMCs.  
 
Real-time RT-PCR analyses confirmed that VDR mRNA was significantly increased 
(10-fold) by 1,25(OH)2D3 (10 nM) (p=0.040) (Figure 4.5A), CYP27B1 mRNA was 
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significantly decreased, by 0.5-fold (p=0.038) by 1,25(OH)2D3 (10 nM) (also by 1 or 
100 nM 1,25(OH)2D3; p=0.021, p=0.042 respectively) (Figure 4.5B), conversely 
CYP24A1 mRNA was elevated by 1000-fold (p=0.021) by 1,25(OH)2D3 (10 nM) 
(also by 100 nM 1,25(OH)2D3; 4000-fold; p=0.033) (Figure 4.5C). When CYP27B1 
mRNA expression was reduced by over a quarter, CYP24A1 mRNA was increased 
by over 4000-fold.  
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Figure 4.5: The effect of 1,25(OH)2D3 on 1α-Hydroxylase (CYP27B1), 24-
Hydroxylase (CYP24A1) and Vitamin D Receptor (VDR) mRNA expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs). Cells were incubated with 
vehicle (0.1% ethanol, control), or 0.1, 1, 10 or 100 nM 1,25(OH)2D3 for 6 hours. 
(A) CYP27B1 mRNA expression (B) CYP24A1 mRNA expression (C) VDR mRNA 
expression, as demonstrated by real-time RT-PCR. All readings were normalised to 
18S rRNA levels. Results represent mean of relative mRNA levels and were plotted 
against treatment concentrations, n=3-4; * p < 0.05; vs. control, as determined by 
one-way ANOVA.  
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In general, changes induced by 1,25(OH)2D3 in mRNA expression corresponded to 
the changes detected in protein expression for VDR, 1α-OHase and 24-OHase, with 
a few exceptions. There was no significant decrease in 1α-OHase (nor the significant 
increase in 24-OHase) protein expression at higher concentration of 1,25(OH)2D3 
(100 nM) (Figure 4.7). Otherwise, at 6 hours VDR protein expression was 
significantly induced (over 2-fold) by 10 nM or 100 nM 1,25(OH)2D3 (p=0.021, 
p=0.027 respectively), compared to control (Figure 4.6). 1α-OHase protein level 
dropped significantly as a result of treatment with 0.1 nM, 1 nM or 10 nM of 
1,25(OH)2D3 (p=0.030, p=0.021, p=0.038 respectively), as compared to control 
(Figure 4.7A). 24-OHase protein was significantly induced 1.36-fold by 10 nM 
1,25(OH)2D3, compared to control (p=0.017) (Figure 4.7B).   
 
 
 
 
Figure 4.6: The effect of 1,25(OH)2D3 on the Vitamin D Receptor (VDR) protein 
expression in Human Aortic Smooth Muscle Cells (HAoSMCs). Cells were 
incubated with vehicle (0.1% ethanol, control) or 0.1, 1, 10 or 100 nM 1,25(OH)2D3 
for 6 hours. VDR protein expression levels were normalised to β-actin. Results 
represent mean of relative protein levels ±SEM, n= 3-9; * p < 0.05; vs. control, as 
determined by one-way ANOVA. Below the graph are the representative Western 
blots.  
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Figure 4.7: The effect of increasing concentrations of 1,25(OH)2D3 on 1α-
Hydroxylase (1α-OHase) and 24-Hydroxylase (24-OHase) protein expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs). Cells were incubated with 
vehicle (0.1% ethanol, control) or 0.1, 1, 10 or 100 nM 1,25(OH)2D3  for 6 hours. 
(A) 1α-OHase protein expression (B) 24-OHase protein expression. 1α-OHase and 
24-OHase protein levels were normalised to β-actin. Results represent mean of 
relative protein levels ± SEM, n= 3-9, * p < 0.05; vs. control, as determined by one-
way ANOVA. Below the graphs are the representative Western blots. 
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4.2.2 Local Synthesis of 1,25(OH)2D3 from 25(OH)D3 in HAoSMCs – 
Time Dependence 
  
 
In order for the treatment with 25(OH)D3 to act via the VDR, 25(OH)D3 has to first 
be converted to 1,25(OH)2D3. HAoSMCs were treated with 25(OH)D3 (100 nM) for 
2, 4, 6 and 24 hours and changes in VDR, CYP27B1 and CYP24A1 mRNA were 
examined by real-time RT-PCR. Results indicated that VDR mRNA expression was 
significantly induced (3.7-fold) at 2 hours  (p=0.007) and by (2.6-fold) at 4 hours 
(p=0.047) compared to control. Interestingly, the mRNA levels dropped to control 
levels by 6 hours and significantly dropped below control levels (0.6-fold) by 24 
hours (p=0.007) (Figure 4.8A). CYP27B1 mRNA expression was significantly 
inhibited at 6 hours (p=0.042) (Figure 4.8B). 25(OH)D3 (100 nM) significantly 
induced CYP24A1 mRNA at 2 hours (18.9-fold) (p=0.021), at 4 hours (143.3-fold) 
(p=0.049), at 6 hours (923.3-fold) (p=0.009) and at 24 hours (153.8-fold) (p=0.046) 
(Figure 4.8C). These results demonstrate local synthesis of 1,25(OH)2D3 from 
25(OH)D3. 
 
Western blot analyses demonstrated that 25(OH)D3 (100 nM)  did not induce VDR 
protein at 48 hours (p=0.28) (Figure 4.9A). 1α-OHase protein was significantly 
induced 1.7-fold at 24 hours, compared to control (p=0.049) (Figure 4.9B).  
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Figure 4.8: The effect of 25(OH)D3 on Vitamin D Receptor (VDR), 1α-
Hydroxylase (CYP27B1) and 24-Hydroxylase (CYP24A1) mRNA expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs) over time. Cells were incubated 
with vehicle (0.1% ethanol, control) or 100 nM 25(OH)D3 for 2, 4, 6, 24 and 48 
hours. (A) VDR mRNA expression (B) CYP27B1 mRNA expression (C) CYP24A1 
expression, as demonstrated by real-time RT-PCR.  VDR, CYP27B1 and CYP24A1 
mRNA levels were normalised to 18S rRNA levels. Results represent mean of relative 
mRNA levels; n =4-5, * p < 0.05; vs. control, as determined by one-way ANOVA.  
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The increase in 1α-OHase protein was preceded by 1.4-fold raise (not-statistically 
significant) in CYP27B1 mRNA at 24 hours (the peak could have occurred at an 
earlier time point – for instance 12 hours, which would allow a sufficient lag for the 
subsequent protein synthesis by 24 hours) (Figure 4.8B). An increase in 1α-OHase 
protein at 24 hours could indicate that there was a need for 1α-OHase protein to 
outcompete 24-OHase due to an abundance of substrate: 25(OH)D3. 24-OHase 
protein expression was not significantly different (Figure 4.9C).  
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Figure 4.9: The effect of 25(OH)D3 on the Vitamin D Receptor (VDR), 1α-
Hydroxylase (1α-OHase) and 24-Hydroxyalse (24-OHase) protein expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs) over time. Cells were incubated 
with vehicle (0.1% ethanol) or 10 nM 1,25(OH)2D3 for 6, 24 and 48 hours. (A) VDR 
protein expression (B) 1α-OHase protein (C) 24-OHase protein expression, as 
demonstrated by Western blot analyses. VDR, 1α-OHase, 24-OHase protein levels 
were normalised to β-actin. Results represent mean of relative protein levels ± SEM, 
n=4-8; * p < 0.05; vs. 6h control, as determined by one-way ANOVA; NS – not 
significant. Next to each graph are the representative Western blots. 
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4.2.3 Local Synthesis of 1,25(OH)2D3 from 25(OH)D3 in HAoSMCs – 
Dose Dependence 
 
In order to examine the impact of substrate availability on VDR signalling dynamics, 
HAoSMCs were incubated with vehicle (0.1% ethanol) or increasing concentrations 
of 25(OH)D3 (0.1, 1, 10, 100 nM for 6 hours – based on my earlier results). VDR, 
CYP27B1 and CYP24A1 mRNA and protein levels were analysed.  
 
Real-time RT-PCR analyses showed that CYP27B1 mRNA was significantly 
decreased 0.5-fold by 100 nM 25(OH)D3 (p=0.03) and 0.6-fold by 1000 nM 
(p=0.03) (Figure 4.10B). CYP24A1 mRNA expression was significantly elevated 
2000-fold by 100 nM 25(OH)D3 (p=0.018) and 1000-fold by 1000 nM 25(OH)D3 
(p=0.014) (Figure 4.10C).  VDR mRNA levels were not significantly different 
(Figure 4.10A). 
 
Western blot analyses revealed, that at 6 hours VDR protein expression was not 
significantly changed (Figure 4.10A). As seen previously, 100 nM 25(OH)D3 did not 
induce a significant change in 1α-OHase protein expression. Also, no changes were 
induced by higher or lower concentrations of 25(OH)D3 (1, 10, 1000 nM) (Figure 
4.11B). There was a lot of variation in 24-OHase protein expression between 
individual experiments, which was reflected in large SEM values.  
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Figure 4.10: The effect of increasing concentrations of 25(OH)D3 on the Vitamin 
D Receptor (VDR), 1α-Hydroxylase (CYP27B1) and 24-Hydroxylase (CYP24A1) 
mRNA expression in Human Aortic Smooth Muscle Cells (HAoSMCs). Cells were 
incubated with vehicle (0.1% ethanol, control) or 1, 10, 100 or 1000 nM 25(OH)D3 
for 6 hours. (A) VDR mRNA expression (B) CYP27B1 mRNA expression (C) 
CYP24A1 mRNA expression, as demonstrated by real-time RT-PCR. Values were 
normalised to 18S rRNA levels. Results represent mean of relative mRNA levels, n 
=4-5;* p < 0.05; vs. control, as determined by one-way ANOVA; NS –not significant. 
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1000 nM 25(OH)D3 had no effect on 24-OHase protein expression (Figure 4.11C).  
It is possible that changes in protein do not reflect activity. 
 
 
 
Figure 4.11: The effect of increasing concentrations of 25(OH)D3 on Vitamin D 
Receptor (VDR), 1α-Hydroxylase (1α-OHase) and 24-Hydroxylase (24-OHase) 
protein expression in Human Aortic Smooth Muscle Cells (HAoSMCs). Cells were 
incubated with vehicle (0.1% ethanol, control) or 1, 10, 100 or 1000 nM 25(OH)D3  
for 6 hours. (A) VDR, (B) 1α-OHase, (C) 24-OHase protein, as demonstrated by 
Western blot analyses. VDR, 1α-OHase and 24-OHase protein levels were 
normalised to β-actin. Results represent mean of relative protein levels ± SEM, n= 3-
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9, * p < 0.05; vs. control, as determined by one-way ANOVA. Next to each graph are 
the representative Western blots. 
 
 
Differences in 24-OHase-Driven Catabolism might be Substrate Dependent  
 
 
High local concentration of 1,25(OH)2D3 (10nM) or very high (100 nM) (equivalent 
to 10 X physiological levels in circulation ~ 0.11 nM)  significantly induced 
CYP24A1 mRNA at 6 hours, as discussed earlier. Similarly, high concentration of 
25(OH)D3 (100 nM) or very high (1000 nM) (physiological level in circulation ~ 50 
nM) also significantly induced CYP24A1 mRNA expression by 6 hours. However, 
when CYP24A1 mRNA increase was almost logarithmic in response to increasing 
doses of 1,25(OH)2D3 (Figure 4.12A), it appeared that highest dose of 25(OH)D3 
(1000 nM) resulted in the 1000-fold drop, compared to CYP24A1 mRNA levels 
induced by 100 nM 25(OH)D3 (Figure 4.12B).  
24-OHase protein expression by 6 hours only partially reflected changes in mRNA. 
1,25(OH)2D3 (10 nM and 100 nM) induced no significant change in 24-OHase 
(Figure 4.13).  
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Figure 4.12: The effect of increasing concentrations of 1,25(OH)2D3 or 25(OH)D3 
on 24-Hydroxylase (CYP24A1) mRNA expression in Human Aortic Smooth 
Muscle Cells (HAoSMCs). Cells were incubated with vehicle (0.1% ethanol, 
control) or 0.1, 1, 10, 100 nM 1,25(OH)2D3 or 1, 10, 100 or 1000 nM 25(OH)D3 for 
6 hours. (A) CYP24A1 mRNA expression was significantly increased by 10 and 100 
nM 1,25(OH)2D3, whereas (B) CYP24A1 mRNA was significantly induced by 100 nM 
and 1000 nM 25(OH)D3. Readings were normalised for 18S rRNA levels. Results 
represent mean of relative mRNA levels, n =4-5; * p < 0.05; vs. untreated control, as 
determined by one-way ANOVA.  
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Figure 4.13:  The effect of increasing concentrations of 1,25(OH)2D3 or 25(OH)D3 
on 24-Hydroxylase (24-OHase) protein expression in Human Aortic Smooth 
Muscle Cells (HAoSMCs). (A) Cells were incubated with vehicle (0.1% ethanol, 
control) or 10 or 100 nM 1,25(OH)2D3 for 6 hours (B) Cells were incubated with 
vehicle (0.1% ethanol, control) or 100 or 1000 nM 25(OH)D3 for 6 hours. Protein 
expression as demonstrated by Western blot analyses. 24-OHase protein levels were 
normalised to β-actin. Results represent mean of relative protein levels, n =4-5; * p 
< 0.05; vs. control, as determined by one-way ANOVA.  
 
 
4.2.4 Vitamin D Signalling in Human Arteries 
 
The Effect of 1,25(OH)2D3 on VDR, CYP27B1 and CYP24A1 mRNA 
Expression in Healthy and CKD Human Artery 
 
 
To translate my previous in vitro findings to organ, artery culture and to confirm that 
the normal functioning of vitamin D system in healthy human artery is altered in 
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CKD, real-time RT-PCR analyses were carried out using RNA isolated from arterial 
explants of healthy and CKD patients. Arterial explants from both groups (n = 11 
healthy, n = 16 CKD) were washed in growth medium and incubated with 10 nM 
1,25(OH)2D3 for 48 hours allowing time for the steroid to penetrate the artery 
(Figure 2.3). All real time RT-PCR analyses human artery data were provided by Dr 
Guerman Molostvov. 
 
In healthy arteries, the basal expression of VDR mRNA was significantly higher 
(50%) than in arteries from patients undergoing kidney transplantation (p<0.01)  
(Figure 4.15A). CYP27B1 mRNA in CKD vessels was increased by almost 100%, 
compared to levels in healthy arteries (p<0.01) (Figure 4.14B). No significant 
differences in expression of CYP24A1 mRNA between healthy and CKD arteries 
were detected (Figure 4.14C).  
 
Real-time analyses indicated a very large increase (470%) in VDR mRNA, as a 
response to 1,25(OH)2D3 in healthy arteries compared to healthy untreated control 
(p<0.05) (Figure 4.14A). This induction was not as strong in CKD, with only a 50% 
increase in VDR mRNA expression (p<0.01) (Figure 4.14A). Treatment with 
1,25(OH)2D3 (10 nM) lead to 24% decrease in  CYP27B1 mRNA in healthy arteries, 
compared to healthy untreated arteries, however the change was not statistically 
significant (Figure 4.14B). Conversely, in CKD arteries, 1,25(OH)2D3 (10 nM) 
induced a 22% increase in CYP27B1 mRNA expression, compared to untreated CKD 
arteries, however the increase was not statistically significant. CYP27B1 mRNA 
basal levels in healthy untreated arteries were 94% lower than in CKD (p<0.01). 
CYP24A1 mRNA levels were 24% lower in CKD arteries, compared to levels in 
healthy untreated arteries. At 48 hours, 1,25(OH)2D3 induced a 2096% increase in 
CYP24A1 mRNA in healthy arteries, compared to healthy untreated arteries 
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(p<0.01). In CKD arteries 1,25(OH)2D3 (10 nM) induced a stunning  increase 
(34352%) in CYP24A1 mRNA levels (p<0.0001). CYP24A1 mRNA induction, as a 
result of 1,25(OH)2D3 (10 nM) 48h treatment, was 32242% higher in CKD than in 
healthy arteries (p<0.001) (Figure 4.14C). 
 
The Relation between CYP27B1 and CYP24A1 mRNA and Protein 
Expression in Normal Human and CKD Arteries  
 
 
In chapter 3 I showed that VDR protein expression was not significantly different in 
CKD arteries, compared to healthy arteries (Figure 3.5). Whereas mRNA data 
showed a significant decrease in VDR expression in CKD (50%) compared to healthy 
arteries (p<0.01) (Figure 4.14A). 
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Figure 4.14: The effect of 1,25(OH)2D3 on the Vitamin D Receptor (VDR), 1α-
Hydroxylase (CYP27B1) and 24-Hydroxyalse (CYP24A1) mRNA expression in 
Healthy and Chronic Kidney Disease (CKD) arteries. Arteries were incubated with 10 
nM 1,25(OH)2D3 for 48 hours. Differences in mRNA expression were examined by real-
time RT-PCR analysis (normalised to 18S rRNA levels). Note different scales. (A) VDR 
mRNA expression, (B) CYP27B1 mRNA expression (C) CYP24A1 mRNA expression. 
Results represent mean of relative mRNA levels; n =11 healthy, 16 CKD, * p < 0.05; vs. 
healthy untreated control and vs. healthy treated control, as determined by one-way 
ANOVA. 
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Although, CYP27B1 mRNA expression was significantly increased in CKD, 
compared to healthy arteries (98%) (p<0.01) (Figure 4.14A), this was not reflected in 
protein levels, which were significantly lower in CKD, compared to control arteries 
(p=0.048) (Figure 3.6). CYP24A1 mRNA levels were 24% lower in CKD than in 
control arteries, however the difference was not statistically significant (Figure 
4.14C). This was not reflected in 24-OHase protein expression, as earlier results 
showed that 24-OHase protein expression was increased by over a quarter in CKD, 
compared to healthy arteries, here too, the change was not statistically significant 
(p=0.12) (Figure 3.7). Despite some of the changes being statistically insignificant, 
the uncoupling between CYP27B1 and CYP24A1 mRNA and protein levels in 
healthy and CKD arteries may be a true phenomenon and a larger sample size is 
required to confirm this finding. 
 
4.2.5 The Assessment of 1α-OHase Activity in HAoSMCs and in Healthy 
and CKD Artery 
 
 
HAoSMCs and human artery samples (healthy, n=8 and CKD, n=11) were collected 
and treated as described in chapter 2.2.4.1 to determine the synthesis of 
1,25(OH)2D3.  
Synthesis of 1,25(OH)2D3 was determined by treating samples for 5 hours with 100 
nM 25(OH)D3. Secreted 1,25(OH)2D3 was assayed by EIA (Dr Guerman Molostvov). 
All samples synthesised 1,25(OH)2D3 indicating 1α-OHase activity.  
 
HAoSMCs are able to synthesise 1,25(OH)2D3 (118.9 fmoles of 1,25(OH)2D3/mg 
protein (/5 hours) indicating 1α-OHase activity (Figure 4.15A). Data from the arterial 
samples indicated that although 1,25(OH)2D3 synthesis could be detected levels were 
significantly lower than that seen in HAoSMCs (Figure 4.15), note different scales. 
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In addition, 1,25(OH)2D3 production was significantly reduced in arteries from CKD 
patients (3.5 fmoles of 1,25(OH)2D3/mg protein/5h vs. 17.6 fmoles of 
1,25(OH)2D3/mg protein/5h), p=0.036 (Figure 4.15B). 
 
 
 
Figure 4.15 Synthesis of 1,25(OH)2D3 in Human Aortic Smooth Muscle Cells 
(HAoSMCs), Healthy Artery and Chronic Kidney Disease (CKD) Artery, as 
determined by EIA; (A)HAoSMCs (B) Arteries; data represent the mean ± SEM, 
healthy n=8, CKD=11, *p<0.05 as determined by Student’s t-test. Note different 
scales. 
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4.3 Discussion 
 
Experimental evidence presented in this chapter strongly suggests that vasculature is 
a target tissue for 1,25(OH)2D3, as confirmed by the increased expression of VDR 
mRNA and protein resulting from the treatment. 10 nM 1,25(OH)2D3 has been 
shown in the past to significantly decrease DNA synthesis, in an in vitro model of 
human VSMCs (Somjen et al. 2005), however as it is extremely difficult to measure 
local concentrations of 1,25(OH)2D3 elsewhere than in plasma, the treatment 
concentrations of 1,25(OH)2D3 used in studying local changes in cell and tissue 
physiology, have been based on previous experimental work of others. 100 nM 
25(OH)D3 has been previously shown to induce optimal cellular 25(OH)D3 to 
1,25(OH)2D3 conversion rate of 4-10%, in osteoblasts (Atkins et al. 2007).  
My studies of vitamin D system in HAoSMCs indicated that exogenous 10 nM 
1,25(OH)2D3 induces responses similar to the ones seen in kidney proximal tubular 
cells. Excess of free and available 1,25(OH)2D3 induced VDR expression in dose 
dependent manner. Increased rate of VDR/1,25(OH)2D3 complex formation 
consequently suppressed CYP27B1 mRNA and protein as early as at 6 hours 
concomitantly inducing astonishing response in CYP24A1 mRNA and protein, to 
counteract the effect of 1,25(OH)2D3/VDR complex formation. On this basis it is not 
unreasonable to state that the vascular vitamin D system is governed by the same 
classical negative feedback regulation as the one in the endocrine system. An 
interesting observation was that 10 nM 1,25(OH)2D3 at 48 hours did not alter 1α-
OHase and 24-OHase protein, which implied that the clearance of 1,25(OH)2D3 in 
HAoSMCs must be very effective. This phenomenon most probably would not be 
observed had the 1,25(OH)2D3 been continually repleted. This mechanism makes 
vascular responses very dynamic and protects cells from excess of 1,25(OH)2D3. It 
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has been postulated that 25(OH)D3 can also bind to VDR, but with much lesser 
affinity (Eisman and DeLuca 1977). In my study 100 nM 25(OH)D3 appeared to 
almost mimic the changes in VDR, CYP27B1 and CYP24A1 mRNA induced in 
HAoSMCs by 1,25(OH)2D3 (10 nM). Interestingly the key difference between 10 nM 
1,25(OH)2D3 and 100 nM 25(OH)D3 was the effect of each on 1α-OHase protein 
expression. The first one rapidly (by 6 hours) inhibited the synthesis of 1α-OHase 
(result of abundance of active vitamin D), whereas the latter induced 1α-OHase 
protein expression (by 24 hours; result of abundance of substrate for 1α-
hydroxylation). Highest concentrations of 1,25(OH)2D3 (100 nM) or 25(OH)D3 
(1000 nM) had different effect on CYP24A1 mRNA expression. This may be due to 
the build up of different catabolites – 1,24,15(OH)3D3, which is inactive and does not 
inhibit CYP24A1 mRNA synthesis (accumulation of which may be an effect of 
1,25(OH)2D3 abundance), or 24,25(OH)2D3, which may exhibit enough activity 
analogous to 1,25(OH)2D3, suppressing CYP24A1 mRNA synthesis (accumulation of 
which may be an effect of 25(OH)D3 abundance). Another factor may be biological 
effect of 25(OH)D3 directly competing with 1,25(OH)2D3 for VDR.  
Originally, 1,25(OH)2D3 synthesis was described in kidney (Fraser DR; Kodicek, E. 
1970, Midgett et al. 1973). Unfortunately, to date only limited cell models of the 
normal human kidney exist: HKC-8 from proximal tubule cells (Racusen et al. 1997) 
and the HCD, distal convoluted tubule cells (Prie et al. 1995). The vitamin D system 
has been well characterized in these cells (Bland et al. 1999, Bland et al. 2001). 
Evidence suggests that renal production of 1,25(OH)2D3 is regulated differently to 
some extra-renal sites. As described Chapter 1.4, in kidney synthesis of 1,25(OH)2D3 
is enhanced by increases in the serum PTH concentration, a drop in serum phosphate 
concentration, and a decrease in the activity of the competing 24-OHase. To date, the 
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most extensively studied extra-renal model of vitamin D system, after colon, 
prostate, decidua, placenta, bone and breast tissue, are human macrophages, and 
therefore will be used for simple comparisons. It is important to note that 
macrophages are cells of the immune system and their role differs vastly from that of 
VSMCs or kidney cells, which consequently highlights the potential variety of 
vitamin D tissue-specific actions. Studies in patients with sarcoidosis (a condition 
characterized by increased intestinal calcium absorption and bone resorption, where 
common symptoms include hypercalcaemia, ultimately resembling 1,25(OH)2D3 
intoxication) demonstrated high levels of 1α-OHase in macrophages isolated from 
the lymph nodes, which was not inhibited by treatment with 1,25(OH)2D3, in vitro 
(Hewison et al. 1989, Reichel et al. 1987). Both renal and macrophage 1α-OHase are 
products of the same gene (Smith S. J. et al. 1999) (existence of a number of non-
coding functionally active splice variants of CYP27B1 has been demonstrated in 
HKC-8 cells (Wu et al. 2007)), activity of both is dependent on the availability of 
nitric oxide, both require the presence of a flavoprotein, ferredoxin reductase, an 
electron source and a molecular oxygen in order to attach an oxygen atom to the 
substrate (Shany et al. 1993), both are inhibited by specific compounds which 
compete for electrons or oxygen (Adams et al. 1994), both require secosterol for a 
substrate (Reichel et al. 1987) and both exhibit highest affinity for 25(OH)D, then 
24,25(OH)2D (Fraser D. R. 1980, Hewison M. 2011). Interestingly though, 
macrophages have no 1,25(OH)2D-directed 24-OHase activity, as opposed to renal 
epithelial cells, where higher levels of 24-OHase can block 25(OH)D or 1,25(OH)2D 
down the catabolic 24-OHase pathway. A possible explanation may be the existence 
of 24-OHase SV (splice variant), which due to specific truncation cannot be targeted 
to mitochondrial membrane, lacks catabolic activity and is highly abundant in 
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cytoplasm, potentially readily binding to 25(OH)D and 1,25(OH)2D (Adams et al. 
2007, Hewison M. 2011). In vasculature, basal levels of CYP24A1 mRNA are higher 
than those of CYP27B1, and for such system to maintain stable levels of 
1,25(OH)2D3, 1α-OHase must have higher affinity for 25(OH)D3 than 24-OHase, as 
described in kidney (Henry H. L. 1979). Regardless of this, 24-OHase through its 
ability to reach high concentrations has a high capacity for acting on 25(OH)D3, 
taking into consideration how readily 24-OHase levels can be upregulated by 
increased 1,25(OH)2D3 (Hewison M. 2011, Omdahl J. L. et al. 2001). Interestingly, 
evidence from studies on adenine induced CKD rats demonstrated, that as 25(OH)D3 
and 1,25(OH)2D3 levels decrease, CYP24A1  mRNA and protein are strongly 
induced and CYP27B1 mRNA and protein levels do not change (Anderson et al. 
2003).  
To recognise the role for extra-renal vitamin D system metabolism and regulation, 
the ground-braking experiments of Dusso and colleagues from over two decades ago 
must be considered (Dusso et al. 1988, Dusso et al. 1991). In these neat studies, 
supplementation of anephric haemodialysed patients with 25(OH)2D3 resulted in 
significantly elevated 1,25(OH)2D3 levels in the serum, indicating that this enhanced 
net synthesis of 1,25(OH)2 must have been attributed to extra-renal sites. What is 
more, no significant changes in serum calcium, i-PTH nor phosphate levels were 
recorded, confirming that the function of the vitamin D system in extra-renal sites 
may vary from the one in kidney. So the question to be asked is what causes the 
impaired serum 25(OH)D3 availability for renal and extra-renal 1,25(OH)2D3 
synthesis and is this relevant to autocrine VDR activation involved in cardiovascular 
protection? Exposure of normal human arteries to the exogenous 10 nM 
1,25(OH)2D3 resulted in the same responses as the ones in our primary cell in vitro 
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model system. Most significant changes occurred at 48 hours. Importantly, real-time 
RT-PCR analyses and Western analyses confirmed that the expression of VDR, 
CYP27B1 and CYP24A1 mRNA were altered in CKD vessels, however these 
changes have not exactly mirrored the changes in protein described in the previous 
chapter. The main distinction was 1α-OHase, which was significantly reduced at 
protein level in vessels from CKD patients and significantly elevated at mRNA level. 
The fact that RNA levels are not reflected in protein may indicate dysregulation of 
the system. Interestingly, macrophages exhibit very low basal 24-OHase activity, as 
opposed that in renal epithelial cells. Activity of 24-OHase in VSMCs has not been 
investigated to date, although based on our experimental work it became evident, that 
basal CYP24A1 mRNA levels are higher than these of VDR and CYP27B1 mRNA 
levels. Previous studies by others have shown that in both systems: macrophages and 
renal epithelial cells, treatment with exogenous 1,25(OH)2D leads to potent increase 
in CYP24A1 mRNA production. Again, one of the explanations could be presence of 
24-OHase-SV. Another plausible rationalization could be action of siRNA species or 
any other factors ultimately involved in undesired post-transcriptional modifications 
of CYP27B1 mRNA, as well as those interfering with protein translation, in VSMCs.  
What is more, a challenge with 10 nM 1,25(OH)2D3 in uraemic arteries had no 
inhibitory effect on CYP27B1 mRNA levels and indeed induced significant 
upregulation of CYP24A1 – a result similar to the one described by Anderson in 
CKD rats. The 24-OHase protein induction was significantly higher in CKD 
compared to the one in healthy arteries. This on the other hand, seems to translate 
into our earlier observations, where CYP24A1 was increased in CKD vessels 
(Chapter 3). Notably, increased expression of 24-OHase in these ureamic tissues may 
attenuate local levels of 1,25(OH)2D3 either by converting the active metabolite to 
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1,24,25(OH)3D3 or by competing with 1α-OHase for a substrate (25(OH)D3), 
generating 24,25(OH)2D3. It is important to note, that the astonishing inhibitory ratio 
of CYP24A1 to CYP27B1 mRNA of 1: 1600 calculated based on the Real Time RT-
PCR results, ought to be interpreted with caution as there are limits to translating 
RNA levels into activity due to possible action of micro RNAs preventing proportion 
of the CYP24A1 mRNAs form being translated into fully functional enzymes. 
Evidence suggests that 24,25(OH)2D may have an effect on bone mass and 
metabolism. It has been reported that in hyperphosphataemic mice it normalized 
bone resorption (Ono et al. 1996). More recently, increased serum 24,25(OH)2D3 
(presumably due to increased 24-OHase activity) has  been reported in children with 
severe osteogenesis imperfecta, a primary bone disorder, where bone mass is reduced 
leading to extremely fragile bones (Edouard et al. 2012). It can be speculated that the 
mechanism, which can be protective in bone, may lead to uncoupling between 1α-
OHase, 24-OHase and VDR in other tissues, with VSMCs being an example. In 
Chapter 3, 24-OHase protein not only was shown to be increased in CKD arteries, 
compared to controls, but also increased 24-OHase protein expression co-localised 
with areas of calcification, RUNX-2 and sclerostin protein expression. On the basis 
of results presented in this chapter, it is plausible that when cells have higher than 
normal 25(OH)D : 1,25(OH)2D3 ratio, 24-OHase may be competing for a substrate, 
by hydroxylating both 1,25(OH)2D3 and 25(OH)D3, It would appear that a 
presumptive build up of 24,25(OH)2D3 inhibited CYP24A1 mRNA expression in 
VSMCs. It is possible that in CKD, this 24-OHase regulating mechanism is not 
functioning properly, leading to increased CYP24A1 mRNA and protein synthesis. 
Or increased 24-OHase in CKD aggravates substrate deprivation, by competing with 
1α-OHase for 25(OH)D3. 
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Decreased VDR mRNA and protein in the examined CKD vessels may further 
explain no significant inhibition in the transcription of CYP27B1 mRNA and 
consequently high CYP24A1 levels. Interestingly, there might be another cellular 
factor either contributing to accumulation of 1α-OHase at a pre-translation stage or a 
factor, which is controlling 1α-OHase protein degradation in CKD in order to explain 
our observations. High basal levels of CYP27B1 mRNA have been documented in 
hyperplastic human parathyroid glands secondary to CKD, as well as in parathyroid 
and breast carcinomas (Segersten et al. 2002, Segersten et al. 2005). 10 out of 15 
parathyroid adenoma and 8 out of 10 hyperplastic parathyroids from uremic patients 
had more than a 2-fold increase of CYP27B1 mRNA content compared to normal 
parathyroid glands. Interestingly, a subset of both adenomatous and hyperplastic 
glands showed reduced 1α-OHase expression. It is important to note that the 
potential effects of variable serum DBP on total versus free vitamin D metabolite 
levels are an important consideration in examining associations between these 
metabolites in CKD or any other pathology. Another factor influencing abnormal 
expression of the arterial vitamin D system in CKD may be a tissue specific uptake 
of vitamin D metabolites.  
Detection of 1,25(OH)2D3 synthesis in both HAoSMCs and human arteries, 
suggested 1α-OHase activity and confirmed the presence of a functional intact 
vitamin D system in vasculature. The significantly higher synthesis of 1,25(OH)2D3 
per milligram of protein in HAoSMCs compared to CKD arteries might have been 
attributed to the abundance of not only SMC protein, but also those from other cell 
types present in the artery. It could be speculated that the VSMCs are the 
predominant producers of 1,25(OH)2D3 in the human vasculature. Decreased 
expression of the 1α-OHase protein in CKD arteries (Chapter 3) is also reflected in 
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significantly decreased synthesis of 1,25(OH)2D3, suggesting that 1α-OHase activity 
may be essential for the maintenance of vascular health, 
In summary, using an in vitro model of HAoSMCs and normal human arteries, the 
presence of a functioning, intact VDR signalling was demonstrated. Data showed 
that the regulation of the VDR metabolism in these systems appeared to be similar to 
the one described by others in proximal tubular cells of the kidney (since challenge 
of HAoSMCs with 1,25(OH)2D3 significantly inhibited CYP27B1 mRNA and protein 
expression) and dissimilar to the vitamin D metabolism is macrophages. What is 
more, it was demonstrated that local 1α-OHase activity allowed VSMCs to 
synthesize 1,25(OH)2D3 from 25(OH)D3. This brings to attention the importance of 
25(OH)D3 sufficiency, i.e. availability of the substrate for local actions. Lastly, the 
data revealed significant changes in expression of VDR, CYP27B1 and CYP24A1 on 
both mRNA and protein level between healthy and CKD arteries. Further to that, it 
became evident that these changes may trigger abnormal responses to exogenous 
1,25(OH)2D3, especially by increasing 24-OHase synthesis. Consequently, from the 
clinical perspective, prolonged treatment with 1,25(OH)2D3 and possibly other active 
vitamin D compounds may result in activation of 24-OHase, potentially causing 
direct vascular therapeutic resistance.  High and dynamic regulation of the vascular 
vitamin D system may be an important feature, which if utilized correctly could 
prevent vascular CKD complications.  
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Chapter 5  
 
Classical Regulators of the  
Vitamin D System: Calcium, 
Phosphate and Inflammatory 
Cytokines 
 
 
 
 
 
5.1 Background  
 
Calcium and phosphate are classical regulators of the endocrine vitamin D system 
where they control of 1α-OHase and 24-OHase in kidney (Hughes et al. 1975, 
Zehnder et al. 2008). Inflammatory cytokines on the other hand, are classical 
regulators of the local auto/paracrine vitamin D system. Nonetheless, there is 
growing evidence that calcium, phosphate, TNF-α and INF-γ play an important role 
in regulating both systemic and local 1,25(OH)2D metabolism.  
The renal 1α-OHase is induced by low dietary calcium both directly and through 
increased PTH/cAMP and is suppressed by high dietary phosphate, through the 
action of FGF-23 (Bland et al. 1999, Hughes et al. 1975, Omdahl J. L. et al. 1972, 
Shimada et al. 2004b, Tanaka and Deluca 1973).  Recent evidence shows, that while 
circulating 1,25(OH)2D3 produced by the kidney regulates systemic calcium and 
phosphate balance through actions on the intestine, parathyroid glands, bone and 
kidney, it appears that 1,25(OH)2D3 produced locally in the parathyroid glands does 
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not exert calcitropic actions (Bikle D. 2009). What is more, Ritter and colleagues 
have demonstrated that high concentrations of calcium significantly upregulate 
CYP27B1 and CYP24A1 mRNA expression and activity of both enzymes in cultured 
hyperplastic human parathyroid cells (Ritter et al. 2012). Previous reports indicated 
similar results in bone (Anderson et al. 2010). This is directly opposite to the effect 
observed in kidney. The current literature on the implications of this sophisticated 
regulation of local vitamin D metabolism by calcium and phosphate in other extra-
renal tissues expressing 1α-OHase activity, especially human vasculature is limited.  
In vasculature, intracellular calcium is an important regulator of the vascular tone 
and blood flow (Green et al. 2006), whereas extracellular calcium sensing may play 
a role in maintenance of vascular health. Evidence shows that the calcium sensing 
receptor (CaSR) is not only expressed in human artery and VSMCs, but also that its 
expression is significantly lower in patients with ESRD (Molostvov et al. 2009, 
Molostvov et al. 2007).  Studies by Schroff and co-workers have further 
demonstrated that CKD vessels, ex vivo, exposed to high calcium and/or high 
phosphate concentrations accumulated calcium, as opposed to normal vessels. High 
calcium and high phosphate have been shown to increase calcification independently 
through induction of apoptosis and excretion of mineralising vesicles (Reynolds et 
al. 2004, Shroff R. C. et al. 2010). There is growing evidence that the systemic 
regulation of mineral homeostasis may be fine-tuned by local 1α-OHase in organs 
such as bone, vasculature and parathyroid.   
As well as mineral and hormonal dysregulation, CKD is a state of mild chronic 
inflammation. Complex interactions between infiltrating immune cells and vascular 
cells result in a production of cytokines and growth factors (Geng et al. 1997).  Local 
1α-hydroxylation may be an important mechanism by which VSMCs can reach the 
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appropriate levels of 1,25(OH)2D needed to shape and control cellular proliferation, 
differentiation, apoptosis an combat inflammation, without affecting systemic levels 
of the hormone.  
The proinflammatory cytokine TNF-α in particular seems to be an important player 
in VC, due to its suppressive action on VDR activation in SMCs of human bronchi 
(Agrawal et al. 2012). Furthermore it plays a role in an enhancement of osteoblastic 
transdifferenciation of human cardiovascular cells by increasing the transcription of 
bone-specific genes, such as RUNX-2, osteocalcin and ALP (Agrawal et al. 2012, 
Tintut et al. 2000). INF-γ, on the other hand inhibits the synthesis of α-SM actin, 
which attenuates cellular proliferation (Hansson et al. 1989). Synergistically, TNF-α 
and INF-γ have been shown to induce SMCs death (Geng et al. 1996). IL-6 is a pro-
inflammatory cytokine, synthesis of which is induced by TNF-α and a synergistic 
action of IL-17A and INF-γ (Eid et al. 2009).   
Taken together, evidence from previous studies demonstrating that calcium, 
phosphate, TNF-α, INF-γ, IL-6 and IL-17A independently affect non-renal 
metabolism of 1,25(OH)2D, in combination with my work described in chapter 4, 
which has demonstrated a functional, self-regulatable vascular vitamin D system, led 
to the assumption that there may be a specific role for all of these factors in 
regulating the vitamin D system locally in vascular cells in an autocrine fashion. 
This chapter examines the effect of calcium or phosphate on the expression of VDR, 
1α-OHase and 24-OHase in primary cultures of HAoSMCs. In addition, the outcome 
of treatment of HAoSMCs with the inflammatory cytokines, such as TNF-α, INF-γ, 
IL-6 and IL-17A on local vitamin D metabolism in these cells was examined.   
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5.2 Results 
 
5.2.1 Regulation of the Vascular Smooth Muscle Cell Vitamin D System 
by Calcium 
 
 
HAoSMCs were grown in DMEM/F-12 in the absence of serum for 24 hours prior to 
culture in media containing 1 mM calcium (basal concentration in DMEM/F-12 and 
the normal physiological concentration of calcium in ionised form) or media 
containing 2 mM or 3 mM of calcium for 6, 24 and 48 hours.  
 
5.2.1.1 Vitamin D Receptor is Modulated by Calcium 
 
 
2 mM calcium increased VDR protein expression at 6 and at 24 hours, but the 
increase was not quite statistically significant (p= 0.068, p= 0.067 respectively; one-
way ANOVA) the maximal effect observed at 24 hours (Figure 5.1). 3 mM calcium 
significantly elevated VDR protein expression by 2.6-fold as early as at 6 hours (p= 
0.007) and 1.7-fold at 24 hours (p= 0.040), compared to the 1 mM control at 
corresponding time points (Figure 5.1).  
 
5.2.1.2 Calcium Induced an Early and Sustained Increase in 1α-OHase and  
24-OHase 
 
2 mM calcium significantly increased 1α-OHase protein expression by 1.7-fold at 48 
hours (p= 0.001) (Figure 5.2). Similarly, 3 mM calcium induced significant 2.3-fold 
increase in 1α-OHase expression at 6 hours (p= 0.009), 1.9-fold increase at 24 hours 
(p= 0.053) and 1.7-fold increase at 48 hours (p= 0.001). 
24-OHase protein expression was significantly elevated by 7.4-fold at 6 hours in 
presence of 2 mM calcium (p= 0.014). 24-hour and 48-hour incubation with 3 mM 
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calcium significantly induced 24-OHase protein expression 2.7-fold (p= 0.033) and 
5.7-fold (p= 0.037) respectively, compared to the respective 1 mM 24-hour and 48-
hour controls (Figure 5.3).  
 
 
 
 
Figure 5.1: The effect of Calcium on expression of the Vitamin D Receptor (VDR) 
protein in Human Aortic Smooth Muscle Cells (HAoSMCs) over time. HAoSMCs 
were cultured in serum-free medium containing 1 mM calcium (normal) or 2 mM or 
3 mM (high), for 6, 24 and 48 hours. (A) VDR protein expression normalised to β-
actin protein levels, as demonstrated by Western blot analyses. Results represent 
mean ± SEM, n = 6, * p < 0.05; vs. 1 mM for each time point; data were analysed by 
one-way ANOVA. (B) Representative Western blot; cell lysates were separated by 
10% SDS-PAGE and blotted with anti-VDR and anti-β-actin.     
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Figure 5.2: The effect of Calcium on the 1α-Hydroxylase (1α-OHase) protein 
expression in Human Aortic Smooth Muscle Cells (HAoSMCs) over time. 
HAoSMCs were cultured in serum-free medium containing 1 mM calcium (normal) 
or 2 mM or 3 mM (high), for 6, 24 and 48 hours. (A) 1α-OHase protein expression, 
normalised to β-actin protein levels, as demonstrated by Western blot analyses. 
Results represent mean ± SEM, n = 6, * p < 0.05; vs. 1 mM for each time point; data 
were analysed by one-way ANOVA (B) Representative western blot - note different 
layout to the graph; cell lysates were separated by 10% SDS-PAGE and Western 
blotted with anti-1α-OHase and anti-β-actin.   
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Figure 5.3: The effect of Calcium on the 24-Hydroxylase (24-OHase) protein 
expression in (Human Aortic Smooth Muscle Cells) HAoSMCs over time. 
HAoSMCs were cultured in serum-free medium containing 1 mM calcium (normal) 
or 2 mM or 3 mM (high), for 6, 24 and 48 hours. (A) 24-OHase protein expression, 
normalised to β-actin protein levels, as demonstrated by Western blot analyses. 
Results represent mean ± SEM, n = 6, * p < 0.05; vs.1 mM for each time point; data 
were analysed by one-way ANOVA. (B) Representative Western blot-note different 
layout to the graph; cell lysates were separated by 10% SDS-PAGE and Western 
blotted with anti-24-OHase and anti-β-actin. 
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5.2.2 Regulation of  the Vascular Smooth Muscle Vitamin D System by 
Phosphate  
 
HAoSMCs were cultured in varying levels of phosphate (1,2 or 3 mM) for 6, 24 and 
48 hours. The basal level of phosphate in the medium was 1 mM (normal 
physiological concentration is 0.5-1 mM in ionised form).  
 
5.2.2.1 Vitamin D Receptor is Not Affected by Phosphate 
 
 
2 mM phosphate had no effect on VDR protein expression (Figure 5.4). 
 
5.2.2.2 Phosphate Induces the 1α-OHase and 24-OHase Expression 
 
 
2 mM phosphate significantly induced 1α-OHase protein expression by 2.3-fold at 
24 hours (p= 0.044) (Figure 5.5), 3 mM phosphate induced no significant change 
(Figure 5.5).  24-OHase protein was also induced by 2 mM phosphate, at 24 hours 
(3.2-fold, p= 0.039) and 48 hours (10-fold, p= 0.005) (Figure 5.6). 3 mM phosphate 
significantly induced 24-OHase protein expression by 6.6-fold by as early as at 6 
hours (p= 0.012); at 48 hours 24-OHase protein levels were increased 12-fold (p= 
0.001), compared to 1 mM phosphate at corresponding time points (Figure 5.6). 
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Figure 5.4: The effect of Phosphate on the Vitamin D Receptor (VDR) protein 
expression in (Human Aortic Smooth Muscle Cells) HAoSMCs over time. 
HAoSMCs were cultured in serum-free medium containing 1 mM phosphate (normal) 
or 2 mM or 3 mM (high), for 6, 24 and 48 hours. (A) VDR protein expression, 
normalised to β-actin protein levels, as demonstrated by Western blot analyses. 
Results represent mean ± SEM, n = 6, * p < 0.05; vs. 1 mM for each time point; data 
were analysed by one-way ANOVA. (B) Representative Western blot-note different 
grouping to the graph; cell lysates were separated by 10% SDS-PAGE and Western 
blotted with anti-VDR and anti-β-actin.  
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Figure 5.5: The effect of Phosphate on the 1α-Hydroxylase  (1α-OHase) protein 
expression in Human Aortic Smooth Muscle Cells (HAoSMCs) over time. 
HAoSMCs were cultured in serum-free medium containing 1 mM phosphate (normal) 
or 2 mM or 3 mM (high), for 6, 24 and 48 hours. (A) 1α-OHase protein expression 
normalised to β-actin, as demonstrated by Western blot analyses. Results represent 
mean ± SEM, n = 6, * p < 0.05; vs. 1 mM for each time point; data were analysed by 
one-way ANOVA. (B) Representative Western blot – note different layout to the 
graph; cell lysates were separated by 10% SDS-PAGE and Western blotted with anti-
1α-OHase and anti-β-actin. 
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Figure 5.6: The effect of Phosphate on the 24-Hydroxylase (24-OHase) protein 
expression in Human Aortic Smooth Muscle Cells (HAoSMCs) over time. 
HAoSMCs were cultured in serum-free medium containing 1 mM phosphate (normal) 
or 2 mM or 3 mM (high), for 6, 24 and 48 hours. (A) 24-OHase protein expression 
normalised to β-actin, as demonstrated by Western blot analyses. Results represent 
mean ± SEM, n = 6, * p < 0.05; vs. 1 mM for each time point; data were analysed by 
one-way ANOVA. (B) Representative Western blot – note different layout to the 
graph; cell lysates were separated by 10% SDS-PAGE and Western blotted with anti-
24-OHase and anti-β-actin. 
 
   
5.2.3 The Effect of TNF-α on the Vitamin D System mRNA and Protein 
Expression in HAoSMCs and in both Healthy and CKD Arteries 
 
The impact of TNF-α on local vitamin D metabolism, both in HAoSMCs and human 
arteries – in health and CKD were examined.  
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5.2.3.1 TNF-α Modulates the Vitamin D System in HAoSMCs 
 
 
In order to examine the effect of TNF-α on HAoSMCs vitamin D system both dose 
and time responses were investigated. Cells were treated with vehicle (PBS with 
0.1% BSA) or 20 ng/ml TNF-α for 6 or 24 hours.  The concentration 20 ng/ml was 
selected according to a prior dose response experiment, where HAoSMCs were 
treated with vehicle (PBS with 0.1% BSA), 1, 10 or 20 ng/ml TNF-α for 24 hours 
(Geng et al. 1996, Pryke et al. 1990, Stenvinkel et al. 2005). Both 1 and 20 ng/ml 
TNF-α appeared to upregulate VDR protein expression, but 20 ng/ml seemed to 
induce a stronger expression (Figure 5.7A). No changes were observed in 1α-OHase 
protein expression (Figure 5.7B), whereas 24-OHase protein appeared to be 
upregulated by 1, 10 and 20 ng/ml TNF-α (Figure 5.7C).   
 
 
 
Figure 5.7: TNF-α dose response in Human Aortic Smooth Muscle Cells 
(HAoSMCs), with effect on the Vitamin D Receptor (VDR), 1α-Hydroxylase  
(1α-OHase) and 24-Hydroxylase (24-OHase) protein expression. Cells were treated 
with vehicle (PBS with 0.1% BSA) or TNF-α (1, 10 or 20 ng/ml) for 24 hours. 
Representative Western blots: (A) VDR (B) 1α-OHase (C) 24-OHase, as 
demonstrated by Western blot analysis, β-actin for equal loading. 
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TNF-α (20 ng/ml) had no effect on VDR mRNA expression (Figure 5.8A). Western 
blot analyses indicated that TNF-α (20 ng/ml) induced significant 1.8-fold increase 
in the VDR protein expression at 24 hours (p= 0.013) (Figure 5.8B).  
 
 
Figure 5.8: The effect of TNF-α on the Vitamin D Receptor (VDR) mRNA and 
protein expression in HAoSMCs. Cells were incubated with vehicle (PBS with 0.1% 
BSA) or TNF-α (20 ng/ml) for 6, 24 and 48 hours. (A) VDR mRNA expression 
normalised to 18S rRNA, as demonstrated by real time RT-PCR (B) VDR protein 
expression with representative Western blots, values normalised to β-actin protein 
levels, as demonstrated by Western blot analyses. Results represent mean±SEM, n = 
6, * p < 0.05; vs. control, as determined by the one-way ANOVA.   
 
Furthermore, TNF-α had no effect on CYP27B1 mRNA (Figure 5.9A) and CYP24A1 
mRNA (Figure 5.9C). TNF-α had no effect on 1α-OHase protein expression and 
caused a significant induction in 24-OHase protein at 6 hours (Figure 5.9B). An 
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increase in 1α-OHase activity induced by TNF-α has been observed previously in 
human umbilical vein endothelial cells (Zehnder et al. 2002b). 24-OHase protein 
expression was significantly induced by 50% at 6 hours (p< 0.0001) (Figure 5.9D). 
 
 
Figure 5.9: The effect of TNF-α on the 1α-Hydroxylase (1α-OHase; CYP27B1) 
and 24-Hydroxylase (24-OHase; CYP24A1) protein and mRNA expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs) over time. Cells were incubated 
with vehicle (PBS with 0.1% BSA) or TNF-α (20 ng/ml) for 6, 24 and 48 hours.  
(A) CYP27B1 mRNA expression (B) 1α-OHase protein expression, with 
representative Western blots (C) CYP24A1 mRNA expression (D) 24-OHase protein 
expression, with representative Western blots. Protein expression was assessed by 
Western blot analyses and normalised to β-actin levels. Results represent 
mean±SEM, n = 6, * p <0.05; vs. control, as determined by one-way ANOVA. mRNA 
expression was assessed by real-time RT-PCR and normalised to 18S rRNA.  
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5.2.3.2 TNF-α Modulates the Vitamin D System in Human Arteries 
 
 
Arterial explants (renal and epigastric) from patients undergoing kidney 
transplantation (n = 11 healthy: donors; n = 16 CKD: recipients) were obtained with 
patients’ informed consent (supplementary patient information Table 3.1). Vessels 
were prepared for treatment by removal of the surrounding fat and the connective 
tissue and by further washing and equilibration in DMEM/F12 medium, in absence 
of serum for 1 hour. Vessels were treated with vehicle (PBS with 0.1% BSA) or 
TNF-α (20 ng/ml) for 48 hours. Differences in mRNA expression were examined by 
real-time RT-PCR analysis, with values normalised to 18S rRNA levels.  
VDR mRNA expression was lower in CKD arteries compared to healthy untreated 
controls. TNF-α significantly induced all three VDR, CYP27B1 and CYP24A1 
mRNAs. The presence of TNF-α significantly induced VDR mRNA expression by 
10-fold in healthy arteries (p<0.001), and 3-fold in CKD arteries (p<0.001) (Figure 
5.10A). CYP27B1 mRNA levels were two times higher in CKD arteries, compared 
with healthy controls (Figure 5.10B). TNF-α induced CYP27B1 mRNA expression 
in healthy arteries by about 200% (p<0.01) and even greater induction (500%) was 
observed in CKD arteries (p<0.001) (Figure 5.10B). CYP24A1 mRNA expression 
levels in healthy and CKD arteries were similar. 48-hour treatment with TNF-α 
caused a raise in CYP24A1 mRNA, both in healthy (230%) (p<0.001) and CKD 
arteries (180%) (p=0.001), however the increase seen in CKD was not as high as the 
one observed in healthy arteries (p=0.007)  (Figure 5.10C). 
 
In order to examine the effect of 1,25(OH)2D3 on inflammation,  IL-6 mRNA 
expression was assessed in presence of 1,25(OH)2D3 and/or TNF-α in healthy human 
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arteries and CKD arteries. Arteries were incubated with vehicle (0.1% ethanol) or 
TNF-α (20 ng/ml) or 1,25(OH)2D3 (100 nM) alone or together for 48 hours. IL-6 
mRNA levels were 54% lower in CKD arteries, compared to controls (p=0.005). 
Treatment with TNF-α massively induced IL-6 mRNA in healthy arteries (1400%, 
p<0.001), and less in CKD (200%, p<0.001). 1,25(OH)2D3 in the presence of TNF-α 
significantly inhibited IL-6 mRNA induction (p<0.001 compared to TNF alone) 
(Figure 5.11). 
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Figure 5.10: The effect of TNF-α on the Vitamin D Receptor (VDR), 1α-
Hydroxylase (CYP27B1) and 24-Hydroxylase (CYP24A1) mRNA expression in 
Healthy and Chronic Kidney Disease (CKD) arteries. Arterial explants were 
incubated with vehicle (0.1% ethanol) or TNF-α (20 ng/ml) for 48 hours. Note the 
different scales (A) VDR mRNA expression, (B) CYP27B1 (C) CYP24A1 mRNA. 
Differences in mRNA expression were examined by real-time RT-PCR analyses 
(normalised to 18S rRNA levels). Results represent mean of relative mRNA levels; n 
=11 healthy, 16 CKD, * p < 0.05; vs. healthy untreated control and vs. healthy treated 
control; determined by one-way ANOVA. Data provided by Dr Guerman Molostvov. 
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Figure 5.11: The effect of TNF-α, 1,25(OH)2D3 and a combination of both on the 
IL-6 mRNA expression in healthy and Chronic Kidney Disease (CKD) arteries. 
Human arterial explants were incubated with vehicle (0.1% ethanol) or TNF-α (20 
ng/ml) or 1,25(OH)2D3 (100 nM) or the combination of both, for 48 hours. 
Differences in mRNA expression were examined by real-time RT-PCR analyses 
(normalised to 18S rRNA levels). Results represent mean of relative mRNA levels; n 
=11 healthy, 16 CKD, * p < 0.05; vs. healthy untreated control or vs. healthy treated 
control, as determined by one-way ANOVA. Data provided by Dr Guerman 
Molostvov. 
 
 
To determine the effect of 1,25(OH)2D3 on osteoblastic marker RUNX-2 mRNA 
expression in presence of TNF-α and/or 1,25(OH)2D3 in arteries from healthy and 
CKD patients was assessed. Human arterial explants were incubated with vehicle 
(PBS with 0.1% BSA) or TNF-α (20 ng/ml) or 1,25(OH)2D3 (100 nM) or the 
combination of both, for 48 hours. RUNX-2 mRNA levels were 175% higher in CKD 
arteries, compared to basal expression in untreated healthy controls (p<0.01). 
Treatment with TNF-α hugely induced (689%) RUNX-2 mRNA in healthy arteries 
(p<0.01), but not in CKD. 1,25(OH)2D3 in presence of TNF-α had no effect on 
RUNX-2 mRNA, 1,25(OH)2D3 on its own significantly induced RUNX-2 mRNA 
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expression by 84% in normal arteries (p<0.01), and decreased RUNX-2 mRNA by 
111% in CKD (p<0.05) (Figure 5.12). 
 
 
Figure 5.12: The effect of TNF-α, 1,25(OH)2D3 and a combination of both on the 
RUNX-2 mRNA expression in healthy and Chronic Kidney Disease (CKD) arteries. 
Human arterial explants were incubated with vehicle (0.1% ethanol) or TNF-α (20 
ng/ml) or 1,25(OH)2D3 (100 nM) or the combination of both, for 48 hours. 
Differences in mRNA expression were examined by real-time RT-PCR analyses 
(normalised to 18S rRNA levels). Results represent mean of relative mRNA levels; n 
=11 healthy, 16 CKD, * p < 0.05; vs. normal untreated control or vs. normal treated 
control, as determined by one-way ANOVA. Data provided by Dr Guerman 
Molostvov. 
 
 
5.2.4 The Effect of INF-γ, IL-6 and IL-17A on VDR, CYP27B1 and 
CYP24A1 mRNA and Protein Expression in HAoSMCs  
 
HAoSMCs were treated with INF-γ, IL-6 or IL-17A at concentrations, which have 
previously shown effect in SMC, in vitro (Agrawal et al. 2012, Eid et al. 2009, Geng 
et al. 1996, Pietrowski et al. 2011). 
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5.2.4.1 INF-γ, IL-6 and IL-17A Suppressed CYP27B1 mRNA  
 
 
Further, studies using HAoSMCs demonstrated that INF-γ (20 ng/ml) or IL-6 or IL-
17A (200 ng/ml) had no significant effect on VDR mRNA expression at 6 or 24 
hours (Figure 5.13A). In contrast, the expression of CYP27B1 mRNA was decreased 
by approximately 50% by exposure to INF-γ (p= 0.01) or IL-6 (p= 0.04) or IL-17A 
(p= 0.049), at 24 hours. There were no significant changes in CYP27B1 mRNA 
expression at 6 hours (Figure 5.13B). INF-γ or IL-6 or IL-17A had no effect on 
CYP24A1 mRNA expression (Figure 5.13C).  
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Figure 5.13: The effect of INF-γ, IL-6 and IL-17A on the Vitamin D Receptor 
(VDR), 1α-Hydroxylase (CYP27B1) and 24-Hydroxylase (CYP24A1) mRNA 
expression in Human Aortic Smooth Muscle Cells (HAoSMCs). Cells were treated 
with vehicle (PBS with 0.1% BSA), INF-γ (20 ng/ml), IL-6 (200 ng/ml) and IL-17A 
(200 ng/ml) for 6 and 24 hours. (A) VDR mRNA expression  (B) CYP27B1 mRNA 
expression (C) CYP24A1 mRNA expression, as demonstrated by real-time RT-PCR 
analyses. Readings were corrected to 18S rRNA expression levels. Results represent 
mean of relative mRNA levels, n =4, * p < 0.05; vs. control as determined by one-
way ANOVA.   
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5.2.4.2 INF-γ Modulated 1α-OHase and 24-OHase Protein Expression 
 
Primary cultures of HAoSMc were incubated with vehicle (PBS with 0.1% BSA) or 
high concentrations of individual cytokines (INF-γ: 20 ng/ml; IL-6: 200 ng/ml; IL-
17A: 200 ng/ml) and changes in protein expression of 1α-OHase, 24-OHase and the 
VDR, at 6 hours and at 24 hours were examined by Western blot analyses. Neither 
VDR (Figure 5.14A), 1α-OHase (Figure 5.14B) nor 24-OHase protein expression 
(Figure 5.14C) was affected by any of the cytokines at 6 hours. However, following 
24 hours of treatment 1α-OHase protein expression was significantly upregulated by 
INF-γ 1.6-fold (p= 0.006) (Figure 5.14B). 24-OHase protein expression was 
significantly decreased by INF-γ, 0.4-fold (p= 0.007) at 24 hours (Figure 5.14C). No 
other significant changes in 1α-OHase, 24-OHase or VDR protein expression were 
induced (Figure 5.14).  
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Figure 5.14: The effect of INF-γ, IL-6 and IL-17A on the Vitamin D Receptor 
(VDR), 1α-Hydroxylase (1α-OHase) and 24-Hydroxylase (24-OHase) protein 
expression in Human Aortic Smooth Muscle Cells (HAoSMCs). Cells were treated 
with vehicle (PBS with 0.1% BSA), INF-γ (20 ng/ml), IL-6 (200 ng/ml) and IL-17A 
(200 ng/ml) for 6 and 24 hours. Results represent mean±SEM, n =3, *p <0.05, as 
determined by one-way ANOVA; each graph is accompanied by representative 
Western blots (A) VDR (B) 1α-OHase (C) 24-OHase. β-actin was used for equal 
loading.  
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5.3 Discussion  
 
 
Results presented in this chapter clearly demonstrated three major findings. Firstly, 
increased calcium upregulates VDR protein expression in VSMC, as well as 1α-
OHase protein and 24-OHase. Secondly, although phosphate has no effect on VDR 
protein expression, it stimulates 1α-OHase and 24-OHase expression. Lastly, TNF-α 
induces both VDR and 24-OHase protein expression in VSMCs. In healthy human 
artery TNF-α increases mRNA expression of VDR, CYP27B1 and CYP24A1. 
1,25(OH)2D3 blunts the effect TNF-α has on the expression of vascular vitamin D 
system in healthy artery, but not in CKD artery - action advantageous to limit 
inflammation.  
The main conclusion from all the above findings is that the role of VDR as a target 
for 1,25(OH)2D in VSMC is crucial – it is important for local 1,25(OH)2D  
production, for feedback regulation through acting on 1α-OHase and 24-OHase and 
also for the endocrine 1,25(OH)2D and importantly, the pharmacological therapy 
with active vitamin D compounds. CKD is characterized by an altered calcium and 
phosphate metabolism on a background on inflammation, and these clearly have 
effects on VSMCs, and although vitamin D signalling is intact in CKD it is altered 
and probably attenuated. The impact of stressors such as calcium, phosphate or TNF-
α on VSMCs VDR’s function can have deleterious consequences. Changes in cell 
can occur as a result of stressor induced - altered gene expression (Wu-Wong et al. 
2007b, c), eventually contributing to phenotypic changes (Jono et al. 2000, Reynolds 
et al. 2004, Tintut et al. 2000). I have shown that 2 and 3 mM calcium increased 1α-
OHase protein expression as early as 6 hours and the increase was sustained by at 
least 48 hours. One explanation could be transformation of cells under calcium 
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stress. However my earlier findings from studies in CKD artery where decreased 
levels of 1α-OHase were observed would contradict this theory, it is important to 
note that the experimental models are different – HAoSMCs treated with calcium 
represent more of an acute model, as the cells were obtained from healthy donors and 
were not previously exposed to long-term stressors to simulate CKD. The 
differentiation stage of cells can also play a role. Interestingly calcium had similar 
effect on both 1α-OHase and 24-OHase protein expression. Perhaps such feature is 
typical of autocrine regulation. From observations in other models such as 
keratinocytes, placenta and macrophages it could be hypothesised that local synthesis 
of 1,25(OH)2D3 is controlled not only by suppression of 1α-OHase but also by the  
supplementary action of  upregulated 24-OHase (Bacchetta J. et al. 2013, Novakovic 
et al. 2009, White 2012, Xie et al. 2002).  Upregulation of locally expressed 1α-
OHase by calcium has been observed in other extra-renal sites - in bone and in 
parathyroid. In kidney proximal tubule cells, 4 –hour treatment with 0.5 mM calcium 
resulted in 4.8-fold increase in CYP27B1 mRNA. 2 mM on the other hand, 
significantly decreased CYP27B1 mRNA expression and activity at 6 and 10 hours. 
Similar pattern was described in CYP24A1 mRNA expression (Bland et al. 1999).  
Studies using hyperplastic ureamic parthyroid tissue demonstrated that exposure to 
2.7 mM calcium for 24 hours induced a 50% increase in CYP27B1 mRNA 
expression and over 100% increase in CYP24A1 mRNA expression (Ritter et al. 
2012). Calcium has previously been shown to induce human macrophage CYP27B1 
mRNA in vitro, and to inhibit the renal enzyme (Hewison et al. 2000). However, the 
fact that high calcium has directly opposite effect on renal CYP27B1 mRNA 
expression and activity, compared to parathyroid and bone, may suggest that calcium 
or phosphate act more like immune stimuli in extra-renal setting.  
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Phosphate did not induce changes in VDR expression, however it significantly 
induced protein levels of 1α-OHase and 24-OHase. Perhaps different effect on VDR 
was to be observed had the concentration of phosphate in the treatment medium was 
higher or time of treatment was extended. The concentration of calcium in the 
treatment medium may also play a role. Previous studies looking at calcium 
incorporation in VSMCs demonstrated that only 4 or 5 mM phosphate had 
significant effect at 24 hours, however when concentration of both was increased to  
2.6 mM (Ca) and 2 mM (P), this was also sufficient to significantly induce calcium 
incorporation (Reynolds et al. 2004).  When looking at the effect phosphate exerted 
on 1α-OHase and 24-OHase protein expression, it becomes apparent that there is a 
clear approximately 24-hour delay in the induction of 24-OHase. This could be 
attributed to combating of the initial raise in local 1,25(OH)2D levels.  
Results presented in this chapter confirmed that TNF-α at 20 ng/ml induced VDR 
protein in HAoSMCs, but the observed increase in VDR mRNA was not statistically 
significant. Similarly, CYP27B1 and CYP24A1 mRNA and protein did not follow the 
same pattern, suggesting possible involvement of micro RNAs. TNF-α induced VDR 
mRNA by 10-fold in healthy arteries, compared to vehicle treated controls. These 
results directly contradict the recently published studies in which Agrawal and 
colleagues demonstrated the opposite effect of modulation of human bronchial SMCs 
with TNF-α, at a concentration of just 10 ng/ml, which is lower than I used (Agrawal 
et al. 2012). Differential regulation in the same cells but in different organs in the 
body may be a possible explanation. Perhaps SMCs of human bronchi are more 
sensitive to cytokine changes, in order to more robustly control allergic inflammation 
of the airway. On the other hand, VDR activation observed in both HAoSMCs and 
normal arteries may serve as a protective mechanism, through induction of 
                                                5. Regulation by Calcium, Phosphate and Cytokines   
 
 212 
1,25(OH)2D3 synthesis and repression of  the proinflammatory INF-γ gene 
transcription.   
Evidence as to whether calcium or phosphate is more potent stimulus in induction of 
medial calcification is contradictory. Some suggests that elevated calcium is more 
potent than elevated phosphate in human arteries, ex vivo (Shroff R. C. et al. 2010). 
Others present evidence which favors phosphate (Jono et al. 2000, Kendrick and 
Chonchol 2011, Wu-Wong et al. 2006c). In CKD contractile VSMCs, in order to 
cope with calcium overload, progressively differentiate into vesicle secreting cells. 
The presence of functional calcification inhibitors in vesicles ensures protection from 
calcification (Reynolds et al. 2004, Shanahan 2006, Shroff R. C. et al. 2008).  
Exposure of such differentiated cells to high calcium for prolonged period of time 
leads to calcium-induced apoptosis (Shanahan 2006). Since 1,25(OH)2D3 has been 
previously shown to have an anti-apoptotic activity in murine osteoblasts and 
osteocytes (Vertino et al. 2005), it is also possible that a local increase in 1α-OHase 
in response to high calcium or phosphate concentrations is a part of an anti-apoptotic 
protective cellular response.  
Previous studies performed on partially nephrectomised ApoE-deficient mice have 
demonstrated that the uremic milieu per se may accelerate atherogenesis (Buzello et 
al. 2003). Results presented in this chapter confirmed that in arteries from CKD 
patients VDR mRNA expression was not induced by TNF-α. This may be attributed 
to complex phenotypic changes in CKD VSMCs. Interesting observations were made 
in our studies on the expression of CYP27B1 mRNA and CYP24A1 in CKD arteries 
treated with TNF-α. CYP27B1 mRNA expression in normal arteries was increased in 
presence of TNF-α by 2-fold, and in CKD arteries the same concentration of TNF-α 
induced a 6-fold increase in the transcript levels of this enzyme.  An increase in 1α-
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OHase activity post-TNF-α challenge has previously been observed in human 
umbilical vein endothelial cells (Zehnder et al. 2002b). A directly opposite effect to 
that for CYP27B1 mRNA was recorded for CYP24A1 in CKD vessels, ultimately 
suggesting that the hampered VDR signalling in CKD may have a knock-on effect 
on uncontrolled increase in CYP27B1 mRNA. 
In conclusion, suppression of the renal 1α-OHase by high levels of calcium is part of 
a feedback loop to reduce 1,25(OH)2D3-mediated intestinal calcium absorption. A 
similar suppression of the 1α-OHase in the VSMCs and parathyroid glands by high 
calcium would diminish endogenous 1,25(OH)2D3 production and could be 
counterproductive to calcium feedback on circulating PTH, but also could be 
counterproductive to regulation of proliferation, differentiation and apoptosis. 
Results presented in this chapter may also suggest that induction of the 1α-OHase 
may be an additional, indirect fine-tuning mechanism for the control of PTH by 
calcium and calcium receptor activators.  
In the light of the research presented in this thesis, it is becoming apparent that 
VSMCs resemble the immune cell model by regulating their 1,25(OH)2D3 synthesis 
through responses to mitogens including TNF-α.  Thus, the data presented suggest 
that the presence of the intact functional local vitamin D system in human VSMCs 
may be a prerequisite for maintenance of cellular protection through synergistic 
actions with cytokines. The results propose that the mineral and inflammatory 
disruption of systemic vitamin D homeostasis have a knock on effect on the local 
vitamin D metabolism, a disruption of which can in consequence lead to 
inappropriate control/responses to chronic/prolonged changes in the local cytokine 
levels.   
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Chapter 6  
 
Novel Regulators of the Vitamin D 
System in Human Artery and 
VSMCs: FGF-23 and Klotho 
 
 
 
 
 
 
6.1 Background 
 
 
Deterioration of renal function in CKD is accompanied by progressively increasing 
levels of serum FGF-23, a mechanism evolved to possibly regulate high phosphate.  
In humans, loss of FGF-23 leads to hyperphosphatemia, increased serum 
1,25(OH)2D3, as well as ectopic soft tissue calcifications (Benet-Pages et al. 2005, 
Topaz et al. 2004). Klotho knockout mice (Kl
-
/
-
) have multiorgan premature ageing, 
hyperphosphatemia, hypercalcemia and associated medial calcification, together with 
elevated 1,25(OH)2D3 and FGF-23 (Brownstein et al. 2008, Ichikawa et al. 2007, 
Kuro-o et al. 1997, Segawa et al. 2007). Treatment of mice with a cleaved variant of 
Klotho results in hypophosphataemia and hypocalcaemia combined with huge 
upregulation of FGF-23 (Smith R. C. et al. 2012). For its action in any target tissue, 
FGF-23 requires Klotho in order to bind and activate the cognate FGF receptors with 
sufficient affinity (Yu et al. 2005). Interestingly, recent evidence demonstrated that 
Klotho does not require action of FGF-23 to induce phosphaturia, as it exhibits a 
direct phosphaturic effect itself (Hu et al. 2010). In CKD patients on haemodialysis, 
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possession of a genetic variant of the Klotho gene (rs577912) has been associated 
with survival (Friedman et al. 2009). FGF-23 levels start increasing early in CKD 
and even the high end of the normal range has been associated with arterial stiffness 
and impaired vasoreactivity (no decrease in pulmonary artery pressure in response to 
vasodilator challenge) in humans (Mirza et al. 2009a, Mirza et al. 2009b). Apart 
from inhibiting 1α-OHase and so 1,25(OH)2D synthesis in the kidney, increased 
levels of FGF-23 have been associated with the reduction of Klotho expression 
(Krajisnik et al. 2007, Shimada et al. 2004b).  
FGF-23 also acts on tissues other than the kidney, which synthesise 1,25(OH)2D3, 
such as monocytes. Studies on two different human monocyte models (healthy donor 
peripheral blood mononuclear cell monocytes (PBMCm) and peritoneal dialysate 
monocyte (PDm) effluent from kidney disease patients) revealed that FGF-23 
suppressed CYP27B1 reducing hydroxylation of 25(OH)D to 1,25(OH)2D, which is 
accompanied by suppression of CYP24A1 mRNA expression and antibacterial 
cathelicidin (Bacchetta J. et al. 2013). These findings suggest that in CKD local 
responses to 1,25(OH)2D can be inhibited by the action of FGF-23 on local 
monocyte vitamin D metabolism. 
Since VSMCs express Klotho and FGFRs, they are potentially a target tissue for 
FGF-23. Membrane bound (mb) and/or soluble (s) Klotho act as co-factors for FGF-
23, by converting FGFR-1 into a specific receptor for FGF-23. This allows binding 
of the FGF-23 to Klotho and the FGFR-1. The Klotho-FGF interaction is thought to 
occur at the FGF-23 C-terminal (Goetz et al. 2007). This interaction results in 
induction of phosphorylation cascade and activation of extracellular signal-regulated 
protein kinase (ERK1/2). ERK1/2 could further influence the regulation of early 
growth response protein 1 (Egr-1) and Nab-2 (Egr-1 binding protein), which allows a 
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negative feedback loop. Egr-1 family of proteins are zinc-finger nuclear proteins, 
which activate promoters of genes responsible for VSMC proliferation and responses 
to sheer stress or vascular injury. Co-repressors, such as Nab-1 and Nab-2 negatively 
regulate the Egr-1 activity, possibly maintaining the VSMC homeostasis (Silverman 
et al. 1999). Signalling via ERK1/2 could also result in a downstream 
phosphorylation of VDR and induction of transcription from VDREs. It is unclear 
whether endogenously expressed Klotho can exert actions similar to FGF-23, in vivo. 
In the light of recent research, it is not unreasonable to assume that Klotho may 
modulate transcription from VDRE via second messengers such as cAMP or via 
direct interactions with VDR. Most recent findings suggest that FGF-23-Klotho axis 
in vasculature plays an important role in maintaining vascular health (Donate-Correa 
et al. 2011, Hu et al. 2011, Lim et al. 2012). There are conflicting data on whether 
FGF-23 has vasculoprotective effects in CKD. The recent findings of Shalhoub and 
co-workers indicated that the neutralization of FGF-23 in CKD rat model, despite 
improving CKD-associated hyperparathyroidism, increased mortality (Shalhoub et 
al. 2012). Further, most recent data from studies on chronic renal insufficiency 
cohort of 1501 patients and in vitro studies on VSMCs support the notion that in 
contrast to serum phosphate, FGF-23 is not associated with arterial nor VSMC 
calcification, suggesting that FGF-23 may contribute to cardiovascular complications 
via alternative mechanisms (Scialla et al. 2013). Studies in mice with partial Klotho 
knockout limited to and specific to distal tubule suggested that high FGF-23 detected 
in these mice implied that human CKD is a state of FGF-23 resistance (Olauson et al. 
2012). However there are strong arguments against partial Klotho deletion being an 
accurate representation of CKD due to the inconsistencies between the experimental 
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mouse and the human CKD phenotype, including 1,25(OH)2D levels (Isakova and 
Wolf 2012).  
To date the collective evidence suggests that FGF-23 is not only involved in the 
bone-kidney axis, but also the bone-parathyroid and intestine-kidney axis (Ben-Dov 
et al. 2007, Razzaque and Lanske 2007). In this chapter the possible bone-
vasculature axis was investigated from the perspective of local vitamin D 
metabolism in VSMCs.  
In chapter 5 I demonstrated that high phosphate (2mM) induced increase in 
endogenous vascular 1α-OHase protein expression by 24 hours and induced an even 
more significant increase in 24-OHase protein in HAoSMCs. Further I showed that 
1α-OHase protein levels returned to basal levels after 48 hours. These findings 
suggested that this might be attributed to the action of an endogenous FGF-23 and/or 
Klotho potentially synthesised by VSMCs. High phosphate initially induced an 
increase in 1α-OHase as a vasculoprotective mechanism, this may have also induced 
FGF-23 and/or Klotho, which acted to decrease phosphate load, and as the mineral 
balance has been reestablished, 1α-OHase protein levels dropped back to basal level. 
The observable increase in 24-OHase protein expression is an expected negative 
feedback regulation of 1α-OHase synthesis.  
The above hypothesis has prompted me to investigate whether the observed changes 
were in fact attributed to the endogenous action of FGF-23 and/or Klotho. Therefore, 
in this chapter the effect of these novel vitamin D system regulators on the 
expression of VDR, 1α-OHase and 24-OHase protein in HAoSMCs were examined 
to better understand their possible contribution in the maintenance of vascular health.  
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6.2 Results 
 
6.2.1 Regulation of VDR, 1α-OHase and 24-OHase Protein Expression 
by FGF-23 in HAoSMCs 
 
6.2.1.1 Identification of the FGF Receptor 1 and FGF Receptor 3 protein in 
HAoSMCs 
 
 
Western blot analyses confirmed the presence of both FGF receptor 1 (FGFR1) and 3 
(FGFR3) protein in primary cultures of HAoSMCs (Figure 6.1). FGFR3 appeared to 
be more abundant than FGFR1. It was not possible to investigate the protein 
expression of FGFR2, as the antibody used did not produce reliable results. The 
presence of mRNA for FGF receptors: FGFR1, FGFR2 and FGFR3 has been 
confirmed recently in human aorta (Donate-Correa et al. 2011) and FGFR1 and 
FGFR3 protein in primary cultures of VSMCs (Lim et al. 2012). 
 
6.2.1.2 Klotho Protein Variants are Expressed in HAoSMCs 
 
 
Cells were grown in basal medium without FCS or with 0.5% FCS, or without FCS, 
but in presence of exogenous human recombinant hrKlotho (60-70 kDa) (200 pM, 24 
hours). Western blot analyses confirmed that HAoSMCs express membrane bound - 
mbKlotho (130 kDa), secreted - sKlotho (80 kDa) and cleaved - cKlotho (68 kDa) 
proteins. In the absence of FCS, HAoSMCs expressed only mbKlotho (130 kDa). 
Expression of sKlotho and cKlotho was stronger in cells grown with FCS and 
weaker in cells treated with hrKlotho (Figure 6.2) 
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Figure 6.1: The Fibroblast Growth Factor (FGF) Receptor 1 (FGFR1) and FGF 
Receptor 3 (FGFR3) protein expression in Human Aortic Smooth Muscle Cells 
(HAoSMCs). FGFR1: a weak band of approximately 115 kDa corresponding to the 
one seen in kidney was detected in HAoSMCs, as demonstrated by Western blot 
analysis. FGFR3: a strong band of about 80 kDa was detected in HAoSMCs. Human 
kidney was used as a positive control.  
 
Figure 6.2: Expression of Klotho protein in Human Aortic Smooth Muscle Cells 
(HAoSMCs). Cells were grown in basal medium with no foetal calf serum (FCS) or 
with 0.5% FCS, or without FCS, but in presence of exogenous human recombinant 
(hr) soluble sKlotho (60-70 kDa) (200 pM, 24h). mb- membrane bound, s- secreted, 
c- cleaved Klotho protein. It appears that in absence of FCS, HAoSMCs express only 
mbKlotho (130 kDa). s- and cKlotho (80 kDa and 68 kDa, respectively) appear to be 
present in cells grown with FCS and to a lesser extent in cells treated with hr 
sKlotho. 
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6.2.1.3 The FGF-23 Signalling in HAoSMCs is via ERK1,2 Phosphorylation 
Pathway 
 
 
Further investigation demonstrated that the treatment of HAoSMCs with 100 ng 
FGF-23 induced phosphorylated ERK (Phospho-ERK1,2) protein expression (42 and 
44 kDa), reaching a peak at 30 minutes compared with the vehicle (0.1% DMSO) 
treated control, as demonstrated by Western blot analysis (Figure 6.3). Inhibition 
was achieved by pre-incubating the cultures with 60 μM of a MEK-1 inhibitor 
(PD98059) for 1 hour prior to treatment with FGF-23 for 30 minutes. Phorbol 12-
myristate 13-acetate (PMA) at 50 μM for 5 minutes was used as a positive control of 
ERK phosphorylation. Treatment of cells with PMA in the absence of FGF-23 and 
PD98069 resulted in a strong upregulation of phosphorylated ERK-1,2, compared to 
vehicle treated control. 
 
 
 
 
Figure 6.3: The effect of Fibroblast Growth Factor-23 (FGF-23) on signal 
transduction via the MAPK Pathway. HAoSMCs were treated with vehicle (0.1% 
BSA) or FGF-23 (100ng/ml) for 10, 30 and 60 minutes. For lane 5, cells were 
incubated with MEK-1 inhibitor (PD98059) (60 μM) 30 minutes before exposure to 
FGF-23, for lane 6 cells were incubated with phorbol 12-myristate 13-acetate 
(PMA) as a positive control for ERK phosphorylation. Cell lysates were prepared in 
the presence of phosphatase inhibitors, and phosphorylated proteins were detected 
by chemiluminescence using rabbit anti-phospho-ERK1,2 antibodies. Equal protein 
loading was monitored by detection of total-ERK1,2 protein.  
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6.2.1.4 FGF-23 Induces VDR and 24-OHase Protein Expression, in the Absence 
of FCS 
 
Previous studies conducted by our group and others have demonstrated the presence 
of endogenous Klotho mRNA and protein in vasculature (Donate-Correa et al. 2011, 
Lim et al. 2012). To test whether Klotho is essential for the action of exogenous 
FGF-23, cells were treated in absence of serum (to avoid Klotho which may be 
present in the serum). HAoSMCs were treated with vehicle (0.1% BSA) or 5 ng/ml 
FGF-23 (concentration previously optimized by Perwad in HKC-8 and mouse renal 
proximal tubule cells (MCT) (Perwad et al. 2007) and Lim in HAoSMCs (Lim et al. 
2012), also ED50 suggested by the supplier). Serum concentration of FGF-23 in 
healthy adults is 0.004 ng/ml ± 0.00017 (Yamazaki et al. 2010), reaching about 50 
ng/ml in early CKD (Larsson et al. 2003) and about or over 100 ng/ml in advanced 
stages of CKD (Dai et al. 2012). Treatment medium was changed every 24 hours.  
 
Western blot analyses demonstrated that FGF-23 induced about a 50% increase in 
VDR protein expression across all time points, but only the 24-hour treatment 
resulted in a significant change (Figure 6.4). 
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Figure 6.4: The effect of the Fibroblast Growth Factor (FGF) 23 on the Vitamin D 
Receptor (VDR) protein expression in Human Aortic Smooth Muscle Cells 
(HAoSMCs) over time. Cells were treated with vehicle (0.1% BSA) or 5 ng/ml FGF-
23 for 6, 24 and 48 hours, as demonstrated by Western blot analyses. Results are 
presented as ratio of VDR protein expression and corresponding β-actin protein 
levels. Results represent mean ± SEM, n = 6, * p < 0.05; vs. control; as analysed by 
one-way ANOVA. 
 
No significant changes in 1α-OHase protein expression were observed following 
FGF-23 treatment of HAoSMCs for 6, 24 or 48 hours (Figure 6.5A). In contrast, 24-
OHase protein expression, was significantly induced by 3-fold following 48 hours of 
treatment (Figure 6.5B).  
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Figure 6.5: The effect of the Fibroblast Growth Factor-23 (FGF-23) on the 1α-
Hydroxylase (1α-OHase) and 24-Hydroxylase (24-OHase) protein expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs) in absence of Foetal Calf Serum 
(FCS) over time. Cells were treated with vehicle (0.1% BSA) or 5 ng/ml FGF-23 for 
6, 24 or 48 hours. (A) 1α-OHasee protein expression (B) 24-OHase protein 
expression, as demonstrated by Western analyses. Results are presented as ratio of 
1α-OHase or 24-OHase protein expression and corresponding β-actin. Results 
represent mean ± SEM, n = 6, * p < 0.05; vs. control; one-way ANOVA. Graphs are 
presented with representative Western blots. 
 
6.2.1.5  FGF-23 Suppresses 1α-OHase in the Presence of FCS 
 
To test whether the previously observed lack of change in 1α-OHase protein 
expression following treatment with FGF-23 was real, or whether the presence of 
FCS, which might contain Klotho and 25(OH)D alters responses, an alternative set-
up was examined. Cells were treated with vehicle (0.1% BSA) or normal (5 ng/ml) 
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or high (100 ng/ml) dose of FGF-23 in absence or in presence of 0.5% FCS, for 24 
and 48 hours. FGF-23 doses of 5 ng/ml and 100 ng/ml have been used previously by 
others (Bacchetta J. et al. 2013, Ben-Dov et al. 2007, Lim et al. 2012, Perwad et al. 
2007). The treatment of HAoSMCs with 100 ng/ml FGF-23 (48 hours) significantly 
inhibited 1α-OHase protein expression, however only in presence of FCS (Figure 
6.6). 
 
Figure 6.6: The effect of the Fibroblast Growth Factor-23 (FGF-23) on the 1α-
Hydroxylase (1α-OHase) protein expression in absence or presence of Foetal Calf 
Serum (FCS) in Human Aortic Smooth Muscle Cells (HAoSMCs) over time. Cells 
were treated with vehicle (0.1% BSA) or 5 ng/ml or 100 ng /ml FGF-23 in absence or 
presence of 0.5% FCS for 24 and 48 hours. Results are presented as ratio of 1α-
OHase protein expression and corresponding β-actin protein levels, as demonstrated 
by Western blot analyses. Results represent mean ± SEM, n = 4, * p < 0.05; vs. 
control; data were analysed by one-way ANOVA. Below the graph are the 
representative Western blots.  
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6.2.2 Regulation of  the VDR, 1α-OHase and 24-OHase Protein 
Expression by hr sKlotho in HAoSMCs  
 
Previous studies by Hu and co-workers (Hu et al. 2010) proposed a model in which 
Klotho can function in the apical membrane of the proximal tubule as a direct 
extracellular enzyme deglycosylating NaP1-2a protein and/or a putative regulatory 
protein to reduce co-transport activity. Evidence supporting the model was a result of 
experiments on FGF-23-null mice injected with intravenous recombinant 
extracellular domain Klotho (64 pM), which responded by lowering phosphate in the 
serum and increasing phosphate excretion in the urine (Hu et al. 2010).  
 
In order to test whether exogenous hr sKlotho exerts a direct action on VDR, 1α-
OHase or 24-OHase protein expression, HAoSMCs were treated with vehicle (0.1% 
BSA) or increasing concentrations of hr sKlotho (200 pM, 400 pM and 600 pM) (Liu 
H. et al. 2007) with heparan sodium (10 μg/ml) (Allen and Rapraeger 2003) for 6, 24 
and 48 hours. Serum levels of sKlotho in healthy adults range between 100-200 pM 
(Yamazaki et al. 2010), however the local tissue concentrations may be higher. 
The concentration of 200 pM was shown to be optimal (Figure 6.7).   
Heparan salts have previously been shown to stabilize FGF-23/Klotho/Receptor 
formation (Allen and Rapraeger 2003), however it is only recently that data have 
emerged suggesting that their presence is dispensable and does not affect the 
complex formation (Goetz et al. 2012). 
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Figure 6.7: The effect of increasing doses of the exogenous human recombinant 
soluble Klotho (hr sKlotho) on the Vitamin D Receptor (VDR), 1α-Hydroxylase 
(1α-OHase) and 24-Hydroxylase (24-OHase) protein expression in Human Aortic 
Smooth Muscle Cells (HAoSMCs) over time. Cells were treated with vehicle (0.1% 
BSA) or increasing concentrations of Klotho (200 pM, 400 pM and 600 pM) with  
heparan sodium (10 μg/ml) for 6, 24 and 48 hours. Concentration of 200 pM has 
been chosen as optimal for further time dependent studies.     
 
6.2.2.1  sKlotho Mirrors FGF-23 by Independently Inducing the VDR and 24-
OHase Protein Expression 
 
Western blot analyses demonstrated that hr sKlotho (200 pM) significantly up-
regulated VDR protein expression (2-fold) at 6 hours, compared to vehicle treated 
control (Figure 6.8). sKlotho did not induce changes in 1α-OHase protein 
expression, 24-OHase protein on the other hand was significantly induced at 6 hours 
and remained slightly elevated at 24 and 48 hours (Figure 6.9). 
Figure 7.7: Effect of increasing doses of 
exogenous Klotho on VDR, 1α-hydroxyalse, 
24-hydroxylase protein expression, over 
time. Cells were treated with with vehicle 
(0.1% BSA) or increasing concentrations of 
Klotho (200 pM, 400 pM and 600 pM) with 
heparan sodium (10 μg/ml) for 6, 24 and 72 
hours. Concentration of 200 pM has been 
chosen as optimal for further time-
dependent studies. 
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Figure 6.8: The effect of human recombinant soluble Klotho (hr sKlotho) on the 
Vitamin D Receptor (VDR) protein expression in Human Aortic Smooth Muscle 
Cells (HAoSMCs) over time. Cells were treated with vehicle (0.1% BSA) or 200 pM 
Klotho for 6, 24 or 48 hours. Results are presented as ratio of VDR protein 
expression and corresponding β-actin protein levels, as demonstrated by Western 
blot analyses. Results represent mean ± SEM, n = 6, * p < 0.05; vs. control; data 
were analysed by one-way ANOVA. Below the graph are the representative Western 
blots.  
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Figure 6.9: The effect of human recombinant soluble Klotho (hr sKlotho) on the 
1α-Hydroxylase (1α-OHase) and 24-Hydroxylase (24-OHase) protein expression in 
Human Aortic Smooth Muscle Cells (HAoSMCs) over time. Cells were treated with 
vehicle (0.1% BSA) or 200 pM hr sKlotho with 10 μg/ml heparan sodium for 6, 24 or 
48 hours. (A) 1α-OHase protein expression (B) 24-OHase protein expression, as 
demonstrated by Western blot analyses. Results are presented as ratio of (A) 1α-
OHase or (B) 24-OHase protein expression and corresponding β-actin protein levels. 
Results represent mean ± SEM, n = 6, * p <0.05; vs. control; data were analysed by 
one-way ANOVA. Below each graph are the representative Western blots. 
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6.2.2.2 sKlotho Potentially Prevents FGF Receptor from Being Blocked by 
Excess of FGF-23 Maintaining Stable mbKlotho Protein Levels 
 
 
In order to determine whether FCS influences the action of FGF-23 on mbKlotho 
protein expression in HAoSMCs, cells were grown and treated with FGF-23 (5 ng/ml 
or 100 ng/ml) in the presence or absence of FCS (0.5%) or in the presence of hr 
sKlotho, for 24 and 48 hours (treatment medium was renewed every 24 hours). In the 
absence or presence of 0.5% FCS in the medium, mbKlotho protein expression 
appeared to be inhibited by 100 ng/ml FGF-23 at 24 hours. However, in the absence 
of FCS, but in presence of hr sKlotho (200 pM) mbKlotho protein expression was 
unchanged (Figure 6.10). However, to fully prove this hypothesis further Western 
analyses and protein binding assays would be required. 
 
 
 
 
Figure 6.10: The effect of the Fibroblast Growth Factor (FGF-23) on the Klotho 
protein expression in Human Aortic Smooth Muscle Cells (HAoSMCs) grown in 
absence or presence of Foetal Calf Serum (FCS) or in presence of human 
recombinant (hr) soluble Klotho. Cells were treated with 5 ng/ml or 100 ng/ml 
FGF-23 for 24 and 48 hours and Klotho protein expression was assessed by Western 
blot analysis. Representative Western blots.  
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6.3 Discussion 
 
The results presented in this chapter show that VSMCs express the machinery 
required for the endocrine action of FGF-23; namely: FGFR1, FGFR3, mbKlotho, 
cKlotho and sKlotho.  Further, my finding that the MEK-1 inhibitor, PD98059 
effectively inhibited FGF-23-induced signalling confirmed that VSMCs respond to 
FGF-23. Previous studies have shown that that FGF-23 signal is also transduced via 
MAPK and phosphorylation of ERK1,2 in human chondrocytes and in human 
proximal tubule epithelial cells  (Orfanidou et al. 2012, Perwad et al. 2007).  An 
alternative approach to the one used in my experiments would involve neutralisation 
of FGF-23 with a specific anti-FGF-23 antibody or less directly, through Klotho 
knockout (Lim et al. 2012, Shalhoub et al. 2012).  
My results demonstrated that FGF-23 modulates the local vitamin D system in 
VSMCs. FGF-23 significantly induced VDR protein expression at 24 hours. 
Significant 3-fold raise in 24-OHase protein was observed later, at 48 hours. 
Interestingly, the lower concentration of FGF-23 (5 ng/ml) had no effect on 1α-
OHase protein expression. The ultimate consequence to VSMCs may be that FGF-23 
makes cells more sensitive to 1,25(OH)2D. It appears that it may inhibit the VDR-1α-
OHase-24-OHase system by upregulating 24-OHase; however enzyme activity data 
would aid the interpretation of these findings. The known positive regulators of bone 
derived FGF-23 are phosphate and 1,25(OH)2D. Evidence shows that both 
circulating 1,25(OH)2D3 and the locally produced fraction can induce FGF-23 in 
primary differentiated osteoblasts (Tang W. J. et al. 2010). It is well known that 
FGF-23 acts on a variety of tissues. Data are currently emerging that highlight the 
importance of extra-renal 1,25(OH)2D3 synthesis. These studies imply that FGF-23 
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can be an important player in regulation of the local and fine-tuning of the systemic 
VDR actions. Recent evidence from studies using chondrocytes suggests that the 
FGF-23 promoter contains two VDREs (Orfanidou et al. 2012).  
 
 
Figure 6.11: Schematic representation of Fibroblast Growth Factor 23 (FGF-23) 
and Klotho signalling in Vascular Smooth Muscle Cell (VSMC). (mb)- membrane 
bound. (Arrow)-activation, (T-line) – inhibition, (double sided arrow) – complex 
formation, (?)- potential interaction. 
 
In human and mouse kidney proximal tubule cells, increasing doses of FGF-23, 
ranging from 1 to 10 ng/ml induced a dose dependent decrease in CYP27B1 mRNA 
expression, with maximum suppression detected after 21 hours of treatment (Perwad 
et al. 2007). Similar effects of exogenous FGF-23 has been observed in monocytes 
from healthy and dialysis patients. Interestingly, suppression of CYP27B1 was 
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accompanied by a decrease in CYP24A1, FGFR1 and Klotho mRNA (Bacchetta J. 
Lisse, T. Hewison, M. 2011). An entirely opposite effect of FGF-23 has been 
observed in the parathyroid glands, where treatment with 100 ng/ml of FGF-23 (the 
same concentration as the one used in the monocytes’ treatments) significantly 
upregulated CYP27B1 mRNA after only 1 hour. Furthermore, FGF-23 regulation in 
chondrocytes demonstrated that despite FGF-23 being produced by osteoblasts or 
osteocytes, it is the VDR signalling in the chondrocytes that regulates the synthesis 
of this phosphatonin (Masuyama et al. 2006).  
 
The FGF-23 inhibitory effect on 1α-OHase expression presented in this chapter is 
similar to the one observed in kidney and monocytes. Interestingly my results 
indicate that 1α-OHase protein suppression was only achieved in the presence of a 
high concentration of FGF-23 (100 ng/ml) and required the presence of 0.5% FCS. It 
is possible that either serum contains sufficient concentration of sKlotho for the 
added FGF-23 to act on VSMCs or that proteins present in the serum stabilised the 
FGF-23, which has a very short half-life, enhancing its biological potency in vitro. If 
the latter were true, one might speculate that the endogenous Klotho expressed by 
HAoSMCs facilitated the action of FGF-23. The combination of both hypotheses 
may also be plausible. Interestingly, our acute in vitro cell model mirrored what is 
observed clinically in CKD arteries: high serum concentration of FGF-23 and 
decreased 1α-OHase protein expression. Measurement of 1,25(OH)2D levels post 
FGF-23 treatment in VSMC would be the next step to confirming whether FGF-23 
has a direct inhibitory effect on 1,25(OH)2D synthesis. 
Klotho consistently induced VDR and 24-OHase protein expression by 6 hours of 
incubation, whereas no change in 1α-OHase protein was detected (similar 
observations were made in FGF-23 treatment). It appears that Klotho has an 
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independent effect on vascular vitamin D system, one that mirrors the effects of 
FGF-23. My results suggest that both Klotho and/or FGF-23 induce catabolism of 
1,25(OH)2D3 on a local level, as seen previously in kidney (Hu et al. 2010).  My 
findings that Klotho independently induces 24-OHase protein expression support the 
observations made previously in Klotho-null mouse in which 1,25(OH)2D levels are 
markedly elevated, despite high FGF-23 (opposite to what is observed in CKD, 
where serum 1,25(OH)2D levels are low) demonstrating that high FGF-23 in absence 
of Klotho is insufficient to suppress the excessive 1,25(OH)2D production (Dai et al. 
2012, Dusso and Rodriguez 2012, Hu et al. 2011). Klotho is expressed on surface of 
cells forming new organs, upon cleavage it is released to circulation. Perhaps 
cleavage and consequently a size decrease facilitate the entry of Klotho into the cell 
allowing a direct interaction with VDR. 
Experiments using in vitro VSMC showed that an increase in the local concentration 
of phosphate results in upregulation of 1α-OHase protein expression (Chapter 5). 
Further results presented in this chapter suggest that VSMCs have a mechanism 
through which they control phosphate homeostasis locally and that Klotho may be an 
important player, due to its ability to act on VDR in vasculature. Recent studies 
endorse my findings with the observation that soluble recombinant Klotho prevents 
phosphate induced VC in murine VSMCs through inhibiting the sodium-phosphate 
co-transporters  Pit-1 and Pit-2 (Hu et al. 2012, Lau et al. 2012). 
 
In conclusion, FGF-23 can act on VDR to exert different outcomes depending on the 
cell type; in vasculature it appears to act in a fashion different to kidney and 
macrophages, by suppressing 1α-OHase production only at extreme concentration 
and by controlling the system by the upregulation of 24-OHase. The interaction 
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between VDR and FGF-23 may be facilitated by cell-specific factors involved in the 
formation of the transcriptional complex. The fact that in the parathyroid cells FGF-
23 stimulates 1α-OHase expression in vitro, exerting an action directly opposite to 
the one seen in kidney, bone and monocytes, may be an important element in the 
systemic FGF-23 regulation. Also, one may assume that increased FGF-23 
contributes to vascular cytoprotection on two levels, first by inducing 1α-OHase 
associated immunoprotection and second, by partly contributing to the beneficial 
effects of calcitriol treatment in CKD. Although in the light of recent studies using a 
rat model, where specific neutralisation of FGF-23 in CKD rats led to increase in 
serum 1,25(OH)2D3, calcium, and phosphate and a decrease in serum PTH levels, 
overall contributing to mortality, only highlights that a control of one factor may not 
necessarily be a best treatment option, ultimately raising many new questions 
(Shalhoub et al. 2012).  
Data presented in this chapter support the existence of a vascular-endocrine FGF-
23/Klotho axis and further provide insights into the complex regulation of mineral 
homeostasis within the vascular milieu.  
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Chapter 7  
 
Conclusions and Future Directions 
 
 
 
 
 
 
7.1 Key Findings 
 
 
-  VSMCs express functional Vitamin D System (VDR, 1α-OHase and 24-OHase 
mRNA and protein) 
 
- Expression of the Vitamin D System is downregulated in CKD arteries compared 
with healthy arteries 
 
- 25(OH)D3 (100 nM) and 1,25(OH)2D3 (10 nM) independently largely induce 
CYP24A1 mRNA; suppress CYP27B1 mRNA and upregulate VDR mRNA in 
VSMCs; changes in mRNA are not mirrored by the changes in protein 
 
- High calcium (2-3 mM) upregulates VDR expression and induces early and 
sustained increase in 1α-OHase and 24-OHase protein levels 
 
- High phosphate (2-3 mM) does not affect the VDR protein expression, however it 
increases both the 1α-OHase and 24-OHase protein expression 
 
- TNF-α strongly induces the VDR mRNA and protein expression in VSMCs and 
human artery. This induction is blunted in CKD arteries and partially reversed in 
presence of 1,25(OH)2D3 
 
- VSMCs express the FGFR1, FGFR3 and respond to the FGF-23 via ERK1,2 
phosphorylation pathway. Low dose of the FGF-23 (5ng/ml) induces the VDR and 
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24-OHase protein expression, whereas high dose (100ng/ml) suppresses 1α-OHase 
protein 
 
 - VSMCs express mbKlotho, sKlotho and cKlotho protein 
 
- sKlotho mirrors FGF-23 by independently inducing the VDR and 24-OHase protein 
expression 
 
- VSMC vitamin D system is regulated differently to the endocrine renal vitamin D 
system. It is also regulated differently to other previously described extra-renal 
vitamin D systems such as macrophages, parathyroid glands and bone (Table 7.1).   
 
 
 
Table 7.1 Regulation of renal and extra-renal 25(OH) - 1α-Hydroxylase protein 
expression. Vascular Smooth Muscle Cell (VSMC), Fibroblast Growth Factor -23 
(FGF-23), Interferon-γ (INF-γ), Tumour Necrosis Factor – α (TNF-α), Human 
Recombinant Soluble Klotho (hr sKlotho), low (0.2-0.5 mM), high (2-3 mM), *TNF-
α: no effect on VSMC 1α-OHase, but induction of VDR, *hr sKlotho: no effect on 
VSMC 1α-OHase, but induction of Vitamin D Receptor and Vitamin D 24-
Hydroxylase. Increase (), decrease (). 
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7.2 Summarising Discussion 
 
 
The experiments conducted for the purpose of this thesis increased the understanding 
of the complex vitamin D system. It is now established that there are multiple 
mechanisms through which 1,25(OH)2D can modify cardiovascular outcomes. Its 
action can be exerted directly via VDR activation or, indirectly through regulation of 
calcium homeostasis. The key findings of this thesis were determination of 
expression of 24-OHase protein and mRNA in human arteries and primary cultures 
of HAoSMCs, followed by discovery that 24-OHase protein expression is elevated in 
arteries of patients with CKD, and 1α-OHase protein levels are decreased. 
These changes may trigger abnormal responses to 1,25(OH)2D3, especially by 
increasing 24-OHase synthesis. Consequently, from the clinical perspective, 
prolonged treatment with 1,25(OH)2D3 and possibly other active vitamin D 
compounds may result in 1,25(OH)2D resistance. This could be proven, by first 
examining whether the protein expression is reflected in enzyme activity then by 
clinical trial.  Furthermore, extensive immunohistochemistry and Western blot 
analyses proved that altered expression of the VDR, 1α-OHase and 24-OHase in 
CKD arteries co-localised with medial calcification and increased levels of RUNX-2 
and sclerostin. Recent clinical trials - seven longitudinal observational cohort studies 
and four randomised trials underline the importance of the described findings with 
the observation of no statistically significant effect of vitamin D supplementation on 
cardiovascular outcomes (Pittas et al. 2010). The available data are insufficient to 
postulate that cardiovascular outcomes can be corrected by increasing vitamin D 
intake or serum or plasma 25(OH)D levels. However according to the author of the 
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review analysing the clinical studies, the results may be skewed by chronic non-
specific illness, smoking, alcohol or vitamin D fortified food intake.   
 
Based on the results presented in this thesis it is not unreasonable to assume, that 
correction of vascular 1α-OHase and 24-OHase protein expression levels in CKD, 
without majorly affecting the circulating elements of vitamin D system and 
ultimately other hormones, could be achieved through local modulation of VSMCs 
with a combination of INF-γ, FGF-23 and TNF-α inhibitors.  However in order to 
confirm that further in vitro studies using human arteries would have to be 
performed. Cell-specific method of administration would have to also be established.   
This method could then be compared with the use of new class of 24-OHase 
inhibitors (Chiellini et al. 2012). 
 
7.3 Future Directions 
 
 
Future work to confirm whether catabolic profile is in fact what induces 
1,25(OH)2D3 resistance in CKD arteries would broaden current perspective - a 
conditional vascular 24-OHase knock-out and over-expressing mice studies could 
prove helpful.  
Continuation of cross-sectional analysis of arterial explants, reaching significantly 
higher number of samples could be useful to confirm the results presented in this 
thesis. Importantly, serum 25(OH)2D3 levels should also be examined for each 
subject, ideally using most recent sensitive methods such as mass spectroscopy 
(Bruce et al. 2013). Furthermore, the selective therapeutic targeting of 24-OHase, 
1α-OHase and VDR could deliver many answers. Recent advancement in the 
application and utilization of nanotechnology may aid the therapeutic stimulation of 
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1α-OHase or inhibition of 24-OHase enzymatic activity (Mai and Meng 2012, Park 
2013). Lastly, establishment of simple and reliable method of measuring levels of 
substrate- 25(OH)D3 and product- 1,25(OH)2D3 could even further improve our 
understanding of the importance of local synthesis of 1,25(OH)2D3 in maintenance of 
healthy phenotype of VSMCs.  
 
Despite our growing knowledge of VDR activation in CKD, we are still yet to fully 
understand the consequences of the auto/paracrine effects of vitamin D production. 
There is overwhelming evidence that its role in vasculature may be more complex - 
not only regulatory at the cellular level, but also systemic due to its fine-tuning 
actions of the endocrine system. Protective versus proactive effects of VDR 
activation in vasculature are a subject of extensive research to improve our current 
understanding of vascular calcification in CKD.  
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